EudraCT: 2019 -003078 -24 
IND Number: 136142  Regeneron Pharmaceuticals, Inc.  
Clinical Study Protocol  
A RANDOMIZED, DOUBLE -BLIND, PLACEBO -CONT ROLLED STUDY 
TO INVESTIGATE THE E FFICACY AND SAFETY OF DUPI[INVESTIGATOR_24714] W ITH ACTIVE EOSINOPHI LIC ESOPHAGITIS  
Compound : Dupi[INVESTIGATOR_24715]:  EoE KIDS  
Clinical Phase:  3 
Protocol Number:  R668 -EE-1877  
Protocol Version:  R668 -EE-1877 Amendment 4  
Amendment 4 Date of Issue  See appended electronic signature [CONTACT_25073] 3 Date of Issue  13 June 2021  
Amendment 2 Date of Issue  18 Nov 2020  
Amendment 1 Date of Issue:  07 Apr 2020  
Original Date of Issue:  18 Nov 2019  
Medical /Study Director:   
  
 
Clinical Scientist:   
 
  
Regeneron Pharmaceuticals, Inc.  
[ADDRESS_24017]  
Tarrytown, NY [ZIP_CODE]  
   
 
 
 
 
 
 
 
 
VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00[STUDY_ID_REMOVED]

Clinical Study Protocol  R668 -EE-[ADDRESS_24018]  Aspartate aminotransferase  
BUN  Blood urea nitrogen  
CCL  Chemokine (C -C motif) ligand  
Cmax Maximal concentration  
CMH  Cochran -Mantel -Haenszel (test)  
COA  Clinical outcome assessment  
CRF  Case report form  
CRO  Contract research organization  
CSR  Clinical study report  
CRSwNP  Chronic rhinosinusitis with nasal polyps  
Ctrough Trough concentration  
DMC  Data monitoring committee  
DSQ  Dysphagia symptom questionnaire  
EC Ethics committee  
eCRF  Electronic case report form  
EDC  Electronic data capture  
EDP  EoE diagnostic panel  
eGFR  Estimated glomerular filtration rate  
EoE Eosinophilic esophagitis  
EoE-EREFS  Eosinophilic Esophagitis -Endoscopic Reference Score 
EoE-HSS EoE Histology Scoring System  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4 
 
Regeneron Pharmaceuticals, Inc.  Page 3 
 CONFIDENTIAL  EOS  End of study (visit)  
eos/hpf  Eosinophils/high power field  
EOT  End of treatment  
EPIT  Epi[INVESTIGATOR_24716]-γ Interferon -gamma  
IgE Immunoglobulin E  
IgG4  Immunoglobulin G4  
IHC Immunohistochemistry  
IL Interleukin  
IL-4Rα Interleukin -[ADDRESS_24019]  
IVRS/IWRS  Interactive voice/web response system  
LDH  Lactate  dehydrogenase  
MedDRA  Medical Dictionary for Regulatory Activities  
NAb  Neutralizing antibody  
NES  Normalized Enrichment Scores  
OIT Oral immunotherapy  
PCSV  Potentially clinically significant value  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24020] Scale  
PESQ  Pediatric EoE Sign/Symptom Questionnaire  
PK Pharmacokinetic  
PPI [INVESTIGATOR_24717] (MedDRA)  
QOL  Quality of life  
Q2W  Once every [ADDRESS_24021]  
 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24022] OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................ .................. 2 
AMENDMENT HISTORY  ................................ ................................ ................................ ........... 11 
CLINICAL S TUDY PROTOCOL SYNOPS IS................................ ................................ ............. 21 
1. INTRODUCTION  ................................ ................................ ................................ ......32 
2. STUDY OBJECTIVES  ................................ ................................ .............................. 35 
2.1. Primary Objective  ................................ ................................ ................................ .......35 
2.2. Secondary Objectives  ................................ ................................ ................................ .35 
2.3. Exploratory Objectives  ................................ ................................ ............................... 35 
3. HYPOTHESIS AND RATIO NALE  ................................ ................................ .......... 36 
3.1. Hypotheses  ................................ ................................ ................................ .................. 36 
3.2. Rationa le ................................ ................................ ................................ ..................... 36 
3.2.1.  Rationale for Study Design  ................................ ................................ ......................... 36 
3.2.2.  Rationale for Dose Selection  ................................ ................................ ...................... 38 
3.3. Benefit -Risk ................................ ................................ ................................ ................ 40 
3.3.1.  Benefit -Risk for Participating in the Study  ................................ ................................ 40 
[IP_ADDRESS].  Benefit  ................................ ................................ ................................ ......................... 40 
[IP_ADDRESS].  Risk ................................ ................................ ................................ ............................. 41 
[IP_ADDRESS].  Benefit -Risk Conclusion  ................................ ................................ ............................. 42 
3.3.2.  Benefit -Risk for Background Treatment  ................................ ................................ ....42 
4. ENDPOINTS  ................................ ................................ ................................ .............. 42 
4.1. Primary and  Secondary Endpoints ................................ ................................ .............. 42 
4.1.1.  Primary Endpoint  ................................ ................................ ................................ ........ 42 
4.1.2.  Secondary Endpoints  ................................ ................................ ................................ ..43 
4.1.3. Exploratory Endpoints  ................................ ................................ ................................ 45 
5. STUDY VARIABLES ................................ ................................ ................................ 47 
5.1. Demographic and Baseline Characteristics  ................................ ................................ 47 
5.2. Efficacy Variables  ................................ ................................ ................................ ......47 
5.3. Safety Variables  ................................ ................................ ................................ .......... 47 
5.4. Pharmacokinetic Variables  ................................ ................................ ......................... 47 
5.5. Immunogenicity Variables  ................................ ................................ .......................... 48 
5.6. Pharmacodynamic and Other Biomarker Variables  ................................ ................... 48 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4 
 
Regeneron Pharmaceuticals, Inc.  Page 6 
 CONFIDENTIAL  6. STUDY DESIGN  ................................ ................................ ................................ .......49 
6.1. Study Description and Duration  ................................ ................................ ................. 49 
6.1.1.  End of Study Definition  ................................ ................................ .............................. 51 
6.2. Planned Interim Analysis  ................................ ................................ ............................ 51 
6.3. Study Committees  ................................ ................................ ................................ .......52 
6.3.1.  Independent Data Monitoring Committee  ................................ ................................ ..52 
7. SELECTION, WITHDRAWA L, AND REPLACEMENT O F PATIENTS  .............. 53 
7.1. Number of Patients Planned  ................................ ................................ ....................... 53 
7.2. Study Population  ................................ ................................ ................................ ......... 53 
7.2.1.  Inclusion Criteria  ................................ ................................ ................................ ........ 53 
7.2.2.  Exclusion Criteria  ................................ ................................ ................................ .......54 
[IP_ADDRESS].  Exclusion Criteria for Part A - Double -Blind Treatment  ................................ ........... 54 
[IP_ADDRESS].  Exclusion Criteria for Part B – Extended Active Treatme nt (and also for 
Entry into Part C for Patients with Uninterrupted Participation in the Study)  ........... 57 
[IP_ADDRESS].  Exclusion Criteria for Patients Re -Entering the Study (for Entry into Part C 
for Patients Who Have Completed Their EOS Visit Prior to Amendment 4)  ............ 57 
7.3. Premature Withdrawal from the Study  ................................ ................................ .......59 
7.4. Replacement of Patients  ................................ ................................ ............................. 59 
8. STUDY TREATMENTS ................................ ................................ ............................ 60 
8.1. Investigational and Reference Treatments  ................................ ................................ ..60 
8.2. Background Treatments  ................................ ................................ .............................. 65 
8.3. Rescue Treatments and Procedures  ................................ ................................ ............ 65 
8.4. Dose Modification and Study Treatment Discontinuation Rules  ............................... 66 
8.4.1.  Dose Modification  ................................ ................................ ................................ ......66 
8.4.2.  Study Drug Discontinuation  ................................ ................................ ....................... 66 
[IP_ADDRESS].  Reasons for Permanent Discontinuation of Study Drug  ................................ ............. 66 
[IP_ADDRESS].  Reasons for Temporary Discontinuation of Study Drug  ................................ ............ 67 
8.5. Management of Acute Reactions  ................................ ................................ ................ 67 
8.5.1.  Acute Injection Reactions  ................................ ................................ ........................... 67 
[IP_ADDRESS].  Systemic Injection Reactions  ................................ ................................ ...................... 67 
[IP_ADDRESS].  Local Injection Site Reactions  ................................ ................................ .................... 68 
8.6. Method of Treatment Assignment  ................................ ................................ .............. 68 
8.7. Blinding  ................................ ................................ ................................ ...................... 68 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4 
 
Regeneron Pharmaceuticals, Inc.  Page 7 
 CONFIDENTIAL  8.8. Emergency Unblinding (Applies to Part A and Part B only)  ................................ .....69 
8.9. Treatment Logistics and Accountability  ................................ ................................ .....69 
8.9.1.  Packaging, Labeling, and Storage  ................................ ................................ .............. 69 
8.9.2.  Supply and Disposition of Treatments  ................................ ................................ .......69 
8.9.3.  Treatment Accountability  ................................ ................................ ........................... 70 
8.9.4.  Treatment Compliance  ................................ ................................ ................................ 70 
8.10.  Concomitant Medications and Procedures  ................................ ................................ .70 
8.10.1.  Prohibited Medications and Procedures  ................................ ................................ .....70 
8.10.2.  Permitted Medications and Procedures  ................................ ................................ ......71 
8.10.3.  Restricted Medications and Procedures during the Follow -Up Period  ...................... 72 
8.11.  Poststudy Treatments and Proce dures  ................................ ................................ ........ 72 
9. STUDY SCHEDULE OF EV ENTS AND PROCEDURES  ................................ ......72 
9.1. Schedule of Events  ................................ ................................ ................................ .....72 
9.1.1.  Footnotes for the Schedule of Events Tables  ................................ ............................. 84 
[IP_ADDRESS].  Footnotes for Table 1  ................................ ................................ ................................ ..84 
[IP_ADDRESS].  Footnotes for Table 2  ................................ ................................ ................................ ..86 
[IP_ADDRESS].  Footnotes for Table 3  ................................ ................................ ................................ ..87 
[IP_ADDRESS].  Footnotes for Table 4  ................................ ................................ ................................ ..88 
9.1.2.  Early Termination Visit  ................................ ................................ .............................. 89 
9.1.3.  Unscheduled Visits  ................................ ................................ ................................ .....89 
9.1.4.  Re-Entry Visit  ................................ ................................ ................................ ............. 89 
9.2. Study Procedures  ................................ ................................ ................................ ........ 90 
9.2.1.  Procedures Performed Only at the Screening/Baseline Visit  ................................ .....90 
9.2.2.  Efficacy Procedures  ................................ ................................ ................................ ....90 
[IP_ADDRESS].  Patient -, Caregiver -, or Clinician -Reported Outcome Mea sures  ................................ 90 
[IP_ADDRESS].  Body Weight and Height  ................................ ................................ ............................ 92 
[IP_ADDRESS].  Endoscopy with EoE -EREFS, Biopsies, and Imaging  ................................ ............... 92 
9.2.3.  Safety Procedures  ................................ ................................ ................................ .......94 
[IP_ADDRESS].  Vital Signs  ................................ ................................ ................................ .................. 94 
[IP_ADDRESS].  Physical Examination  ................................ ................................ ................................ .94 
[IP_ADDRESS].  Laboratory Testing  ................................ ................................ ................................ ......94 
9.2.4.  Drug Concentration and Measurements  ................................ ................................ .....96 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4 
 
Regeneron Pharmaceuticals, Inc.  Page 8 
 CONFIDENTIAL  9.2.5.  Immunogenicity Measurements and Samples  ................................ ............................ 96 
9.2.6.  Pharmacodynamic and Exploratory Biomarker Procedures  ................................ .......96 
[IP_ADDRESS].  Type 2 Inflammatory and Disease -Related Biomarkers  ................................ ............. 96 
[IP_ADDRESS].  EoE Diagnostic Panel and Type 2 Inflammation Transcriptomics  ............................ 97 
9.2.7.  Biopsy Analyses  ................................ ................................ ................................ ......... 97 
9.2.8.  Future Biomedical Research (Optional)  ................................ ................................ .....97 
[IP_ADDRESS].  Pharmacogen omic Analysis (Optional)  ................................ ................................ ......[ADDRESS_24023]/Ethics Committee, 
and Investigators  ................................ ................................ ................................ .......104 
11. STATISTICAL PLAN ................................ ................................ .............................. 105 
11.1.  Statistical Hypothesis  ................................ ................................ ................................ 105 
11.2.  Justification of Sample Size ................................ ................................ ...................... 105 
11.3.  Analysis Sets  ................................ ................................ ................................ ............. 106 
11.3.1.  Efficacy Analysis Sets for Part A  ................................ ................................ ............. 106 
11.3.2.  Safety Analysis Set for Part A  ................................ ................................ .................. 106 
11.3.3.  Analysis Set for Parts B and C  ................................ ................................ ................. 106 
11.3.4.  Pharmacokinetic Analysis Sets for All Parts  ................................ ............................ 106 
11.3.5.  Immunogenicity Analysis Sets for All Parts  ................................ ............................ 106 
11.4.  Statistical Methods  ................................ ................................ ................................ ....106 
11.4.1.  Patient Disposition  ................................ ................................ ................................ ....107 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4 
 
Regeneron Pharmaceuticals, Inc.  Page 9 
 CONFIDENTIAL  11.4.2.  Demography and Baseline Characteristics  ................................ ............................... 107 
11.4.3.  Efficacy Analyses  ................................ ................................ ................................ .....107 
[IP_ADDRESS].  Primary Efficacy Analysis  ................................ ................................ ........................ 107 
[IP_ADDRESS].  Secondary Efficacy Analysis  ................................ ................................ .................... 108 
11.4.4.  Control of Multiplicity  ................................ ................................ .............................. 109 
11.4.5.  Safety Analysis  ................................ ................................ ................................ ......... 109 
[IP_ADDRESS].  Adverse Events  ................................ ................................ ................................ ......... 110 
[IP_ADDRESS].  Other Safety  ................................ ................................ ................................ .............. 110 
[IP_ADDRESS].  Treatment Exposure  ................................ ................................ ................................ ..111 
[IP_ADDRESS].  Treatment Compliance  ................................ ................................ .............................. 111 
11.4.6.  Pharmacokinetics  ................................ ................................ ................................ ......111 
[IP_ADDRESS].  Analysis of Drug Concentration Data  ................................ ................................ .......111 
11.4.7.  Analysis of Immunogenicity Data  ................................ ................................ ............ 111 
11.4.8.  Analysis of Pharmacodynamic and Exploratory Biomarker Data  ............................ 112 
11.4.9.  Timing of Statistical Analysis  ................................ ................................ .................. 112 
11.5.  Statistical Considerations Surrounding t he Premature Termination of a Study  .......113 
12. QUALITY CONTROL AND QUALITY ASSURANCE  ................................ .......114 
12.1.  Data Management and Electronic Systems  ................................ .............................. 114 
12.1.1.  Data Management  ................................ ................................ ................................ .....114 
12.1.2.  Electronic Systems  ................................ ................................ ................................ ....114 
12.2.  Study Monitoring  ................................ ................................ ................................ ......114 
12.2.1.  Monitoring of Study Sites  ................................ ................................ ......................... 114 
12.2.2.  Source Document Requirements  ................................ ................................ .............. 115 
12.2.3.  Case Report Form Requirements  ................................ ................................ .............. 115 
12.3.  Audits and Inspections  ................................ ................................ .............................. 115 
12.4.  Study Documentation  ................................ ................................ ............................... 116 
12.4.1.  Certification of Accuracy of Data  ................................ ................................ ............. 116 
12.4.2.  Retention of Records  ................................ ................................ ................................ 116 
13. ETHICAL AND REGULATO RY CONSIDERATIONS  ................................ ........ 117 
13.1.  Good Clinical Practice Statement  ................................ ................................ ............. 117 
13.2.  Informed Consent  ................................ ................................ ................................ .....117 
13.3.  Patients Confidentiality and Data Protection  ................................ ............................ 118 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24024]/Ethics Committee  ................................ ......................... 118 
13.5.  Clinical Study Data Transparency  ................................ ................................ ............ 118 
14. PROTOCOL AMENDMENTS  ................................ ................................ ................ 119 
15. PREMATURE TERMINATIO N OF THE STUDY OR CL OSE -OUT OF A 
SITE  ................................ ................................ ................................ .......................... 119 
15.1.  Premature Termination of the Study  ................................ ................................ ......... 119 
15.2.  Close -out of a Site  ................................ ................................ ................................ ....119 
16. CONFIDENTIALITY  ................................ ................................ .............................. 120 
17. FINANCING AND INSURA NCE  ................................ ................................ ........... 120 
18. PUBLICATION POLICY  ................................ ................................ ........................ 120 
19. REFERENCES  ................................ ................................ ................................ ......... 121 
20. INVESTIG ATOR’S AGREEMENT  ................................ ................................ ........ 126 
SIGNATURE [CONTACT_11715] ’S RESPONSIBLE OFFIC ERS ................................ ................... [ADDRESS_24025] OF TABLES  
Table  1: Schedule of Events - Screening and Double -Blind Treatment Period  ....................... 73 
Table  2: Schedule of Events - Extended Active Treatment Period and Re -Entry Visit  ........... 75 
Table  3: Schedule of Events - Early Termination Visits and Unscheduled Visits  ................... 78 
Table  4: Schedule of Events Open -Label Extension Part C (OLE) and EOS Schedule 
of Events  ................................ ................................ ................................ ..................... [ADDRESS_24026] OF FIGURES  
Figure  1: Study Flow Diagram  ................................ ................................ ................................ ...49 
Figure  2: Endoscopy/Biopsy Procedure Flow Diagram  ................................ ............................. 50 
Figure  3: Part A Weight -Tiered Dosing Regimens  of Study Drug  ................................ ............ 63 
Figure  4: Part B Weight -Tiered Dosing Regimens of Study Drug  ................................ ............ 64 
Figure  5: Part C (OLE) Weight -Tiered Dosing Regimens of Study Drug  ................................ .65 
 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 11 
 CONFIDENTIAL  AMENDMENT HISTORY  
Amendment 4  
The primary purpose of this protocol  amendment is  for the 
addition of a long -term extension  period  to evaluate the long -term safety of dupi[INVESTIGATOR_24718] 1 to less than 12 years of age with active eosinophilic esophagitis. This long -term 
extension period will add up to 108 weeks of open -label treatment or until dupi[INVESTIGATOR_24719] (whichever comes first).  
Description of Change  Rationale  Section Changed  
Added an open -label 
extension (OLE) period 
(Part C) for patients 
completing Part B of this 
study.  Patients who have 
completed their end of study 
(EOS) visit prior to 
amendment 4 will be re -
evaluated for eligibility at a 
Re-Entry visit for 
participation in the open -
label exte nsion period (Part 
C) and Safety Follow -up 
period.  To assess the long -term safety of repeat doses 
of dupi[INVESTIGATOR_24720].  
 
 Clinical Study Protocol 
Synopsis: Objectives , Study 
Design, Study Duration, 
Treatments , Endpoints, 
Statistical Plan  
Section  2.2  Secondary 
Objectives  
Section  3.2.1  Rationale for 
Study Design  
Section  3.2.2  Rationale for Dose 
Selection  
Section  4.1.2  Secondary 
Endpoints  
Section  4.1.3 Exploratory 
Endpoints  
Section  6.1 Study Description 
and Duration  
Figure  1 Study Flow Diagram  
Section  [IP_ADDRESS]  Exclusion 
Criteria for Part B – Extended 
Active Treatment (and also for 
Entry into Part C for Patients 
with Uninter rupted Participation 
in the Study)  
Section  8.1 Investigational and 
Reference Treatments  
Figure  5 Part C (OLE) Weight -
Tiered Dosing Reg imens of 
Study Drug  
Section  8.7 Blinding  
Table  2 Schedule of Events - 
Extended Active Treatment 
Period and Re -Entry Visit  
Table  4 Schedule of Events 
Open -Label Extension Part C 
(OLE) and EOS Schedule  of 
Events  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 12 
 CONFIDENTIAL  Description of Change  Rationale  Section Changed  
Section  [IP_ADDRESS]  Footnotes for 
Table 2 ; Footnotes 12 and 13  
Section  [IP_ADDRESS]  Footnotes for 
Table 4  
Section  9.1.4  Re-Entry Visit  
Section  [IP_ADDRESS]  Endoscopy with 
EoE-EREFS, Biopsies, and 
Imaging  
Section  [IP_ADDRESS]  Secondary  
Efficacy Analysis  
Section  11.4.5  Safety Analysis  
Section [IP_ADDRESS]  Adverse Events  
Section  11.4.9  Timing of 
Statistical Analysis  
Updated the Risk section  The language has been updated with recently 
identified risks of dupi[INVESTIGATOR_24721]  [IP_ADDRESS]  Risk 
Changed study drug dosing 
for OLE Part C  
• Changed the weight 
threshold from ≥60 
kg to ≥40 kg to 
receive  mg 
QW in Part C of the 
study  
• Changed the dosing 
regimen for the 
≥5kg to <15kg 
weight tier from 
mg Q2W to 
mg Q3W  The pharmacokinetics of dupi[INVESTIGATOR_24722] 6 years 
of age. The weight tier is being modified to 
align with the US -approved dose (  mg 
QW) for adult and adolescent patients with 
EOE weighing at least 40 kg to ensure 
patients <12 years of age and ≥40 kg achieve 
exposures that were associated with clinically 
meaningful and significant symptomatic 
improvement in adults and adolescents.  
Similarly, the dose for patients ≥5 to <15 kg 
in Part C has been adjusted from  mg 
Q2W to  mg Q3W in order to provide 
exposures closer to that was observed in adult 
and adolescents with EOE receiving  mg 
QW. Clinical Study Protocol 
Synopsis : Treatment  
Section  3.2.2  Rationale for Dose 
Selection  
Section  8.1 Investigational and 
Reference Treatments  
Figure  5 Part C (OLE) Weight -
Tiered Dosing Regimens of 
Study Drug  
 
Updated the exploratory 
objective and endpoints 
assessing the impact of 
dupi[INVESTIGATOR_24723] .  Clinical Study Protocol 
Synopsis: Objectives and 
Endpoints  
Section  2.2 Secondary 
Objectives  
Section  4.1.2  Secondary 
Endpoints  
Section  4.1.3  Exploratory 
Endpoints  
Section  [IP_ADDRESS]  Secondary 
Efficacy Analysis  
 
Updated language in the 
confidentialy statement  To align with Regeneron’s recent Clinical 
Study Protocol template  Title Page  
Minor editorial corrections  For clarification  Throughout  the protocol  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 13 
 CONFIDENTIAL   
Amendment 3  
The primary purpose of this protocol amendment is  for 
including an exit interview, to add symptom/sign -free days based on the PESQ -P or PESQ -C as a 
secondary endpo int, and to update the definition of primary estimand for patients treated with 
corticosteroids.  
Description of Change  Rationale  Section Changed  
Added a new procedure for an exit 
interview at Week 16/Visit 8 with 
caregivers. Patients aged ≥8 to <12 
years  old (determined at the time of 
screening visit 1) may also join a 
portion of the exit interview.   
 
 Clinical Study Protocol Synopsis: 
Procedures and Assessments  
Table  1 Schedule of Events - Screening 
and Double -Blind Treatment Period  
Section  [IP_ADDRESS]  Footnotes for Table  1, 
footnote number 16  
Section  [IP_ADDRESS].6  Exit Interview  
Added seco ndary endpoints for 
assessing sign -free days as reported in 
the PESQ -C for all patients and 
symptom -free days as reported in the 
PESQ -P for patients aged ≥8 to <12 
years.   
 
 Clinical Study Protocol Synopsis: 
Secondary Endpoints  
Section  4.1.2  Secondary Endpoints  
Section  [IP_ADDRESS].1  Pediatric EoE 
Sign/Symptom Questionnaire (PESQ)  
Updated the primary estimand 
intercurrent event for initiation of 
treatment with systemic corticosteroids 
to include use of systemic and/or 
swallowed topi[INVESTIGATOR_11930].   
 
 Section  [IP_ADDRESS]  Primary Efficacy Analysis  
Added a physical examination at the 
baseline visit   
 
 Table  1 Schedule of Events - Screening 
and Double -Blind Treatment Period  
Added tippi[INVESTIGATOR_24724] -MI approach as sensitivity 
analyses for primary endpoint and 
removed the singl e imputation method 
for sensitivity analyses.   
 
 Clinical Study Protocol Synopsis: Analysis 
Methods  
Section  [IP_ADDRESS]  Primary Efficacy Analysis  
Section  [IP_ADDRESS]  Secondary Efficacy 
Analysis  
Added that the randomization 
stratification of baseline weight gr oup 
may be pooled for CMH test adjusting 
for the randomization stratification 
factor (baseline weight group)  The randomization 
stratification of baseline 
weight group may be 
pooled to ensure 
sufficient sample size of 
each stratum.  Clinical Study Protocol S ynopsis: 
Statistical Plan  
Section  [IP_ADDRESS]  Primary Efficacy Analysis  
Editorial changes to statistical analysis 
sections  To improve clarity.  Clinical S tudy Protocol Synopsis: 
Statistical Plan  
Section  11 Statistical Plan  
Section  11.1 Statistical Hypothesis  
Section  11.2 Justification of Sample Size  
Section  11.4.1  Patient Disposition  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 14 
 CONFIDENTIAL  Description of Change  Rationale  Section Changed  
Section  [IP_ADDRESS]  Adverse Events  
Section  [IP_ADDRESS]  Treatment Exposu re 
Section  11.4.7  Analysis of 
Immunogenicity Data  
  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24027] the new study 
design. There will be 90 patients 
randomized in a 1:1:1 ratio to receive 
either dupi[INVESTIGATOR_24725] a higher (N=30) or 
lower (N=30) exposure dose arm, o r 
matching placebo (N=30). There will 
be high exposure and low exposure 
placebo groups to match dupi[INVESTIGATOR_24726]/web response system 
(IVRS/IWRS) re quirement document. 
High exposure and low exposure 
placebo groups will be pooled for 
analysis.  
Part A:  
Higher exposure regimens:  
•  mg once every 2 weeks (Q2W) 
in patients who weigh ≥5  kg to <15 
kg 
•  mg Q2W in patients who 
weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who 
weigh ≥30 kg to <60 kg  
Lower  exposure regimens:  
•  mg once every 4 weeks (Q4W) 
in patients who weigh ≥5  kg to <15 
kg 
•  mg Q4W in patients who 
weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who 
weigh ≥30 kg to <60 kg  
Part B  
Higher exp osure regimens:   
 
 Clinical Study Protocol Synopsis: Site 
Locations , Study Design, Population, 
Treatments, Statistical Plan  
Section  3.2.1   Rationale  for Study Design  
Section  3.2.2  Rationale for Dose Selection  
Section  6.1 Study Description  and 
Duration  
Section  7.1  Number of Patients Planned  
Section  8 Study Treatments  
Section  8.1 Investigational  and Reference 
Treatments  
Figure  3 Part A Weight -Tiered  Dosing 
Regimens of Study Drug  
Figure  4 Part B Weight -Tiered Dosing 
Regimens of Study Drug  
Section  8.6 Method of Treatment 
Assignment  
Section  8.7 Blinding  
Section  [IP_ADDRESS]  Footnotes  for Table 1, 
footnote # 6  
Section  [IP_ADDRESS]  Footnotes  for Table 2, 
footnote # 4b  
Section  11.1 Statistical Hypothesis  
Section  11.2 Justification  of Sample Size  
Section  11.4.4  Control of Multiplicity  
Section  11.4.5  Safety Analysis  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 16 
 CONFIDENTIAL  Description of Change  Rationale  Section Changed  
•  mg Q2W in patients who 
weigh ≥5  kg to <15 kg  
•  mg Q2W in patients who 
weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who 
weigh ≥30 kg to <60 kg  
•  mg QW in patients who weigh 
≥60 kg  
Lower exposure regimens:  
•  mg Q4W in patients who 
weigh ≥5  kg to <15 kg  
•  mg Q4W in patients who 
weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who 
weigh ≥30 kg to <60 kg  
•  mg Q2W in patients who 
weigh ≥60 kg  
Added re -assignment of weight tiered 
extended active treatment during Part 
B if weight has increased to a larger 
weight  tier at visit 12 / week 32.  To maintain appropriate 
study drug exposure 
throughout  the extended 
active treatment period.  Clinical  Study Protocol Synopsis: 
Treatments  
Section  3.2.2  Rationale for Dose Selection  
Section  8.1 Investigational and Reference 
Treatments  
Figure  4 Weight -Tiered Dosing  Regimens 
of Study  Drug – Part B  
Section  [IP_ADDRESS]  Footnotes for Table 2, 
footnote  #4b 
Updated language referring to a “36 -
week open -label treatment period” to 
be “36 -week extended active treatment 
period”.  For clarification that 
treatment will remain 
blinded for the extended 
active treatment period.  Clinical Study  Protocol Synopsis: Study 
Design, Statistical Plan  
Section  2.3 Exploratory  Objectives  
Section  6.1 Study Description  and 
Duration  
Section  11.3.1  Efficacy Analysis  Sets 
Section  [IP_ADDRESS]  Adverse Events  
Section  11.4.9  Timing of Statistical  
Analysis   
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 17 
 CONFIDENTIAL  Description of Change  Rationale  Section Changed  
Updated text referring to an ongoing 
phase 3 trial evaluating t he efficacy 
and safety of dupi[INVESTIGATOR_24727] (R668 -
EE-1774) to clarify that Part A has 
now been completed.  To align with the most 
recent data from R668 -
EE-1774.  Clinical Study Protocol  Synopsis : 
Statistical Plan  
Section  1 Introduction  
Section  3.2.1   Rationale  for Study Design  
Section  3.2.2  Rationale for Dose Selection  
Section  [IP_ADDRESS]  Benefit  
Section  [IP_ADDRESS]  Benefit -Risk Conclus ion 
Section  11.[ADDRESS_24028] ( AESIs) definitions and 
adverse drug reactions (ADRs) for the 
dupi[INVESTIGATOR_24728].  For program consistency 
 
 and to 
align with the most 
recent  Investigator’s 
Brochure . Section  [IP_ADDRESS]   Risk 
Section  10.1.3  Events that Require 
Expedited  Reporting to Sponsor  
Added a pri mary estimand for the 
primary endpoint . To implement a concept 
estimand in our primary 
analysis approaches  for 
the primary endpoints  
based on ICH E9 (R1).  Section  [IP_ADDRESS]  Primary  Efficacy Analysis  
Minor editorial corrections . For clarification . Throughout  the protocol.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 18 
 CONFIDENTIAL  Amendment 1  
The purpose of this amendment is to add the Pediatric Eosinophilic Esophagitis Symptom Score 
(PEESSv2.0 - caregiver version) questionnaire as a secondary endpoint and to change the Pediatric 
EoE Sign/Symptom Questionnaire (PESQ -Caregiver and PESQ -Patient) q uestionnaires from 
exploratory to secondary endpoints. Additionally, the Eosinophilic Esophagitis -Endoscopic 
Reference Score  (EoE -EREFS) procedure was revised to allow for centralized reading and scoring. 
Minor changes were made to clarify inclusion and ex clusion criteria. Other minor changes were 
made  for general clarification. The following table 
outlines the changes made to the protocol and the rationale.  
Description of Change  Brief Rationale  Section # and  Name  
[CONTACT_25074] 16 and added 
corresponding secondary objectives and 
endpoints.   
 
 Clinical Study Protocol Synopsis: 
Objectives, Endpoints, Procedures and 
Assessments, Statistical Plan  
Section  2.2 Secondary Objectives  
Section  3.2.1  Rationale for Study Design  
Section  4.1.2  Secondary Endpoints  
Section  5.2 Efficacy Variables  
Table  1 Schedule of Events - Screening 
and Double -Blind Treatment Period  
Table  2: Schedule of Events - Extended 
Active Treatment Period and 12 -Week 
Follow -Up Period  
Table  3: Schedule of Events - Early 
Termination Visits and Unscheduled Visits  
Section  [IP_ADDRESS]  Footnotes for Table 1, 
footnote # 15  
Section  [IP_ADDRESS]  Footnotes for Table 2, 
footnote # 11  
Section  11 Footnotes for Table 3, footnote 
#6  
Section  [IP_ADDRESS].5  Pediatric Eosinophilic 
Esophagitis Symptom Score (PEESS)  
Section  19 References  
Updated the PESQ -Caregive r and PESQ -
Patient questionnaires from exploratory 
objectives and endpoints to secondary 
objectives and endpoints.  
  
 
 Clinical Study Protocol Synopsis: 
Objectives, Endpoints, Statistical Plan  
Section  2.2 Secondary Objectives  
Section  2.3 Exploratory objectives  
Section  3.2.1  Rationale for Study Design  
Section  4.1.2  Secondary Endpoints  
Section  4.1.3  Exploratory Endpoints  
Section  [IP_ADDRESS]  Secondary Efficacy 
Analysis  
Revised the EoE -EREFS procedure to 
allow fo r centralized reading and scoring To minimize inter -
rater variability for 
this endpoint.  Clinical Study Protocol Synopsis: 
Procedures and Assessments  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 19 
 CONFIDENTIAL  Description of Change  Brief Rationale  Section # and  Name  
[CONTACT_25075] v ideo is the preferred 
method of imaging.  Section  [IP_ADDRESS]  Footnotes for Table 1,  
footno tes #2 and # 9 
Section  [IP_ADDRESS]  Footnotes for Table 2, 
footnote # 7 
Section  11 Footnotes for Table 3, footnote 
#4 
Section  [IP_ADDRESS]  Endoscopy with EoE -
EREFS and Biopsies, and Imaging  
Section  [IP_ADDRESS]  Secondary Efficacy 
Analysis  
Clarified the endpoints and variables for 
transcriptome sequencing for analyzing 
RNA expression of EoE and type 2 
inflammation.  For clarification.  
 Clinical Study Protocol Synopsis: 
Objectives, Endpoints, Procedures and 
Assessments  
Section  2.2 Secondary Objectives  
Section  4.1.2  Secon dary Endpoints  
Section  [IP_ADDRESS]  EoE Diagnostic Panel and 
Type 2 Inflammation Transcriptomics  
Section  [IP_ADDRESS]  Secondary Efficacy 
Analysis  
Section  19 References  
Added endpoints at week 52 
(corresponding to assessments already 
included in this study) for all  secondary 
and exploratory endpoints (except for the 
PEESSv2.0 caregiver version).  For clarification  Clinical Study Protocol Synopsis: 
Endpoint(s)  
Section  4.1.2  Secondary Endpoints  
Section  4.1.3  Exploratory Endpoints  
Added laboratory collection and analysis 
of blood samples at visit 5/week 4 and 
visit 12/week 32 for chemistry and 
hematology.   
 
 Table  1 Schedule of Events - Screening 
and Double -Blind Treatment Period  
Table  2: Schedule of Events - Extended 
Active Treatment Period and 12 -Week 
Follow -Up Period  
Updated the permanent discontinuation of 
study drug for severe abnormal laboratory 
value requirements for neutrophil count, 
platelet count, alanine aminotransferase 
(ALT), and aspartate aminotransf erase 
(AST) values to include all events of these 
severe laboratory values, regardless of 
assessment of relatedness to study drug.   
 
 Section  [IP_ADDRESS]  Reasons for Permanent 
Discontinuation of Study Drug  
 
Updated inclusion criteria to add the 
requirement for completion of at least 8 
out of 14 days of eDiary for the PESQ -C 
prior to baseline/visit  3.  For clarification.  Section  7.2.1  Inclusion Criteria, criterion 
#5 
Section  [IP_ADDRESS]  Patient -, Caregiver -, or 
Clinician -Reported Outcome Measures  
Clarified exclusion criterion #13 for the 
double -blind period and prohibited 
medications to allow for one -time steroid 
use with the anesthetic preparation (not For clarification.  Section  [IP_ADDRESS]  Part A – Double -Blind 
Treatment , criterion # 13 
Section  8.10.1  Prohibited Medications and 
Procedures  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 20 
 CONFIDENTIAL  Description of Change  Brief Rationale  Section # and  Name  
[CONTACT_25076]) used during the endoscop y 
procedures.  
Clarified the requirement that all pre -
dosing procedures (including endoscopy 
with biopsy) at the schedul ed visit 8/week 
[ADDRESS_24029] occur prior to dosing with Part 
B/Extended Active Treatment study drug.  For clarification.  Section  [IP_ADDRESS]  Footnotes for Table 2, 
footnote # 1 
Minor changes in language.  For clarification and 
consistency 
throughout the 
protocol.  Section  [IP_ADDRESS]  Footnotes for Table 1, 
footnote # 14 
Section  11 Footnotes for Table 3, footnote 
#5 
Section  [IP_ADDRESS].3  Global Impression of 
Change (GIC)  
Section  [IP_ADDRESS]  Laboratory Testing  
Section  9.2.8  Future Biomedical Research 
(Optional)  
Section  [IP_ADDRESS]  Pharmacogenomic Analysis 
(Optional)  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 21 
 CONFIDENTIAL  CLINICAL STUDY PROTO COL SYNOPSIS  
Title  A Randomized, Double -Blind, Placebo -Controlled Study to Investigate the 
Efficacy and Safety of Dupi[INVESTIGATOR_24729] 30 global study sites  
To be determined  
Objectives  Primary:  
To demonstrate the efficacy of dupi[INVESTIGATOR_24730] (EoE) based on 
histologic improvement meeting validated histologic criteria.  
Secondary:  
• To demonstrate the efficacy of dupi[INVESTIGATOR_24731] 16 weeks of treatment as 
assessed by [CONTACT_24953] u sing 
the Eosinophilic Esophagitis -Endoscopic Reference Score (EoE -
EREFS) and histologic abnormalities as measured by [CONTACT_24954] (EoE -HSS)  
• To evaluate the safety, tolerability, and immunogenicity of dupi[INVESTIGATOR_24732] 16 wee ks in pediatric patients with active EoE  
• To evaluate the effects of dupi[INVESTIGATOR_24733] 2 inflammation  
• To study the effects of dupi[INVESTIGATOR_24734] 2 inflammation gene 
expression signature  
• To evaluate the concentration -time profile of functional dupi[INVESTIGATOR_24735]  
• To assess efficacy of long -term (up to 160 weeks) dupi[INVESTIGATOR_24736]  
• To assess the impact of dupi[INVESTIGATOR_24737] -label extension 
period of the study  
• To assess safety, tolerability, and immunogenicity of long -term (up to 
160 weeks) dupi[INVESTIGATOR_24736]  
• To evaluate the impact of dupi[INVESTIGATOR_24738]  
• To assess the impact of dupi[INVESTIGATOR_24739] -label extension period of 
the study  
Study Design  This is a phase 3, multicenter, randomized, 3 -part, double -blind, placebo -
controlled study investigating the efficacy, safety, tolerability, 
pharmacokinetics  (PK), and immunogenicity of dupi[INVESTIGATOR_24718] (ages ≥1 year to <12 years) with active EoE. This study consists of 
a screening period of up to 85  days, a double -blind 16 -week treatment period 
(Part A), a 36 -week extended active treatment period (Part B), a 108 -week 
open -label extension period (Part C) and a 12 -week follow -up period.  
After patients and their legal parents/legal guardians provide informed 
assent (as appropriate) and informed consent, patients will b e assessed for 
study eligibility.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24030] a documented diagnosis of EoE that may be 
established either by a prior historical biopsy, as demonstrated by 
[CONTACT_24955][INVESTIGATOR_24740] (peak eosinophils/high power field 
≥15 e os/hpf) (400×) from at least [ADDRESS_24031] 8 weeks of treatment with an approved proton pump inhibitor (PPI) 
regimen, or by [CONTACT_24956] 8 weeks of PPI 
[INVESTIGATOR_24741] d uring the screening period, which 
demonstrates ≥15 eos/hpf) (400×) from at least 2 of the 3 esophageal regions 
(proximal, mid, and distal).  
Patients who are on PPIs during the screening period to rule out EoE disease 
management with this treatment, and are  eligible to enroll in the study, have 
the choice either to remain on the PPI [INVESTIGATOR_24742] (visit 3); they then must remain off of 
PPIs during the entire study.  
Biopsies will be obtained by [CONTACT_24957] 2, the week 16 
visit, the week 52 visit, the week 100 visit, the week 160 visit, or 
immediately prior to start of rescue medication or procedures (only applies 
to rescue medication and/or procedures that occur before the week 52 vis it). 
A total of at least 9 mucosal pi[INVESTIGATOR_24743] 3 esophageal regions: 3 proximal, 3  mid, and 3  distal. Two 
samples from each region will be used for histology (needed for study 
inclusion criteria, as well as endp oint assessment) and the other for RNA 
extraction.  
Patients may receive concomitant medications (except for prohibited 
medications specified in the protocol body) as needed, at the discretion of 
the investigator, while continuing study treatment. Frequency  of use and 
type of product will be documented.  
Efficacy, safety, laboratory assessments, and samples for assay of 
concentration of functional dupi[INVESTIGATOR_24744] -drug 
antibody (ADA) response to dupi[INVESTIGATOR_12458], as well as research samples, wi ll be 
performed or collected at specified time points throughout the study 
according to Schedule of Events specified in the protocol body.  
Study Duration  The duration of the study for a patient is up to [ADDRESS_24032] to follow -up (ie, the study 
patient can no longer be contact[CONTACT_19379]).  
Population   
 Sample Size:  Approximately 90 patients  
 Target Population:  Eligible patients for this study consist of patients with active EoE.  
Key inclusion criteria include the following:  
• Males and females aged ≥1 year to <12 years.  
• A documented diagnosis of EoE by [CONTACT_24958], as demonstrated by [CONTACT_24955][INVESTIGATOR_24740] 
(peak eosinophil count ≥15 eos/hpf) (400×) from at least [ADDRESS_24033] 
been performed within 2 weeks of the date of discontinuation.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 23 
 CONFIDENTIAL  If a prior (documented) endoscopic biopsy meeting these criteria is 
not available (or no prior biopsy is ava ilable), patients who meet 
other clinical and laboratory eligibility criteria will undergo 
treatment with a PPI [INVESTIGATOR_24745] 8 weeks during the 
screening period before their baseline endoscopy/biopsies.  
• Baseline endoscopic biopsies with a demonstr ation on central reading 
of intraepi[INVESTIGATOR_24740] (peak eosinophil count ≥15 
eos/hpf) in at least 2 of the 3 biopsied esophageal regions (proximal, 
mid, or distal).  
• History (by [CONTACT_24959]) of symptom(s) determined by 
[CONTACT_24960] (eg, abdominal pain, chest pain, 
acid reflux, food regurgitation, dysphagia, vomiting, or refusal to eat) 
in the month prior to screening.  
Treatments   
 Study Drug  
 Dose/Route/Schedule:  Dupi[INVESTIGATOR_24746] A:   Part A is the double -blind, placebo -controlled portion of the study. 
Subcutaneous (SC) administration at tiered dosing regimens based on body 
weight at baseline.  
Higher exposure dupi[INVESTIGATOR_24747] (Part A):  
•  mg once every 2 weeks (Q2W) in patients who  weigh ≥5  kg to <15 
kg 
•  mg Q2W in patients who weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who weigh ≥30 kg to <60 kg  
Lower exposure dupi[INVESTIGATOR_24747] (Part A):  
•  mg once every 4 weeks (Q4W) in patients who weigh ≥5  kg to <15 
kg  
•  mg Q4W in patients who weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who weigh ≥30 kg to <60 kg  
NOTE: In Part A, patients will receive dupi[INVESTIGATOR_24748] Q2W or Q4W with matching placebo alternating with dupi[INVESTIGATOR_24749] Q2W for both groups for regimen -blinding 
purposes per treatment assignment.  
Part B:   Part B is the extended active treatment portion of the study. All 
patients (Part A active and placebo) will receive dupi[INVESTIGATOR_24750]  8 (week 16, end of double -blinded treatment period or start 
of extended treatment period) per the higher and lower exposure group to 
which they were assigned at randomization. If weight tier has increased at 
visit 12 / week 32, patients will be re -assigned to an extended active 
treatment regimen based on weight tiered dosing regimens below.  
Higher exposure dupi[INVESTIGATOR_24747] (Part B):  
•  mg Q2W in patients who weigh ≥5  kg to <15 kg  
•  mg Q2W in patients who weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who we igh ≥30 kg to <60 kg  
•  mg QW in patients who weigh ≥60 kg  
Lower exposure dupi[INVESTIGATOR_24747] (Part B):  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 24 
 CONFIDENTIAL  •  mg Q4W in patients who weigh ≥5  kg to <15 kg  
•  mg Q4W in patients who weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who weigh ≥30 kg to <60 kg  
•  mg Q2W in patients who weigh ≥60 kg  
NOTE: In Part B, study drug or matching placebo will be administered Q2W 
for all patients in <60 kg weight -groups and QW for all patients in ≥60 kg 
weight -groups. Patients will receive alternating doses of dupi[INVESTIGATOR_24751] Q2W for patients <60 kg assigned to Q4W regimens or QW for 
patients ≥60 kg assigned to Q2W regimens for regimen -blinding purposes.  
Part C:   Part C is the open -label extension portion of the study. All patients 
(Part C) will receive higher exposure dupi[INVESTIGATOR_24752] 17 (week 52, end of extended active treatment period) or start 
of open -label period (for re -entry  patients). All patients who received lower 
exposure dupi[INVESTIGATOR_24753] B will be re -assigned to higher exposure 
dupi[INVESTIGATOR_24754] -label (Part C) period.  If weight 
increases place a patient into a higher weight tier at visit 1 7 / week 52 (or 
start of open -label period for re -entry patients) or at specified in -clinic visits 
in Part C, the patient will be re -assigned to an open -label treatment regimen 
based on the weight tiered dosing regimen specified below.  
Higher exposure dupi [INVESTIGATOR_24747] (Part C):  
•  mg Q3W in patients who weigh ≥5  kg to <15 kg  
•  mg Q2W in patients who weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who weigh ≥30 kg to <40 kg  
•  mg QW in patients who weigh ≥40 kg  
NOTE: In Part C, only active study drug (du pi[INVESTIGATOR_12458]) will be administered.  
No matching placebo will be administered in Part C. The weight -based 
dosing regimens will be as listed above.  
For Part C only: Patients located in a country where dupi[INVESTIGATOR_24755] p atients ≥12 years old will 
be provided treatment with study drug until they are both (1) at least 12 years 
of age and (2) weigh at least [ADDRESS_24034] an end of treatment 
visit at the next scheduled study visit upon meeting both criteria, followed 
by [CONTACT_24961] -up visit after 12 weeks.  
 Placebo  
 Route/Schedule:  Matching dupi[INVESTIGATOR_24756] -weight tier and exposure 
regimen (Part A and B only).  
Placebo for Part A: Dose matching placebo Q2W or alternating with 
dupi[INVESTIGATOR_12458] Q4W so the frequency will be Q2W for both groups for regimen -
blinding purposes in Part A.   
Placebo for Part B: Dose matching placebo alternating with dupi[INVESTIGATOR_12458] Q2W 
or Q4W so the fr equency will be Q2W for the weight -based groups <60kg 
and QW for the weight -based group of ≥[ADDRESS_24035] 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 25 
 CONFIDENTIAL   Dose/Route/Schedule:  the choice either to remain on the PPI [INVESTIGATOR_24742]; they t hen must remain off of PPIs 
during the entire study.  
Endpoints   
 Primary:  Proportion of patients achieving peak esophageal intraepi[INVESTIGATOR_24757] ≤6 eos/hpf (400×) at week 16  
 Secondary:  Secondary Efficacy Endpoints for Part A and B:  
• Proportion of patients achieving peak esophageal intraepi[INVESTIGATOR_24758] <15 eos/hpf at week 16  
• Percent change in peak esophageal intraepi[INVESTIGATOR_24759] 
(eos/hpf) from baseline to week 16  
• Absolute change in mean EoE grade score from t he EoE -HSS from 
baseline to week 16  
• Absolute change in mean EoE stage score from the EoE -HSS from 
baseline to week 16  
• Absolute change in EoE -EREFS from baseline to week 16  
• Change from baseline in the type 2 inflammation transcriptional 
signature [CONTACT_25077] w eek 16  
• Change from baseline to week 16 in the proportion of days with 1 or 
more EoE signs as measured by [CONTACT_24962]/Symptom 
Questionnaire -caregiver version (PESQ -C) (for patients aged ≥1 to <12 
years)  
• Number of sign -free days during the 14 -day period preceding week 16 
as measured by [CONTACT_24963] -C (for patients aged ≥1 to <12 years)  
• Change from baseline to week 16 in the proportion of total segments 
within a day (night, morning, afternoon, evening) with 1 or more EoE 
signs as measured by [CONTACT_24964] -C (fo r patients aged ≥1 to <12 years)  
• Change from baseline to week 16 in the proportion of days with 1 or 
more EoE symptoms as measured by [CONTACT_24964] -P (patient version) (for 
patients aged ≥8 to <12 years)  
• Number of symptom -free days during the 14 -day period precedin g 
week 16 as measured by [CONTACT_24963] -P (patient version) (for patients aged 
≥8 to <12 years)  
• Change from baseline to week 16 in the proportion of total segments 
within a day (night, morning, afternoon, evening) with 1 or more EoE 
symptoms as measured by [CONTACT_24964] -P (for patients aged ≥8 to <12 years)   
• Change in total score from baseline to week 16 as measured by [CONTACT_24965] (PEESS) v2.0 - 
caregiver version questionnaire (for patients aged ≥1 to <12 years)  
• Normalized Enrichmen t Scores (NES) for the relative change from 
baseline to week 16 in the EoE diagnostic panel (EDP) transcriptome 
signature  
• NES for the relative change from baseline to week 16 in the type 2 
inflammation transcriptome signature  
[CONTACT_25078]:  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 26 
 CONFIDENTIAL  o All the above primary and secondary endpoints (except for 
PEESSv2.0 - caregiver version questionnaire) assessed at 
week 16 will be assessed at week 52 as secondary endpoints 
and summarized with descriptive statistics based on the 
treatment assignment in the double -blind treatmen t period as 
well as the extended active treatment assignment for patients 
previously in the placebo group.  
• Change from baseline in body weight for age percentile at week 52  
• Change in body mass index for age z -score from baseline to week 52 
for patients ≥2 years of age  
• Change in weight for age z -score from baseline to week 52  
• Change in weight for height z -score from baseline to week 52  
 
Secondary Efficacy Endpoints for Part C (open -label extension period) 
only: 
• Proportion of patients achieving peak esophageal intraepi[INVESTIGATOR_24758] ≤6 eos/hpf (400×) at week 100 and week 160  
• Proportion of patients achieving peak esophageal intraepi[INVESTIGATOR_24758] <15 eos/hpf at week 100 and week 160  
• Percen t change in peak esophageal intraepi[INVESTIGATOR_24759] 
(eos/hpf) from baseline to week 100 and week 160  
• Absolute change in mean EoE grade score from the EoE -HSS from 
baseline to week 100 and week 160  
• Absolute change in mean EoE stage score from the EoE-HSS from 
baseline to week 100 and week 160  
• Absolute change in EoE -EREFS from baseline to week 100 and week 
160 
• Normalized Enrichment Scores (NES) for the relative change from 
baseline to week 100 and 160 in the EoE diagnostic panel (EDP) 
transcriptome signature  
• NES for the relative change from baseline to week 100 and week 160 
in the type 2 inflammation transcriptome signature  
• Change in total score from baseline to week 160 as measured by [CONTACT_24966]2.0 - caregiver version questionnaire  
• Proportion of pat ients (with food elimination diet regimens at baseline) 
that have a re -introduction of a previously eliminated food group by 
[CONTACT_5875] 100 and by [CONTACT_5875] 160  
• Change from baseline in body weight for age percentile up to week 160  
• Change in body mass index for age z-score for patients ≥2 years of age 
from baseline to up to week 160  
• Change in weight for age z -score from baseline to up to week 160  
• Change in weight for height z -score from baseline to up to week 160  
Safety Endpoints (Parts A, B, and C):  
• Incidence of tre atment -emergent adverse events (TEAEs) during the 
16-week double -blind treatment period  
• Incidence of TEAEs during the 36 -week extended treatment period  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 27 
 CONFIDENTIAL  • Incidence of TEAEs during the 108 -week open -label extension period  
• Incidence of treatment -emergent serious adverse events (SAEs) during 
the 16 -week double -blind treatment period  
• Incidence of treatment -emergent SAEs during the 36 -week extended 
treatment period  
• Incidence of treatment -emergent SAEs during the 108 -week open -label 
extension period  
• Incidence of treatment -emergent adverse events of special interest 
(AESIs) during the 16 -week double -blind treatment period  
• Incidence of treatment -emergent AESIs during the 36 -week extended 
treatment period  
• Incidence of treatment -emergent AESIs during the 108 -week o pen-
label extension period  
• Incidence of TEAEs leading to permanent discontinuation of study 
treatment during the 16 -week double -blind treatment period  
• Incidence of TEAEs leading to permanent discontinuation of study 
treatment during the 36 -week extended tr eatment period  
• Incidence of TEAEs leading to permanent discontinuation of study 
treatment during the 108 -week open -label extension period  
• Incidence of treatment -emergent ADA responses and titer during the 
16-week double -blind, 36 -week extended treatment pe riods, and 108 -
week open -label extension period  
Clinical Pharmacology Endpoint:  
• Concentrations of functional dupi[INVESTIGATOR_24760]-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 28 
 CONFIDENTIAL  Procedures and Assessments  Efficacy procedures and assessments  include the following:  
• Endoscopy with EoE -EREFS and biopsies  
o EoE-EREFS imaging will be performed to assess the presence 
of exudates, edema, furrows, esophageal rings, and strictures. 
EoE-EREFS imaging will be read and scored by a  qualified 
centralized reading center. For all endoscopi[INVESTIGATOR_014], the 
investigators will assess minor esophageal features including 
mucosal inflammatory and remodeling features.  
o Esophageal endoscopy with biopsies: After EoE -EREFS 
imaging has been completed, biop sies will be obtained for 
histologic assessments including intraepi[INVESTIGATOR_24761] -HSS (EoE grade score and EoE stage score). 
Biopsies will be evaluated by [CONTACT_24967] a central 
pathology laboratory who will be blinded to treatment 
assignment.  
• Patient -, caregiver -, or clinician -reported outcome measures  
o Pediatric EoE Sign/Symptom Questionnaire (PESQ), 
including a patient version (PESQ -P) and caregiver version 
(PESQ -C) 
o Pediatric EoE Impact Scale (PEIS), including a patient version 
(PEIS -P) and a caregiver version (PEIS -C) 
o Global Impression of Change (GIC), including a patient 
version (GIC -P), a caregiver version (GIC -C), and a clinician 
version (GIC -Clin)  
o Global Impression of Severity (GIS), including a patient 
version (GIS -P), a ca regiver version (GIS -C), and a clinician 
version (GIS -Clin)  
o The Pediatric Eosinophilic Esophagitis Symptom Score 
(PEESS) v2.0 - caregiver version questionnaire  
o Telephone exit interview  
• Body weight and height (or length for patients <2 years of age); b ody 
mass index will be programmatically calculated based on the weight 
and height /length  data 
Safety and tolerability procedures and assessments  include vital signs, 
physical examination, clinical laboratory tests, ADA assessment, and 
clinical evaluations. Patients will be asked to report all adverse events  (AEs) 
experienced from the time of informed assent/consent until their last study 
visit.  
Pharmacokinetics : Serum samples will be collected at specified time points 
for assay of functional dupi[INVESTIGATOR_24762].  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 29 
 CONFIDENTIAL  Statistical Plan  Sample Size:  
The planned sample size is a total of approximately 90 patients (1:1:1 ratio, 
30 patients in the higher dupliumab exposure group and 30 patients in the 
lower dupi[INVESTIGATOR_24763] 30 patients in the placebo group).  
The assumptions used in sample siz e calculation were based on Part A of 
the R668 -EE-1774 study (a phase 3 study for adults and adolescents with 
EoE) and R668 -EE-1324 (a phase 2 study for adults with EoE). In Part A of 
the R668 -EE-1774, the proportions of patients achieving peak esophageal 
intraepi[INVESTIGATOR_24764] ≤6 eos/hpf at week 24 were 59.5% and 
5.1% for dupi[INVESTIGATOR_24765], respectively. The proportions of 
adolescent patients achieving peak esophageal intraepi[INVESTIGATOR_24757] ≤6 eos/hpf at week 24 were 36.4% and  0% for dupi[INVESTIGATOR_24766], respectively. The treatment group difference observed in 
adolescents was approximately 36.5%. In the R668 -EE-1324 study, the 
proportions of patients achieving histologic response at week 12 were 65% 
and 0% for dupi[INVESTIGATOR_24767] p lacebo, respectively. The efficacy of dupi[INVESTIGATOR_24768] 12. Based upon the similarity of 
pathophysiology and expected similarity of response between adults and 
pediatric patients, a similar proportion of responders at week [ADDRESS_24036] as the higher exposure 
dupi[INVESTIGATOR_24769]. The treatment group difference observed in the R668 -EE-
1774 Part A adolescents was assumed for t he sample size calculation for this 
study in children aged ≥1 year to <12 years. It is estimated that with a total 
number of 90 patients (30  patients in the higher exposure dupi[INVESTIGATOR_24769], 
30 patients in the lower exposure dupi[INVESTIGATOR_24769], and 30 patients  in the 
placebo group), at the 2 -sided 5% significance level using Fisher’s exact 
test, the study can provide 95% power to detect a treatment difference of 
35.6% in the proportion of histologic responders (ie, patients achieving peak 
esophageal intraepi[INVESTIGATOR_24770] ≤6  eos/hpf) at week 16 between 
placebo (5.1%) and each dupi[INVESTIGATOR_24771] (40.7%).  
Efficacy Analysis Set  for Part A : 
The full analysis set (FAS) includes all randomized patients in Part A; it is 
based on the treatment allocated (as randomized). Efficacy endpoints in 
Part A (double -blind treatment period) will be analyzed using the FAS.  
Safety Analysis Set  for Part A : 
The safety analysis set (SAF) includes all randomized patients who received 
any Part A study drug; it is  based on the treatment received (as treated). 
Treatment compliance/administration and all clinical safety variables will 
be analyzed using the SAF.  
Analysis Set for Part B and Part C  
For efficacy and safety analys es of Parts B and C, only a subset of SAF for 
Part A will be included, which is defined as those patients who received at 
least 1 dose of corresponding Part B or/and C study drug .  
Analysis Methods : 
Primary Efficacy Analysis in Part A  
The primary analysis of proportion of patients achieving a hist ologic 
response of peak esophageal intraepi[INVESTIGATOR_24759] ≤6 eos/hpf at 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 30 
 CONFIDENTIAL  week  16 will be analyzed using the Cochran -Mantel -Haenszel (CMH) test 
to assess the difference in the proportion of responders in the full analysis 
set (FAS), adjusting for t he randomization stratification factor (baseline 
weight group). The randomization stratification of baseline weight group 
may be pooled to ensure the sufficient sample size of each stratum.  
To account for use of rescue treatment, patients will be considere d as non -
responder after rescue treatment.  
If a patient has missing value for the histological response (peak esophageal 
intraepi[INVESTIGATOR_24759] ≤6 eos/hpf) at week 16, the patient will be 
classified as a non -responder at week 16.  
Sensitivity ana lyses will assess alternative methods to impute missing data. 
The sensitivity analyses will include a tippi[INVESTIGATOR_24772] a 
worst observation carried forward -Multiple Imputation (WOCF -MI) 
approach.  
Subgroup analyses (eg, by [CONTACT_8497]) may be performed. Details will be 
specified in the SAP.  
Secondary Efficacy Analysis  
Analysis of secondary endpoints in Part A  
Secondary efficacy endpoints that measure binary responses (eg, peak 
esophageal intraepi[INVESTIGATOR_24759] <15 eos/hpf) will be analyzed in 
the same fashion as the primary endpoint.  
Continuous secondary efficacy endpoints will be analyzed using an analysis 
of covariance (ANCOVA) model for the FAS with treatment group, 
randomization stratification factor, and relevant baseline measu rement as a 
covariate included in the model.  
For continuous efficacy data that are scheduled to be measured repeatedly 
post-baseline up to week 16, missing data will be imputed by [CONTACT_24968] -
mixture approach. Specifically, the WOCF -Multiple Imputation (WO CF-
MI) approach.  
Analysis of secondary endpoints in Part B  
Efficacy data in Part B will be summarized with descriptive statistics for 
treatment received in Part B as well as by [CONTACT_24969] A 
(double -blind treatment period). No missing values  will be imputed.  
Analysis of secondary endpoints in Part C  
Efficacy data in Part C will be summarized with descriptive statistics for 
treatment received in Part C as well as by [CONTACT_7238] A (double -
blind treatment period) and Part B (extended  active treatment period). No 
missing values will be imputed.  
Multiplicity Consideration  
For multiplicity adjustment, a hierarchical procedure will be used to control 
the overall Type -1 error rate at 0.05 for the primary endpoint and the 
selected secondary  efficacy endpoints for each dupi[INVESTIGATOR_24773] A only. Each hypothesis will be formally tested only 
if the preceding one is significant at the 2 -sided 0.05  significance level. The 
primary endpoint will be tested for the higher e xposure dupi[INVESTIGATOR_24774]-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24037] and then for the lower exposure dupi[INVESTIGATOR_24769]. The hierarchical 
order of the selected secondary endpoints will be specified in the SAP.  
Part B and Part C data will be summarized using descriptive statistics, there 
is no mult iplicity issue.  
Safety Analysis  
Safety analysis will be based on the safety analysis set (SAF) in the 
respective study part . This includes reported TEAEs and other safety data 
(ie, clinical laboratory evaluations and vital signs). A descriptive summary 
of safety results will be presented by [CONTACT_24970].  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 32 
 CONFIDENTIAL  1. INTRODUCTION  
Eosinophilic esophagitis (EoE) is a chronic inflammatory disease characterized by [CONTACT_24971]; it is thought to  be triggered by [CONTACT_24972] 2 immune response to food allergens (Furuta, 2017 ) (Liacouras, 2011 ). Chronic 
esophageal inflammation leads to progressive remodeling, stricture formation, and fibrosis 
(Hirano, 2014 ) (Schoepfer, 2014 ) (Dellon, 2018 ). Although considered a rare disease, the current 
preva lence is estimated at 22.7 people per 100,000 worldwide (Arias, 2016 ) and appears to be on 
the increase  (Dellon, 2014 ). There is a low rate of spontaneous remission. Eosinophilic esophagitis 
has been reported in all ages; h owever, most cases are in children and adults younger than 50 years 
(Dellon, 2014 ) (Dellon, 2007 ) (Kapel, 2008 ) (Liacouras, 2011 ) (Spergel, 2009 ). Children under 
the age of 18 represent approximately 30% of the EoE patient population (Dellon, 2014 ) 
(Prasad,  2009 ). In the United Sates, based on data from in surance claims within the Truven 
MarketScan database, the estimated number of patients between newborn and [ADDRESS_24038] been consistently reported, with 
males affected 3 to 4 times more of ten than females (Dellon, 2014 ), but there are no gender -related 
differences in the clinical symptoms (Kapel, 2008 ) (Prasad, 2009 ) (Veerappan, 2009 ) (Hruz, 2011 ) 
(Ally, 2015 ). The prim ary clinical manifestations of EoE in both adults and children over 10 years 
of age are dysphagia and food impaction  (Lucendo, 2017 ). Clinical features in younger children 
are non -specific in nature and vary significantly depending on the patient’s age and ability of the 
patient to describe salient symptoms. Infants and toddlers are more likely to present with feeding 
difficulties, vomiting, or r egurgitation with the potential for failure to thrive, whereas school -age 
children present with complaints of abdominal pain and heartburn (Iuliano, 2018 ). Older children 
with symptomatic EoE may also modify their dietary and eating behavior by [CONTACT_24973], 
chewing thoroughly, eating slowly, drinking copi[INVESTIGATOR_24775], and avoiding food consistencies that 
stick, which is highly suggestive of dysphagia, as this is a feeding behavior reported in adults as 
an attempt to prevent esophageal food impa ctions (Iuliano, 2018 ). These symptoms lead to 
substantially impaired quality of life (DeBrosse, 2011 ) (Falk, 2014 ) (Straumann, 2008 ) 
(Straumann, 2003 ). Endoscopic findings are related to the inflammation in the esophagus and 
consist of fixed or transient concentric rings, longitudinal furrows, white plaques, reduced mucosal 
vascularity, fragile or crepe -like mucosa, and strictures. Furrows and whi te plaques are likely the 
most common finding in children. Rings are not common in children, although rings and furrows 
are the most commonly seen in nearly half of adult patients (Singla, 2016 ). Some patients 
(particularly pediatric) may present with a normal -appearing esophagus, but still have 
histologically active EoE (Wechsler, 2018 ).  
Current standard of care for EoE consists of food -elimination diets, off -label proton pump 
inhibitors (PPIs), off -label use of swallowed topi[INVESTIGATOR_11930], and esophageal dilation. 
Esophageal dilation is frequently utilized to relieve dysphagia sy mptoms caused by [CONTACT_24974]. Since strictures do not occur as commonly in children, esophageal dilation is not as 
commonly performed in children with EoE as compared to in adults with EoE (Chehade, 2018 ) 
(Furuta, 2017 ). The standard therapi[INVESTIGATOR_24776], relapse after 
therapy cessation, and adverse effects on quality of life. These limitations lead to a significant 
unmet need for new treatments targeting key pathways driving EoE inflammation (Spergel, 2012 ) 
(Greuter, 2017 ). Dietary modification is a s tandard treatment for patients with EoE. Diets 
eliminating specific foods can be effective in a significant percentage of patients; however, 30% 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 33 
 CONFIDENTIAL  to 40% of patients do not have resolution of disease with dietary modification (Nhu, 2019 ). Proton 
pump inhibitors can result in histologic remission in approximately 50% of patients with EoE  
(Lucendo, 2017 ) with the remaining patients unresponsive. Swallowed topi[INVESTIGATOR_24777]; 
however, they are not  uniformly effective and may be associated with local fungal infections, as 
well as a risk of growth suppression and hypothalamic –pi[INVESTIGATOR_2117] –adrenal axis suppression 
following systemic absorption (Golekoh, 2016 ), limiting their use to short term. Emergency 
endoscopy for prolonged and/or painful food impaction, and esophageal dilation to provide relief 
from strictures, are associated with a risk of severe esophageal injury and do not alter the 
underlying pathogenesis or progression of the disease. To date, the [LOCATION_002] (US) Food and 
Drug Administration (FDA) has not approved pharmacologic therapi[INVESTIGATOR_24778] 12 years; the European Commission has approved budesonide oral dispersible tablets for the 
treatment of EoE in adults, but no approved medicinal product is available for the treatment of 
EoE in children in the European Union (EU).  
Growing evidence suggests that a type [ADDRESS_24039] ays an important pathogenic role in 
the development of EoE in genetically susceptible individuals. Food allergens permeate an 
impaired esophageal epi[INVESTIGATOR_24779]  2 
helper T cells (Th2) increase tissue levels of type 2 cytokines, such as interleukin (IL) -5, IL -13, 
and IL -4. These cytokines are responsible for driving eosinophil recruitment and activation. 
Several genes in the epi[INVESTIGATOR_24780] ( FLG ), desmogelin 1 
(DSG1 ), and the esophagus -specific esophagin (small proline -rich protein 3 [ SPRR3 ]), are down -
regulated by [CONTACT_24975] 2 cytokines with resultant epi[INVESTIGATOR_24781] (Blanchard, 2007 ) 
(Blanchard, 2010 ) (Wen, 2013 ). Eotaxin -3 (chemokine [C -C motif] ligand 26 gene [CCL26]) is a 
potent eosinophil chemoattractant which is highly regulated by [CONTACT_8668] -13 and IL -4, and variants in the 
gene are associated with increased EoE risk; it is 1 of the top upregulated genes in esophage al 
pi[INVESTIGATOR_24782]  (Blanchard, 2006 ) (Sherrill, 2014 ). Upon 
activation, eosinophils can secrete a variety of pro -inflammatory cytokines and chemokines or 
degranulate, releasing preformed granules containing cationic and cytotoxic proteins that are 
injurious to the tissues. While EoE involves an eosinophil -predominant inflammat ion, there is 
evidence to suggest that other immune cells, such as mast cells, basophils, and invariant natural 
killer T cells also mediate the inflammation (Straumann, 2012 ) (O'Shea, 2018 ).  
Dupi[INVESTIGATOR_24783] a human monoclonal immunoglobulin G4 (IgG4) antibody (Ab) that inhibits IL -4 
and IL -13 signaling by [CONTACT_24976] I L-4 receptor alpha (IL -4Rα) subunit shared by 
[CONTACT_24977] -4 and IL -13 receptor complexes. Blocking IL -4Rα with dupi[INVESTIGATOR_24784] -4 and IL -13 
type 2 cytokine -induced responses, including the release of pro -inflammatory cytokines, 
chemokines, and immunoglobul in E (IgE) (Hamilton, 2014 ). Additionally,  preclinical data 
demonstrate that treatment with dupi[INVESTIGATOR_24785]. 
Dupi[INVESTIGATOR_12458] (brand name [CONTACT_25079][INVESTIGATOR_24786]®) is approved in the US and EU for the treatment of adult 
and adolescent patients aged 12 years and older with ato pic dermatitis (AD). Dupi[INVESTIGATOR_24787] -on maintenance treatment for adults and adolescents (age 12 
and older) with moderate -to-severe asthma with an eosinophilic phenotype or with oral 
corticosteroid -dependent asthma; it is approved in the EU for severe asthma with type 2 
inflammation characterized by [CONTACT_24978]/or raised fractional exhaled nitric 
oxide (FeNO) in patients who are inadequately controlled with a high -dose inhaled  corticosteroid 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24040] for maintenance treatment. Dupi[INVESTIGATOR_24788] (CRSwNP).    Dupi[INVESTIGATOR_24789] [ADDRESS_24041] 40 kg, with eosinophilic esophagitis (EoE) . 
Dupi[INVESTIGATOR_24790] a phase 2, multicenter, double -blind, 
randomized, placebo -controlled study (R668 -EE-1324), where it demonstrated s ubstantial 
improvements in clinical, histologic, and endoscopic aspects of the disease (Hirano, 2019a ). In the 
dupi[INVESTIGATOR_24769], Straumann Dys phagia Index Patient -Reported Outcome scores were reduced by 
a mean value of 3.0 at week 10, compared with a mean reduction of 1.3 in the placebo group 
(P=.0304). At week 12, dupi[INVESTIGATOR_24791] a 
mean 86.8  eos/high power field (hpf) (reduction of 107.1  %, P  <.0001 vs placebo), and the 
endoscopic reference score was reduced by 1.6 (P=.0006 vs placebo). Dupi[INVESTIGATOR_24792], with safety data generally consistent with other dupi[INVESTIGATOR_24793] (Hirano, 2019b ). 
These results support pursuing further development of dupi[INVESTIGATOR_24794], 
adolescent, and pediatric patients. As such, a phase 3 trial evaluating the efficacy and safety of 
dupi[INVESTIGATOR_24795] (R668 -EE-1774) was initiated. The co -
primary endpoint for the adult and adolescent trial includes both a validated symptom 
measurement utilizing the dysphagia symptom questionnaire (DSQ) and histologic evaluation.  
R668 -EE-1774 Part A met both of its co -primary endpoints in symptomatic (dysphagia) and 
histological response, as well as all key secondary endpoints in histologic, endoscopic, and 
molecular (transcriptomic) domains for patients treated with dupi[INVESTIGATOR_24796]. 
R668 -EE-[ADDRESS_24042], treatment with dupi[INVESTIGATOR_24797] Q2W did not meet the co -primary 
endpoint of  symptomatic improvement but demonstrated statistically significant improvement in 
the co -primary endpoint for histological response. Further, dupi[INVESTIGATOR_24797] Q2W demonstrated 
a similar magnitude in response as  mg QW for other secondary histologic, en doscopic, and 
molecular (transcriptomic) endpoints.  
Histological and molecular evidence suggest that the disease has the same underlying pathogenesis 
in different age groups and responds similarly to swallowed topi[INVESTIGATOR_24798] (Straumann, 2012 ). Therefore, for the pediatric trial, where sympto ms are more 
heterogeneous, success of the trial will be determined by [CONTACT_24979]; however, symptom 
assessments will be evaluated through exploratory endpoints.  
The R668 -EE-1877 phase 3 Part A study met its primary endpoint (proportion of patients with 
peak eosinophil count ≤6/high power field [hpf] in esophageal biopsy tissue) for both higher and 
lower exposure dupi[INVESTIGATOR_24799] 16 (p -values < 0.0001). Additionally, as part of a 
prespecified exploratory analysis, the dupi[INVESTIGATOR_24800] 16.  Safety results from 
R668 -EE-[ADDRESS_24043] 40 kg.  
Additional background information on the study drug and development program can be found in 
the Investigator’s Brochure.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 35 
 CONFIDENTIAL  2. STUDY OBJECTIVES  
2.1. Primary Objective  
To demonstrate the effic acy of dupi[INVESTIGATOR_24801].  
2.2. Secondary Objectives  
The secondary objectives of the study are:  
• To demonstrate the efficacy of dup ilumab compared to placebo in pediatric patients 
with active EoE after 16 weeks of treatment as assessed by [CONTACT_24980] -Endoscopic 
Reference Score (EoE -EREFS) and histologic abnormal ities as measured by [CONTACT_24954] (EoE -HSS)  
• To evaluate the safety, tolerability, and immunogenicity of dupi[INVESTIGATOR_24802] 16 weeks in pediatric patients with active EoE  
• To evaluate the effects of dupi[INVESTIGATOR_24803] 2 inflammation  
• To study the effects of dupi[INVESTIGATOR_24734] 2 inflammation gene expression signature  
• To evaluate the concentration -time profile of functional dupi[INVESTIGATOR_24804]  
• To assess efficacy  of long -term (up to 160 weeks) dupi[INVESTIGATOR_24736]  
• To assess the impact of dupi[INVESTIGATOR_24805] -label extension period of the study  
• To assess safety, tolerability, and immunogenici ty of long -term (up to 160 weeks) 
dupi[INVESTIGATOR_24736]  
• To evaluate the impact of dupi[INVESTIGATOR_24806]  
• To assess the impact of dupi[INVESTIGATOR_24807] -label extension pe riod of the study   
2.3. Exploratory Objectives  
The exploratory objectives of the study are:  
• To explore impact of dupi[INVESTIGATOR_24808] -related quality of life  
• To explore impact of dupi[INVESTIGATOR_24809]  
• To explore impact of dupi[INVESTIGATOR_24810] -blind phase.  
• To conduct exploratory research to study EoE and dupi[INVESTIGATOR_24811], including predictive biomarker discovery and/or valid ation  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 36 
 CONFIDENTIAL  3. HYPOTHESIS AND RATIO NALE  
3.1. Hypotheses  
In pediatric patients (ages ≥1 year to <12 years) with active EoE, dupi[INVESTIGATOR_24812], as measured by [CONTACT_24981]  (assessed by [CONTACT_24982][INVESTIGATOR_24813]-HSS score).  
3.2. Rationale  
3.2.1.  Rationale for Study Design  
This is a randomized, 3 -part, double -blind, placebo -controlled study to evaluate the efficacy and 
safety of dupi[INVESTIGATOR_24814]. Children with active EoE, ages ≥1 year to <12 years, who 
are PPI [INVESTIGATOR_24815] -responsive, will be randomized 1:1:1 to receive either higher exposure 
dupi[INVESTIGATOR_12458] (N=30) or lower exposure dupi[INVESTIGATOR_12458] (N=30) (in a tiered, weight -based dosing sche ma) 
or placebo (N=30) over 16 weeks. In the absence of valid and reliable clinical outcomes assessment 
(COA) tools for symptom assessment, primary efficacy will be assessed by a histological endpoint:  
proportion of patients with histologic remission (≤6 e os/hpf). A total sample size of 90 patients is 
based on the number of patients to inform the primary clinical efficacy histological endpoint and 
to characterize the safety profile of dupi[INVESTIGATOR_24816].  
Rationale for Endpoints  
In 201 7, guidelines on EoE were published to optimize diagnosis and treatment of the condition. 
An extensive literature search was completed with systematic evidence -based reviews. A task 
force of 21 physicians and researchers addressed questions related to EoE.  There was agreement 
among members of the task force that clinical symptoms and signs are variable across age groups; 
however, objectively, the histologic criterion of EoE is at least 15  eos/hpf in esophageal mucosa 
(Lucendo, 2017 ). 
Given the key disease feature of EoE is esophageal dysfunction, and esophageal health is the only 
consistent way to observe treatment difference in children, the proposed primary endpoint in this 
study is th e proportion of patients achieving peak esophageal intraepi[INVESTIGATOR_24764] 
≤6 eos/hpf (400×). It is also a responder endpoint that was significantly improved by [CONTACT_24983][INVESTIGATOR_24817] 2 study R668 -EE-1324 (65.2% responders at week 12) and  is a co -primary 
endpoint in the adult/adolescent phase 3 study R668 -EE-1774. In Part A of this phase 3 study, the 
proportions of patients achieving peak esophageal intraepi[INVESTIGATOR_24764] ≤6 eos/hpf at 
week 24 were 59.5% and 5.1% for dupi[INVESTIGATOR_24818], respectively. The consensus 
recommendation for diagnosis of EoE is peak esophageal intraepi[INVESTIGATOR_24819] 
≥15 eos/hpf. Reduction to ≤6 eos/hpf may be an optimal response threshold for clinical trials, as it 
identified most pati ents who had a combined symptomatic and endoscopic response 
(Dellon,  2007 ). 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24044] 
external reliability and this scoring system is highly re sponsive to treatment  (Collins, 2017 ) 
(Warners, 2018 ). 
The visual EoE esophage al anatomical characteristics will be analyzed based on the EoE -EREFS, 
a validated scoring system for inflammatory and remodeling features of disease using both overall 
scores and scores for each individual characteristic (Hirano, 2013 ). The EoE -EREFS utilizes a 
composite score usi ng standardized methodology to assess clinical signs of EoE disease. The 
proximal and distal esophageal regions will be scored separately; the score for each region ranges 
from 0 to 9 and the overall score ranges from 0 to 18. The major esophageal features  include:  
Edema (absent, present); Rings (absent, mild, moderate, severe); Exudates (absent, mild, severe); 
Furrows (absent, mild, severe); and Stricture (absent, present). Endoscopic findings in EoE have 
been well described and are observed in the vast m ajority of EoE patients, though the type and 
frequency vary by [CONTACT_654]. The EoE -EREFS scoring system has been externally validated to identify 
disease in EoE children and adults, to reflect changes in disease severity after treatment, and it has 
been used in m ultiple clinical trials (Hirano, 2017 ) (Wechsler, 2018 ). 
Other efficacy endpoints, endoscopic analysis of severity by [CONTACT_24984] -EREFS, and EoE -HSS histologic 
response will be collected as secondary efficacy endpoints. In a phase [ADDRESS_24045] with expertise in eosinophilic disorders. This study showed that 
reductions in mean adjusted EoE -HSS grade scores of 31 points and s tage scores of 27 points 
between RPC4046 and placebo were statistically significant after 16 weeks of anti -IL-13 treatment 
in adults with active EoE (Hirano, 2019a ). In R668 -EE-1877 Part A, as part of a prespecified 
exploratory analysis, the dupi[INVESTIGATOR_24820] 16. Given that growth rate and weight 
changes are important efficacy indicators of dupi[INVESTIGATOR_24821], weight 
and growth changes will be assessed as secondary endpoints for the extended active and open label 
extension treatment periods.  
In terms of clinical outcomes, the caregiver -reported versions of the Pediatric EoE Sign/Symptom 
Questionnaire (PESQ -C) and the Pediatric Eosinophilic Esophagitis Symptom Score (PEESSv2.0) 
questionnaire will be used as secondary endpoints. Since patient -reported symptoms are expected 
to be reliable for pediatric patients >8 years of age (Matza, 2013 ), the patient -reported version of 
the PESQ (PESQ -P) will also be used as a secondary endpoint. Finally, health -related quality of 
life (HRQoL) and EoE disease status will be measured as exploratory endpoints using the Pediatric 
EoE Impact Scale (PE IS) and the Global Impression of Severity (GIS) and Global Impression of 
Change (GIC) questionnaires.  
Safety of dupi[INVESTIGATOR_24822] a key question, and therefore safety 
endpoints will also be included as secondary endpoints i n this study. In addition, pharmacokinetics 
(PK) will also be analyzed as a secondary endpoint.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 38 
 CONFIDENTIAL  3.2.2.  Rationale for Dose Selection  
Based on the known safety, efficacy, and PK of dupi[INVESTIGATOR_12458], which has been studied in adults, 
adolescents, and children as young as 6 months of age, the dose regimen to be investigated in this 
study in children with EoE aged ≥1 year to <12 years is weight -based dosing as follows:  
Higher exposure dupi[INVESTIGATOR_24823] A, B, and C (approximates C trough of  mg QW 
regimen in adults):  
•  
 
•  
•  
•  
 
•  
Lower exposure dupi[INVESTIGATOR_24824] A and B (approximates Ctrough of  mg Q2W 
regimen in adul ts): 
•  mg once every 4 weeks (Q4W) in patients who weigh ≥5  kg to <15 kg  
•  mg Q4W in  patients who weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who weigh ≥30 kg to <60 kg  
•  mg Q2W in patients who weigh ≥60 kg (Part B Only)  
NOTE: Patients ≥ 60  kg are excluded from enrollment into Part A, but patients may reach this 
weight tier during the extended active period (Part B) or open label extension period  (Part C). All 
patients will be reassigned a weight -tiered dose for the higher exposure dupi[INVESTIGATOR_24825] n in 
Part C at visit 17 / week 52 (or start of open label period for re -entry patients).  At specified in -
clinic visits in Part C, patients that have increased in body weight to a higher weight tier will be 
re-assigned to an appropriate open -label treatmen t regimen for their corresponding weight.  
During Part A and Part B, patients will receive dupi[INVESTIGATOR_24826], 
Q2W, or Q4W with matching placebo alternating with dupi[INVESTIGATOR_24827] -blinding purposes. Patients will remain within the 
originally assigned higher or lower dosing exposure arm throughout Part A and Part B.   
For Part C, patients will receive the higher exposure dupi[INVESTIGATOR_24828].  No 
matching placebo will be administered in Part C. The doses and regimens of dupi[INVESTIGATOR_24829] -state trough concentrations (C trough) observed in adult patients 
receiving  mg QW for the higher exposure regimen. In order t o achieve similar exposures 
across this broad age range, the doses will be assigned by [CONTACT_24985].   
In adults, dupi[INVESTIGATOR_24830] Q2W were shown to be well tolerated and efficacious in 
patients with asthma, AD and CRSwNP. The  mg QW dose in  adult patients has shown 
significant clinical and histological efficacy in a previous proof -of-concept study (R668 -EE-1324) 
as well as in an on -going study in adolescent and adult patients with EoE (R668 -EE-1774). The 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24046] been observed between healthy subjects or patients with 
asthma, AD, CR SwNP, or EoE.  
The dupi[INVESTIGATOR_24797] Q2W dose is an approved dosing regimen in adult patients with atopic 
dermatitis, chronic rhinosinusitis with nasal polyposis, or asthma (in the US), as well as in 
adolescent patients 12 years of age or older with asthma ( in the US) and adolescents and children 
(≥6 years of age) with atopic dermatitis who weigh ≥60 kg. The weight -tiered pediatric regimen 
of dupi[INVESTIGATOR_24797] Q4W in ≥15 to <30 kg or  mg Q2W in ≥30 to <60 kg was also approved 
in the US in patients ≥6 to <12  years of age with AD and was selected to produce exposures in 
pediatric patients similar to those in adults receiving  mg Q2W. The safety profile also has 
been comparable between adult and pediatric (≥6 to <18 years) patients in AD as well as in asthma  
populations receiving dupi[INVESTIGATOR_24797] Q2W regimen.  
In adults and adolescents with EoE receiving dupi[INVESTIGATOR_24831] Q2W (R668 -EE-1774 
Part B), both regimens significantly improved histologic endpoints relative to placebo, but only 
 mg QW also impr oved dysphagia symptoms. Dupi[INVESTIGATOR_24832] 40 kg.  Given the higher exposure and 
lower exposure dupi[INVESTIGATOR_24833] -state (C trough) observed in adult 
patients receiving  mg QW and Q2W, respectively, the higher exposure regimen will be 
administered in Part C of this study to provide the maximum potential benefit to pediatric patients 
with EoE. Within the higher exposure dupi[INVESTIGATOR_24834], the body wei ght threshold at which 
patients switch from  mg Q2W to  mg QW will be changed from [ADDRESS_24047] 6 years of age and by 
[CONTACT_24986], pediatric patients ≥40 kg will receive the same dupi[INVESTIGATOR_24835] C as approved in the US for adult and adolescent patients with EoE of similar body weight. It 
is expected that pedia tric patients who weigh  ≥[ADDRESS_24048] 6 years of age 
(CDC  Growth  Charts: [LOCATION_002], 2000 ). The dose for patients ≥5 to <15 kg in Part C will also 
be adjusted from  mg Q2W to  mg Q3W for the higher exposure dupi[INVESTIGATOR_24836] a closer approximation of the trough concentrations in adults and adolescents with EOE 
receiving  mg QW.  
From trials in the dupi[INVESTIGATOR_24837] Q2W doses in adult patients with AD  or in adult and adolescent patients with EoE, the 
 mg Q2W regimen has a similar safety profile to that of  m g QW regimen, with the 
exception of a higher incidence of injection site reactions in the  mg QW regimen, which is 
likely associated with more frequent injections with drug substance. No loading dose is proposed 
in this study, consistent with the dosing  regimens being evaluated in the phase 3 study of adult and 
adolescent patients (≥12 years of age) with EoE (R668 -EE-1774).  
Due to the rarity of EoE in children ≥1 year to <12 years, larger studies evaluating multiple dose 
regimens are not feasible. Dupi[INVESTIGATOR_24838] a 
population PK model developed including data collected across multiple studies in pediatric 
patients with AD ≥6 months to <18 years of age. Both the higher and lower exposure regimens 
were selected  to provide steady -state exposures that did not exceed the 95th percentile of maximal 
concentrations (C max) for the  mg QW adult dose, and did not fall below the 5th percentile of 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 40 
 CONFIDENTIAL  Ctrough for the  mg Q2W adult dose.  The subset of patients ≥5 to <15 k g receiving  mg Q3W 
or ≥40 to <60 kg receiving  mg QW in Part C may exhibit  C max values higher than the overall 
adult  mg QW population, but are expected to be within the range of exposures observed for 
adolescents ≥[ADDRESS_24049] been identified, hence the higher C max in these groups is not considered 
to be clinically relevant.  
Enrollment in Part A is limited to patients weighing <60 kg, but it is possible th at patient weight 
may increase above this threshold during the study. Patients weighing ≥60 kg at the time of dose 
assignment at visit 8 / week 16 and/or visit 12 / week 32 or ≥40 kg at visit 17 / week 52 of Part B 
(or at start of open label period for re -entry patients) and/or during specified in -clinic visits for 
Part C of the study will receive regimens equivalent to the reference adult dose(s).  Patients located 
in a country where dupi[INVESTIGATOR_24839] ≥12 years 
old will be provided treatment with study drug until they are both (1) at least 12 years of age and 
(2) weigh at least [ADDRESS_24050] been effective and well tolerated in 
multiple indications in adults and adolescents. For th e higher exposure regimens, these predicted 
Ctrough values are similar to what has been demonstrated to be effective in adult patients with EoE. 
For the lower exposure regimens, the predicted C trough values are similar to what has been 
demonstrated to be e ffective in other type 2 inflammatory indications.  
3.3. Benefit -Risk  
3.3.1.  Benefit -Risk for Participating in the Study  
Recognizing that the “Coronavirus Disease 2019” (COVID -19) pandemic will have an impact on 
the conduct of clinical trials, the sponsor does not inte nd to screen any patients in this study until 
the impact of the COVID -[ADDRESS_24051], see Section  9. 
[IP_ADDRESS].  Benefit  
The efficacy and safety of dupi[INVESTIGATOR_24840] a phase 2, ran domized, 
double -blind, placebo -controlled study (R668 -EE-1324). In the initial phase 2 study, treatment 
with weekly dupi[INVESTIGATOR_24841] (SC) for 12 weeks in patients with EoE reduced 
the frequency and intensity of dysphagia. Improvement in clin ical symptoms was accompanied by 
[CONTACT_24987][INVESTIGATOR_24842], esophageal mucosal inflammation, and improved esophageal distensibility.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 41 
 CONFIDENTIAL  Additionally, data from the ongoing phase 3 randomized, double -blind, placebo -controlled study 
(R668 -EE-1774 -Part A) showed a substantial and statistically significant improvements in clinical, 
endoscopic, and histologic measures of the disease in adult an d adolescent patients treated with 
dupi[INVESTIGATOR_24843] (N=42) versus placebo (N=39) at week 24. R668 -EE-[ADDRESS_24052], treatment 
with dupi[INVESTIGATOR_24797] Q2W did not meet the co -primary endpoint of symptomatic improvement 
but demonstrated statistically significant improvement in the co -primary endpoint for histological 
response. Fu rther, dupi[INVESTIGATOR_24797] Q2W demonstrated a similar magnitude in response as  
mg QW for other secondary histologic, endoscopic, and molecular (transcriptomic) endpoints. 
Dupi[INVESTIGATOR_24844] [ADDRESS_24053] 40 kg, with eosinophilic esophagitis (EoE).  
This is the first time a phase 3 trial with a biologic treatment has reported improvement in patients’ 
ability to swallow food, as reported by a dail y questionnaire.  
The R668 -EE-1877 phase 3 Part A study met its primary endpoint (proportion of patients with 
peak eosinophil count ≤6/high power field [hpf] in esophageal biopsy tissue) for both higher and 
lower exposure dupi[INVESTIGATOR_24799] 16 (p -values < 0.0001). Additionally, as part of a 
prespecified exploratory analysis, the dupi[INVESTIGATOR_24845] 16.  
Although presenting symptoms of EoE may v ary when comparing children to adolescents and 
adults, the underlying disease is thought to be the same. Therefore, the efficacy demonstrated in 
adults and adolescents with EoE who were treated with dupi[INVESTIGATOR_24846] p opulation. Study patients could potentially benefit from dupi[INVESTIGATOR_24736], 
including patients randomized to receive placebo in Part  A, as all patients have the opportunity to 
receive dupi[INVESTIGATOR_24847]  B and open -label exten sion Part C of the 
study.  
[IP_ADDRESS].  Risk  
Dupi[INVESTIGATOR_24848] a favorable safety profile in clinical studies across all approved 
indications. Dupi[INVESTIGATOR_24849] R668 -EE-[ADDRESS_24054] 40 kg.  
The identified adverse drug reactions (ADR) across all indications are Injection S ite Reactions 
(ISRs), Sickness -like Reaction/Serum Sickness and Anaphylactic Reaction. Though serious serum 
sickness and serum sickness -like reactions were observed rarely and only in atopic dermatitis (AD) 
clinical trials; and dupi[INVESTIGATOR_12458] -related anaphylact ic reaction was observed rarely and only in an 
asthma clinical trial, they are considered ADRs across all indications as hypersensitivity is not 
expected to be indication specific. As protein therapeutics, all mA bs are potentially immunogenic. 
Systemic hyp ersensitivity is considered an important identified risk for dupi[INVESTIGATOR_12458].  
Eosinophilia associated with clinical symptoms in asthma patients is an important potential risk, 
based on cases of eosinophilic granulomatosis with polyangiitis and eosinophilic pneu monia 
reported in asthma clinical trials (as well as in adult patients with co -morbid asthma in the 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 42 
 CONFIDENTIAL  CRSwNP development program). These events usually, but not always, may be associated with 
the reduction of oral corticosteroid therapy. A causal association  between dupi[INVESTIGATOR_24850]. The DUPI[INVESTIGATOR_24786]® US Prescribing Information lists upper 
respi[INVESTIGATOR_6014] (composed of several terms including, but not limited to, COVID -19, 
sinusitis, and upper respi[INVESTIGATOR_4352] i nfection) in the 'Adverse Reactions' section for the adult and 
adolescent EoE indication. In the AD clinical studies, Conjunctivitis, Conjunctivitis Allergic, 
Conjunctivitis Bacterial, Blepharitis, Dry Eye, Eye Pruritus, Herpes Simplex (primarily 
mucocutan eous in nature), Eosinophilia and Oral Herpes were identified ADRs. The eye and 
herpes related ADRs appear to be predominantly AD indication specific. Conjunctivitis is also 
considered an ADR for the CRSwNP indication, although it occurred at a lower incid ence in these 
studies than in AD studies. Most events were mild in intensity, transient in nature, and did not 
necessitate treatment discontinuation. In the completed AD studies in children aged [ADDRESS_24055] -marketing setting.  
[IP_ADDRESS].  Benefit -Risk Conclusion  
The safety data available to date across multiple indications, in conjunction with the clinical benefit 
of dupi[INVESTIGATOR_24851] [ADDRESS_24056] to the overall clinical development program is provided in  
the Investigator’s Brochure.  
3.3.2.  Benefit -Risk for Background Treatment  
Proton pump inhibitors are FDA -approved for the short -term treatment in children for healing of 
EoE (CMS, 2013 ). A trial of PPIs prior to endoscopy with biopsy will ensure that pediatric patients 
with EoE who show improvement/resolution in their signs and symptoms of EoE with this 
treatment are appropriately excluded from this trial. Proton pum p inhibitors are generally well 
tolerated, and risks associated with short -term use are minimal. The most common adverse 
reactions seen in pediatric patients are headache, diarrhea, constipation, and nausea. Chronic acid 
suppression can minimize the effect iveness of any medication requiring an acidic environment for 
absorption. Commonly prescribed medications affected by [CONTACT_24988][INVESTIGATOR_24852], 
digoxin, atazanavir, ketoconazole, and iron salts.  
4. ENDPOINTS  
4.1. Primary and Secondary Endpoints  
4.1.1.  Primary Endpoint  
• Proportion of patients achieving peak esophageal intraepi[INVESTIGATOR_24764] 
≤6 eos/hpf (400×) at week 16  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 43 
 CONFIDENTIAL  4.1.2.  Secondary Endpoints  
Secondary Efficacy Endpoints for Part A and B:  
• Proportion of patients achieving peak esophageal intraepit helial eosinophil count of 
<15 eos/hpf at week 16  
• Percent change in peak esophageal intraepi[INVESTIGATOR_24759] (eos/hpf) from 
baseline to week 16  
• Absolute change in mean EoE grade score from the EoE -HSS from baseline to week  16 
• Absolute change in mea n EoE stage score from the EoE -HSS from baseline to week  16 
• Absolute change in EoE EREFS from baseline to week 16  
• Change from baseline in the type 2 inflammation transcriptional signature [CONTACT_25080] 16   
• Change from baseline to week 16 in the proportion of days with 1 or more EoE signs 
as measured by [CONTACT_24962]/Symptom Questionnaire -caregiver version 
(PESQ -C) (for patients aged ≥1 to <12 years)  
• Number of sign -free days during the 14 -day period preceding week 16 as measured 
by [CONTACT_24963] -C (for p atients aged ≥1 to <12 years)  
• Change from baseline to week 16 in the proportion of total segments within a day 
(night, morning, afternoon, evening) with 1 or more EoE signs as measured by [CONTACT_24964] -
C (for patients aged ≥1 to <12 years)  
• Change from baseline to w eek 16 in the proportion of days with 1 or more EoE 
symptoms as measured by [CONTACT_24964] -P (patient version) (for patients aged ≥8 to <12 years)  
• Number of symptom -free days during the 14 -day period preceding week 16 as 
measured by [CONTACT_24963] -P (patient version) (for  patients aged ≥8 to <12 years)  
• Change from baseline to week 16 in the proportion of total segments within a day 
(night, morning, afternoon, evening) with 1 or more EoE symptoms as measured by 
[CONTACT_24964] -P (for patients aged ≥8 to <12 years)   
• Change in total sco re from baseline to week 16 as measured by [CONTACT_24989]2.0 - 
caregiver version questionnaire (for patients aged ≥1 to <12 years)  
• Normalized Enrichment Scores (NES) for the relative change from baseline to week 
16 in the EoE diagnostic panel (EDP) transcriptom e signature  
• NES for the relative change from baseline to week 16 in the type 2 inflammation 
transcriptome signature  
• NOTE:  
− All the above primary and secondary endpoints (except for PEESSv2.0 - caregiver 
version questionnaire) assessed at week 16 will be asse ssed at week 52 as 
secondary endpoints and summarized with descriptive statistics based on the 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 44 
 CONFIDENTIAL  treatment assignment in the double -blind treatment period as well as the extended 
active treatment assignment for patients previously in the placebo group.  
• Change from baseline in body weight for age percentile at week 52  
• Change in body mass index for age z -score from baseline to week 52 for patients  ≥2 
years of age  
• Change in weight for age z -score from baseline to week 52  
•  Change in weight for height z-score from baseline to week 52  
 
Secondary Efficacy Endpoints for Part C (open -label extension period) only : 
• Proportion of patients achieving peak esophageal intraepi[INVESTIGATOR_24764] ≤6 
eos/hpf (400×) at week 100 and week 160  
• Proportion of pati ents achieving peak esophageal intraepi[INVESTIGATOR_24764] 
<15 eos/hpf at week 100 and week 160  
• Percent change in peak esophageal intraepi[INVESTIGATOR_24759] (eos/hpf) from 
baseline to week 100 and week 160  
• Absolute change in mean EoE grade sc ore from the EoE -HSS from baseline to week 
100 and week 160  
• Absolute change in mean EoE stage score from the EoE -HSS from baseline to week 
100 and week 160  
• Absolute change in EoE -EREFS from baseline to week 100 and week 160  
• Normalized Enrichment Scores (N ES) for the relative change from baseline to week 
100 and 160 in the EoE diagnostic panel (EDP) transcriptome signature  
• NES for the relative change from baseline to week 100 and week 160 in the type 2 
inflammation transcriptome signature  
• Change in total sc ore from baseline to week 160 as measured by [CONTACT_24989]2.0 - 
caregiver version questionnaire  
• Proportion of patients (with food elimination diet regimens at baseline) that have a re -
introduction of a previously eliminated food group by [CONTACT_5875] 100 and by [CONTACT_5875] 160 
• Change from baseline in body weight for age percentile up to week 160  
• Change in body mass index for age z -score for patients ≥2 years of age from baseline 
to up to week 160  
• Change in weight for age z -score from baseline to up to week 160  
• Change in weight for height z -score from baseline to up to week 160  
 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 45 
 CONFIDENTIAL  Safety Endpoints (Part A, B, and C):  
• Incidence of treatment -emergent adverse events (TEAEs) during the 16 -week double -
blind treatment period  
• Incidence of TEAEs during the 36 -week extended treatment  period  
• Incidence of TEAEs during the 108 -week open -label extension period  
• Incidence of treatment -emergent serious adverse events (SAEs) during the 16 -week 
double -blind treatment period  
• Incidence of treatment -emergent SAEs during the 36 -week extended treat ment period  
• Incidence of treatment -emergent SAEs during the 108 -week open -label extension 
period  
• Incidence of treatment -emergent adverse events of special interest (AESIs) during the 
16-week double -blind treatment period  
• Incidence of treatment -emergent AESIs during the 36 -week extended treatment 
period  
• Incidence of treatment -emergent AESIs during the 108 -week open -label extension 
period  
• Incidence of TEAEs leading to permanent discontinuation of study treatment during 
the 16 -week double -blind treatment pe riod 
• Incidence of TEAEs leading to permanent discontinuation of study treatment during 
the 36 -week extended treatment period  
• Incidence of TEAEs leading to permanent discontinuation of study treatment during 
the 108 -week open -label extension period  
• Incidenc e of treatment -emergent ADA responses and titer during the 16 -week double -
blind, 36 -week extended treatment periods, and 108 -week open -label extension 
period  
Clinical Pharmacology Endpoint:  
Concentrations of functional dupi[INVESTIGATOR_24853]  
4.1.3.  Exploratory Endpoints  
The exploratory endpoints are:  
• Proportion of patients achieving peak esophageal intraepi[INVESTIGATOR_24764] 
≤1 eos/hpf at week 16  
• Percent change in total score of Pediatric EoE Impact Scale -caregiver version (PEIS -
C) from baseline to week 16 (for caregivers of patients aged ≥1 to <12 years)  
• Percent change in total PEIS -P (patient version) score from baseline to week 16 (for 
patients aged ≥8 to <12 years)  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 46 
 CONFIDENTIAL  • Change in G IC-patient, caregiver, and clinician version score at up to week 52  
• Change in GIS -patient, caregiver, and clinician version score from baseline to up to 
week 160/EOT  
• Change from baseline in body weight for age percentile at week 16  
• Change in body mass inde x for age z -score from baseline to week 16 for patients ≥2 
years of age  
• Change in weight for age z -score from baseline to week 16  
• Change in weight for height z -score from baseline to week 16  
 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24057] demography (eg, age, sex, race, weight, height, etc.), 
EoE disease characteristics, medical history, and medication history for each patient.  
5.2. Efficacy Variables  
The efficacy variables include measurements or scores for individual patients of the following:   
• From the endoscopy with EoE -EREFS and biopsies  procedure: peak esophageal 
intraepi[INVESTIGATOR_24854], score of EoE -HSS (including EoE grade and stage 
scores), and score of EoE -EREFS  
• Patient -, caregiver -, or clinician -reported outcomes:   
− score of the PESQ -P (for patients aged ≥8 to <12 years) a nd the PESQ -C (for 
patients aged ≥1 to <12 years)  
− score of the PEIS -P (for patients aged ≥8 to <12 years) and the PEIS -C (for 
caregivers of patients aged ≥1 to <12 years)  
− score of the GIC -P (for patients aged ≥8 to <12 years), GIC -C (for caregivers of 
patients aged ≥1 to <12  years), and GIC -Clin (for patients aged ≥1 to <12 years)  
− score of the GIS -P (for patients aged ≥8 to <12 years), GIS -C (for caregivers of 
patients aged ≥1 to <12 years), and GIS -Clin (for patients aged ≥1 to <12 years)  
− score of the PEES Sv2.0 - caregiver version (for patients aged ≥1 to <12 years)  
• Measurement of body weight and height or length for patients <2 years of age; body 
mass index will be programmatically calculated based on weight and height/length 
data 
5.3. Safety Variables  
Safety v ariables include recording, measurements, or laboratory test results for individual patients 
of the following: adverse events (AEs); vital signs including heart rate, blood pressure, respi[INVESTIGATOR_11943], and body temperature; physical examination findings; re sults of laboratory tests including 
hematology, blood chemistry, urinalysis, and pregnancy test.  
5.4. Pharmacokinetic Variables  
The PK variable is the concentration of functional dupi[INVESTIGATOR_24855]. These sampling timepoi nts are specified in  Table  1, Table  2, Table  3, and 
Table  4.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 48 
 CONFIDENTIAL  5.5. Immunogenicity Variables  
The immunoge nicity variables are ADA status, titer, neutralizing antibody (NAb) status, and 
time point/visit. Samples in this study will be collected at the clinic visits  specified in  Table  1, 
Table  2, Table  3, and Table  4.  
5.6. Pharmacodynamic and Other Biomarker Variables  
Pharmacodynamic and biomarker variables include laboratory test results for individual patients 
of the following: serum total IgE and eotaxin -3. 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 49 
 CONFIDENTIAL  6. STUDY DESIGN  
6.1. Study Description and Duration  
This is a phase 3, multicenter, randomized, 3 -part, double -blind, placebo -controlled study 
investigating the efficacy, safety,  tolerability, PK, and immunogenicity of dupi[INVESTIGATOR_24718] (ages ≥1  to <12 years) with active EoE.  
Approximately 90 patients will be randomized (1:1:1 ratio for higher exposure dupi[INVESTIGATOR_24769]: 
lower exposure dupi[INVESTIGATOR_24769]: placebo) at appr oximately 30 study sites globally. The dosing 
of the placebo group will be matched with higher exposure and lower exposure dupi[INVESTIGATOR_24856]. The 
details on the randomizatio n will be specified in an interactive voice/web response system 
(IVRS/IWRS) requirement document.  
This study consists of a screening period of up to 85 days, a double -blind 16 -week treatment period 
(Part  A), a 36 -week extended active treatment period (Par t B), a 108 -week open -label extension 
period (Part C) and a 12 -week follow -up period. The open -label extension period (Part C) will add 
up to 108 weeks of open -label treatment or until dupi[INVESTIGATOR_24857] (whichever comes first).      
The study flow diagram is provided in Figure  1. 
Figure  1: Study Flow Diagram  
 
After patients and their legal parents/legal guardians provide informed assent (as appropriate) and 
informed consent, patients will be assessed for study eligibility.  
Patients who have completed their end of study (EOS) visit prior to amendment 4 will be re -
evaluated for eligibility at a Re -Entry visit for participation in the open -label extension period (Part 
C) and Safety Follow -up period ( see Section  [IP_ADDRESS] ). Patients who have entered the safety follow -
up period after completing Part B at the time of amendment 4 approval may immediately enter the 
open -label extension (Part C) without being required to complete an EOS visit prior to enteri ng 
Part C.  
Patients are required to have a documented diagnosis of EoE which may be established either  by 
a prior historical biopsy, as demonstrated by [CONTACT_24955][INVESTIGATOR_24740] (peak 
eosinophils/high power field ≥15  eos/hpf) (400×) from at  least [ADDRESS_24058] 8  weeks of treatment with an approved PPI [INVESTIGATOR_24858], or by [CONTACT_24990] 8 weeks of PPI [INVESTIGATOR_24859], 
which demonstrates  ≥15 eos/hpf) (400×) from at least 2 of the 3 esophageal regions (proximal, 
mid, and distal); if the PPI [INVESTIGATOR_24860], biopsies must occur within 2 weeks of stoppi[INVESTIGATOR_24861]. See Figure  2 for endoscopy/biopsy procedure flow chart.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 50 
 CONFIDENTIAL  Figure  2: Endoscopy/Biopsy Procedure Flow Diagram  
Historical esophageal biopsy showing at least 15 (eos/hpf) after 8-weeks of PPI
[INVESTIGATOR_24862]/Biopsies* at visit 2If other clinical and laboratory eligibility criteria are metYes No
Proceed to Screening Endoscopy/Biopsies* at visit 2
Endoscopy/Biopsies must be performed while on PPI
[INVESTIGATOR_24863] a qualified 
central histology laboratory*
Peak intraepi[INVESTIGATOR_24864] (visit 3)If other clinical and laboratory eligibility criteria are met
8-week trial of PPIs
Note:  the PPI [INVESTIGATOR_24865]
 
* Biopsy specimens from the antrum and duodenum will be obtained in all patients to rule out alternate etiologies. 
All randomized patients found to have stomach and/or duodenal abnormalities at baseline will have follow -up 
stomach and/or duodenal biopsies at week 16, week 52, week 100, and week 160.  
Patients wh o are on PPIs during the screening period to rule out EoE disease management with 
this treatment, and are eligible to enroll in the study, have the choice either to remain on the PPI 
[INVESTIGATOR_24866] ; they then must remain 
off of PPIs during the entire study.  
Biopsies will be obtained by [CONTACT_24991] 2, week 16 visit, week 52, week 100 
and week 160 visits, or immediately prior to start of rescue medication or procedures  (only appli es 
to rescue medication and/or procedures that occur before  the week 52 visit) . A total of at least 9 
mucosal pi[INVESTIGATOR_24867] 3  esophageal regions: 3 proximal, 
3 mid, and 3  distal. Two samples from each region will be used for histology (needed for study 
inclusion criteria, as well as endpoint assessment) and the others for RNA extraction. Biopsies will 
be used for exploratory research to study EoE, dupi[INVESTIGATOR_24868], and to identify or 
validate predictiv e biomarkers (efficacy and/or safety). Exploratory analyses of the biopsies may 
include but are not limited to immunohistochemistry [IHC] and RNA sequencing (or other 
methods for assessing RNA expression and RNAscope).  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24059] occur within 6 months of the screen failure.  
Patients may receive concomitant medications (except for prohibited medications specified in 
Section  8.10.1 ) as needed, at the discretion of the investigator, while continuing study treatment. 
Frequency of use and type of product will be documented.  
Efficacy, safety, laboratory assessments, and samples for a ssay of concentration of functional 
dupi[INVESTIGATOR_24869], as well as research samples, will 
be performed or collected at specified time points throughout the study according to the Schedule  
of Events in Table  1, Table  2, Table  3, and Table  4. 
NOTE: If there are restrictions to the clinical study as a result of the COVID -[ADDRESS_24060] the visit schedule, convert in -person visits to telephone contacts, and 
postpone study procedures until the next available in clinic study visit. It is necessary that the 
randomization visit (visit 3), the first visit of Part B and the first visit of Part C occur in the clinic. 
Endoscopi[INVESTIGATOR_24870] [ADDRESS_24061] to follow -up (ie, the study patient can no longer be contact[CONTACT_24992]).  
6.2. Planned Interim Analysis  
No interim analysis is planned for this study.  
The primary a nalysis may be performed once all patients in the study have completed the 16 -week 
double -blind treatment period in Part A as specified in the protocol (week 16 visit or earlier for 
those patients who are withdrawn prematurely from the study). If performed , this primary analysis 
will be considered the final analysis for the primary and week 16 secondary efficacy endpoints. A 
description of the statistical methods to be employed and blinding implications are in Section  11. 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 52 
 CONFIDENTIAL  6.3. Study Committees  
6.3.1.  Independent Data Monitoring Committee  
An independent data monitoring committee (DMC), composed of members who are independent 
from the sponsor and the study investigato rs, will monitor patient safety by [CONTACT_24993]; if requested, the DMC 
may have access to the treatment allocation code or any other requested data for the purposes of a 
risk-benefit assessment.  
The DMC will provide the sponsor with appropriate recommendations on the conduct of the 
clinical study to ensure the protection and safety of the patients enrolled in the study.  
All activities and responsibilities of the DMC are describe d in the DMC charter.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24062] of patients with active EoE, ages  ≥1 to <[ADDRESS_24063] meet the following criteria to be eligible for inclusion in the study:  
1. Male or female, ages ≥1 year to <12 years  
2. A documented diagnosis of EoE by [CONTACT_24994], as demonstrated 
by [CONTACT_24955][INVESTIGATOR_24740] (peak eosinophil count ≥15  eos/hpf) (400×) from 
at least [ADDRESS_24064] been performed 
within 2 weeks of the date of discontinuation.  
If a prior (documented) endoscopic biopsy meeting these criteria is not available (or no 
prior biopsy is available), patients who meet other clinical and laboratory eligibility criteria 
will undergo treatment with a PPI [INVESTIGATOR_24745] 8 weeks during the screening period 
before their baseline endoscopy/biopsies.  
3. Baseline endoscopic biopsies with a demonstration on central reading of intraepi[INVESTIGATOR_24871] (peak eosinophil count  ≥15 eos/hpf) in at least 2 of the 3 biopsied 
esophageal regions (proximal, mid, or distal)  
4. History (by [CONTACT_24959]) of symptom(s) determined by [CONTACT_24995] (eg, abdominal pain, chest pain, acid reflux, food reg urgitation, 
dysphagia, vomiting, or refusal to eat) in the month prior to screening  
5. Patients ≥8 to <[ADDRESS_24065] 8  out of  14 days of eDiary for the PESQ -C should be completed prior to 
baseline/visit  3. 
6. Parents or legal guardians must provide signed informed consent. Assent should be 
collected from patient, if applicable, as per local regulato ry (competent authority/ethics) 
guidelines, based upon the age and level of maturity of the patient.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 54 
 CONFIDENTIAL  7.2.2.  Exclusion Criteria  
[IP_ADDRESS].  Exclusion Criteria for Part A - Double -Blind Treatment  
A patient who meets any of the following criteria will be excluded from the study : 
1. Body weight <5 kg or ≥[ADDRESS_24066] remain on the same diet throughout the study.  
4. Other causes of esophageal eosinophilia or the following conditions: eosinophilic 
gastroenteritis, hypereosinophilic syndrome, and eosinophi lic granulomatosis with 
polyangiitis (Churg -Strauss syndrome)  
5. Active Helicobacter pylori  
6. Helminthic infection  
7. History of Crohn’s disease, ulcerative colitis, celiac disease, or prior esophageal 
surgery  
8. Any esophageal stricture unable to be passed with a s tandard, diagnostic, upper 
endoscope or any critical esophageal stricture that requires dilation at screening  
9. Treatment with swallowed topi[INVESTIGATOR_24872] [ADDRESS_24067] of care endoscopy  
10. Treatment with subcutaneous immunothe rapy (SCIT) unless on a stable maintenance 
dose for at least 1 year  
11. Prior treatment with sublingual immunotherapy (SLIT), epi[INVESTIGATOR_24873] 
(EPIT), or oral immunotherapy (OIT)  
12. Initiation, discontinuation, or change in the dosage regimen of the fol lowing 
medications within 8 weeks prior to the baseline endoscopy: PPIs, leukotriene 
inhibitors, and nasal and/or inhaled corticosteroids  
13. Treatment with systemic immunosuppressant/immunomodulating drugs, including but 
not limited to systemic corticosteroids, mepolizumab, omalizumab, cyclosporine, 
mycophenolate -mofetil, interferon -gamma (IFN -γ), Janus kinase inhibitors, 
azathioprine, and methotrexate within 3 months prior to screening  
a. NOTE: One -time use of a corticosteroid as a part of the anes thetic preparation 
used during each endoscopy procedure is allowed.  
14. Treatment with an investigational drug within 2 months or within 5 half -lives (if 
known), whichever is longer, prior to baseline visit  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 55 
 CONFIDENTIAL  15. History of bleeding disorders or esophageal varices t hat, in the opi[INVESTIGATOR_1070], would put the patient at undue risk for significant complications from an 
endoscopy procedure  
16. Planned or anticipated use of any prohibited medications and procedures during the 
study  
17. Planned or anticipated major sur gical procedure during the study  
18. Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit  
NOTE: For patients who have vaccination with live, attenuated vaccines planned 
during the course of the study (based on national vaccinatio n schedule/local 
guidelines), it will be determined, after consultation with a pediatrician, whether the 
administration of vaccine can be postponed until after the end of study, or preponed to 
before the start of the study, without compromising the health of the patient:  
− Patients for whom administration of live (attenuated) vaccine can be safely 
postponed would be eligible to enroll into the study  
− Patients who have their vaccination preponed can enroll in the study only after at 
least 4  weeks following admi nistration of the vaccine  
19. Active parasitic infection or suspected parasitic infection, unless clinical and (if 
necessary) laboratory assessments have ruled out active infection before randomization  
20. Chronic or acute infection requiring treatment with system ic antibiotics, antivirals, or 
antifungals within 2 weeks before baseline visit  
NOTE:  Patients may be re -screened after the infection resolves  
21. Known or suspected immunodeficiency disorder, including history of invasive 
opportunistic infections (eg, tuberc ulosis [TB], non -tuberculous mycobacterial 
infections, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, 
aspergillosis) despi[INVESTIGATOR_12468], or otherwise recurrent infections of 
abnormal frequency, or prolonged infections suggesting  an immune -compromised 
status, as judged by [CONTACT_24996]:  Tuberculosis testing will be performed on a country -by-country basis 
according to local guidelines if required by [CONTACT_24997] 
(ECs).  
22. Known history of human  immunodeficiency virus (HIV) infection or positivity for 
Hepatitis B or Hepatitis C antigens  
23. On current treatment for hepatic disease including but not limited to acute or chronic 
hepatitis, cirrhosis, or hepatic failure, or has evidence of liver disease as indicated by 
[CONTACT_24998] (confirmed by [CONTACT_24999] ≥2 weeks apart) elevated transaminases (alanine 
aminotransferase [ALT] and/or aspartate aminotransferase [AST]) more than 3 times 
the upper limit of normal [ULN] during the screening period)  
24. Any of th e following abnormal laboratory values at screening:  
− Platelets <100 × 103/μL 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 56 
 CONFIDENTIAL  − Neutrophils ≤1.5 × 103/μL  
− Estimated  glomerular filtration rate (eGFR) (Totri, 2017 ) <30 mL/min/1.73 m2 
NOTE:  If an abnormal value is detected at screening, a repeat test should be performed 
to confirm the abnormality.  Only if the repeat test confirms the abnormality would the 
patient be categorized as a screen failure. Estimated glomerular filtration rate  will be 
calculated using the Bedside Schwartz formula.  
25. Severe concomitant illness(es) that, in the investigator’s judgment, would adversely 
affect the patient’s participation in the study. Examples include but are not limited to 
active malignancy, short life expectancy, uncontrolled diabetes, cardiovascular 
conditions (eg, [LOCATION_001] Heart Association Class III or IV cardiac failure), severe 
renal conditions (eg, patients on dialysis), hepatobiliary conditions (eg, Child -Pugh 
class B or C), neurological con ditions (eg, demyelinating diseases), active major 
autoimmune diseases (eg, lupus, inflammatory bowel disease, rheumatoid arthritis, 
etc.), and other severe endocrinologic, gastrointestinal, metabolic, pulmonary, or 
lymphatic diseases. The specific justifi cation for patients excluded under this criterion 
will be noted in study documents (chart notes, case report forms [CRF], etc.).  
26. History of malignancy within [ADDRESS_24068] a new and/or 
insufficiently understood disease, may present an unr easonable risk to the study patient 
as a result of his/her participation in this clinical trial, may make patient’s participation 
unreliable, or may interfere with study assessments. The specific justification for 
patients excluded under this criterion wil l be noted in study documents.  
29. Patient’s immediate family is a member of the investigational team.  
30. Patient is female who is pregnant, breastfeeding, or planning to become pregnant or 
breastfeed during the study.  
31. Patient is of childbearing potential* who i s unwilling to practice highly effective 
contraception prior to the initial dose/start of the first treatment, during the study, and 
for at least [ADDRESS_24069] dose. Highly effective contraceptive measures 
include:  
a. stable use of combined (estrog en and progestogen -containing) hormonal 
contraception (oral, intravaginal, transdermal) or progestogen -only hormonal 
contraception (oral, injectable, implantable) associated with inhibition of ovulation 
initiated 2 or more menstrual cycles prior to screeni ng 
b. intrauterine device; intrauterine hormone -releasing system (IUS)  
c. and/or sexual abstinence†, ‡.  
*Women of childbearing potential (WOCBP) are defined as women who are fertile 
following menarche until becoming postmenopausal, unless permanently sterile. 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 57 
 CONFIDENTIAL  Permanent sterilization methods include hysterectomy, bilateral salpi[INVESTIGATOR_1656], and 
bilateral oophorectomy.  
† Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of r isk associated with 
the study drugs. The reliability of sexual abstinence needs to be evaluated in relation to 
the duration of the clinical trial and the preferred and usual lifestyle of the patient.  
‡ Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal 
(coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are 
not acceptable methods of contraception. Female condom and male condom should not 
be used together.  
32. Female patients who experience menarche and who are unwilling to follow the precautions 
for WOCBP  
33. Known systemic hypersensitivity to dupi[INVESTIGATOR_24874]  
[IP_ADDRESS].  Exclusion Criteria for Part B – Extended Active Treatment (and also for Entry 
into Part C for Patients with Uninterrupt ed Participation in the Study)  
1. Patients who, during the double -blind treatment period (for entry into the extended active 
period) or during the extended active treatment period (for entry into the open -label 
extension period), developed an SAE and/or AE d eemed related to study drug and which 
led to discontinuation of investigational product (patients who are prematurely 
discontinued from study drug due to lack of efficacy are eligible to enter Part B and/or Part 
C) 
2. Patients who, during the double -blind tre atment period (for entry into the extended active 
period), or extended active treatment period (for entry into the open -label extension period) 
were prematurely withdrawn because of a protocol violation, poor compliance, or inability 
to complete required s tudy assessments  
3. Patients who did not undergo endoscopy with biopsies at week 16 and/or week 52 or prior 
to receiving rescue treatment  
Note: If the endoscopy with biopsies could not occur due to COVID -19 restrictions 
and rescue treatment was needed to be initiated without delay, these patients will 
be eligible to participate in Part C.  
4. Female patients who experience menarche and who are unwilling to follow the precautions 
for WOCBP  
[IP_ADDRESS].  Exclusion Criteria for Patients Re -Entering the Study (for Entry into Part C for 
Patients Who Have Completed Their EOS Visit Prior to Amendment 4)  
A patient who meets any of the following criteria will not be p ermitted to re -enter the study:  
1. Patients who are ≥12 years old, weigh ≥40 kg (or minimum weight for which dupi[INVESTIGATOR_24875] ), and dupi[INVESTIGATOR_24876].  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 58 
 CONFIDENTIAL  2. Patients who, during their previous  participation in this clinical trial, developed an SAE 
and/or AE deemed related to dupi[INVESTIGATOR_12458], which in the opi[INVESTIGATOR_24877] e patient.  
3. Patients who did not undergo endoscopy with biopsies at week 16 and/or week 52 or prior 
to receiving rescue treatment . 
Note: If the endoscopy with biopsies could not occur due to COVID -19 
restrictions and rescue treatment was needed to be initi ated without delay, these 
patients will be eligible to participate in Part C.  
4. Patients who became pregnant during their previous participation in this dupi[INVESTIGATOR_24878]. 
5. Patients who, during their previous participation in this trial, were prematur ely withdrawn 
because of a protocol violation, poor compliance, or inability to complete required study 
assessments.  
6. Known history of HIV infection or HIV seropositivity.  
7. Known history of positive HBsAg, HBcAb, or hepatitis C antibody.  
NOTE: Patients who are HBsAg negative and HBsAb positive are considered  immune after 
a natural infection has cleared or they have been vaccinated against hepatitis  B. Therefore, 
they are acceptable for the study.  
8. Treatment with an investigational drug (other than dupi[INVESTIGATOR_12458])  within 2 months or within 
5 half -lives (if known), whichever is longer, prior to the re -entry visit  
9. Treatment with systemic immunosuppressant/immunomodulating drugs, including but not 
limited to mepolizumab, omalizumab, cyclosporine, mycophenolate -mofetil , interferon -
gamma (IFN -γ), Janus kinase inhibitors, azathioprine, and methotrexate within 3 months 
prior to re -entry visit  
10. Treatment with a live (attenuated) vaccine within 4 weeks before the re -entry visit.  
11. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or 
antifungals within 2 weeks before re -entry visit  
12. Pregnant or breastfeeding females  
13. Females unwilling to use adequate birth control, if of reproductive potential and sexually 
active (see Exclusion Criterion 31  above for applicable definitions).  
14. Any other medical or psychological condition that, in the opi[INVESTIGATOR_871], may 
suggest a new and/or insufficiently understood disease, may pres ent an unreasonable risk 
to the patient as a result of his/her participation in the trial, may make the patient’s 
participation unreliable, or may interfere with study assessments. The specific justification 
for patients excluded under this criterion will be noted in the source documents.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 59 
 CONFIDENTIAL  7.3. Premature Withdrawal from the Study  
A patient has the right to withdraw from the study at any time, for any reason, and without 
repercussion.  
The investigator and/or sponsor have the right to withdraw a patient from the study if it is no longer 
in the interest of the patient to continue in the study, or if the patient’s continuation in the study 
places the scientific outcome of the study at risk (eg, if a patient does not or cannot follow study 
procedures). An excessive r ate of withdrawals would render the study uninterpretable; therefore, 
unnecessary withdrawal of patients should be avoided.  
Patients who are withdrawn prematurely from the study will be asked to complete the early 
termination visit, as described in Section  9.1.2 . 
Rules for discontinuation of study treatment (permanent or temporary) are discussed in 
Section  8.4.2 . 
7.4. Replacement of Patients  
Patients prematurely discontinued from study or study drug will not be replaced.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24070] will be provided. Instructions on dose preparation are provided in the 
pharmacy manual.  
Patients will receive dupi[INVESTIGATOR_24826], Q2W, or Q4W with matching 
placebo alternating with dupi[INVESTIGATOR_24879] -blinding purposes (Parts A and B). Patients will remain within the originally 
assigned higher or lower dosing exposure arm throughout the study (Part A and Part B).  For 
Part C, all patients will receive the higher exposure dupi[INVESTIGATOR_24880] (QW, 
Q2W, or Q3W).  No matching placebo will be administered in Part C.  
Study drug administration at the study sites will be performed only by [CONTACT_25000]/procedures (this restriction is not required during Part C) 
(Table  1, Table  2, Table  3, and Table  4). 
Dupi[INVESTIGATOR_12458]:  
• Dupi[INVESTIGATOR_24797]/m L: Each 2.25 mL single -use, prefilled syringe with cap delivers 
 mg of study drug (2.0 mL of a  mg/mL solution)  
• Dupi[INVESTIGATOR_24797]/mL: Each 1.14 mL single -use, prefilled syringe with cap delivers 
 mg of study drug (1.14 mL of a  mg/mL solution)  
• Dupi[INVESTIGATOR_24797]/mL: Each 0.67 mL single -use, prefilled syringe with cap delivers 
 mg study drug (0.67 mL of a  mg/mL solution).  
Placebo -matching dupi[INVESTIGATOR_12458] (for Parts A and B):  
• 2 mL placebo matching  mg dupi[INVESTIGATOR_24881]  
• 1.14 mL placebo matching  mg dupi[INVESTIGATOR_24881]  
• 0.67 mL placebo matching  mg dupi[INVESTIGATOR_24881]  
8.1. Investigational and Reference Treatments  
The weight -tiered dosing regimens of the study drug are described below . 
• Part A:  16 -Week Double -Blind Treatment Period: Part A is the double -blind, 
placebo -controlled portion of the study. Subcutaneous (SC) administration at tiered 
dosing regimens based on body weight at baseline.  
Higher exposure dupi[INVESTIGATOR_24747] (Part A):  
•  mg Q2W in patients who weigh ≥5  kg to <15 kg  
•  mg Q2W in patients who weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who weigh ≥30 kg to <60 kg  
Lower exposure dupi[INVESTIGATOR_24747] (Part A):  
•  mg Q4W in patients who weigh ≥5  kg to <15 kg  
•  mg Q4W in  patients who weigh ≥15 kg to <30 kg  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 61 
 CONFIDENTIAL  •  mg Q2W in  patients who weigh ≥30 kg to <60 kg  
NOTE: In Part A, patients will receive dupi[INVESTIGATOR_24882] Q2W or 
Q4W with matching placebo alternating with dupi[INVESTIGATOR_24883] Q2W for both groups for regimen -blindi ng purposes per treatment assignment in 
Part A.  
− Placebo for Part A: Dose matching placebo Q2W or alternating with dupi[INVESTIGATOR_12458] Q4W 
so the frequency will be Q2W for both groups for regimen -blinding purposes in Part 
A.  
− See Figure  3: Weight -Tiered Dosing Regimens of Study Drug – Part A.  
• Part B:  36 -Week Extended Active Treatment Period:   Part B is the extended active 
treatment portion of the study. All patients (Part A active and placebo) will receive 
dupi[INVESTIGATOR_24884] 8 (week 16, end of double -blinded treatment 
period or start of extended treatment period) per the higher and lower exposure group 
to which they were assigned at randomization.  If weight tier has increased at visit 12 / 
week 32, patients will be re -assigned to an extended active treatment regimen based on 
weight tiered dosing regimens below.  
Higher exposure dupi[INVESTIGATOR_24747] (Part B):  
•  mg Q2W in patients who weigh ≥5  kg to < 15 kg  
•  mg Q2W in patients who weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who weigh ≥30 kg to <60 kg  
•  mg QW in patients who weigh ≥60 kg  
Lower exposure dupi[INVESTIGATOR_24747] (Part B):  
•  mg Q4W in patients who weigh ≥5  kg to <15 kg  
•  mg Q4W in patients who weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who weigh ≥30 kg to <60 kg  
•  mg Q2W in patients who weigh ≥60 kg  
NOTE: In Part B, study drug or matching placebo will be administered Q2W for all patients  
in <60 kg weight -groups an d QW for all patients in ≥60 kg weight -groups. Patients will 
receive alternating doses of dupi[INVESTIGATOR_24885] Q2W for patients <60 kg assigned to 
Q4W regimens or QW for patients ≥60 kg assigned to Q2W regimens for regimen -blinding 
purposes  
− Placebo for Par t B: Dose matching placebo alternating with dupi[INVESTIGATOR_12458] Q2W or Q4W 
so the frequency will be Q2W for the weight -based groups <60kg and QW for the 
weight -based group of ≥60 kg for regimen -blinding purposes in Part B.  
See Figure  4: Part B Weight -Tiered Dosing Regimens of Study Drug.  
 
 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 62 
 CONFIDENTIAL  • Part C:  Up to 108 -Week Open -Label Extension Period:  Part C is the open -label 
extension period of the study. All patients (P art C) will receive higher exposure 
dupi[INVESTIGATOR_24886]  17 (week  52, end of extended active 
treatment period) or start of open -label period (for re -entry patients). All patients who 
received lower exposure dupi[INVESTIGATOR_24887] B will be re -assigned to higher 
exposure dupi[INVESTIGATOR_24754] -label (Part C) period.  If weight 
increases place a patient into a higher weight tier at visit 17 / week 52 (or start of open -
label period for re -entry patients) or at sp ecified in -clinic visits in Part C, the patient 
will be re -assigned to an open -label treatment regimen based on the weight tiered 
dosing regimen specified below.  
Higher exposure dupi[INVESTIGATOR_24747] (Part C):  
•  mg Q3W in patients who weigh ≥5  kg to <15 kg  
•  mg Q2W in patients who weigh ≥15 kg to <30 kg  
•  mg Q2W in patients who weigh ≥30 kg to <40 kg  
•  mg QW in patients who weigh ≥40 kg  
NOTE: In Part C, only active study drug (dupi[INVESTIGATOR_12458]) will be administered.  No 
matching placebo will be administered i n Part C. The weight -based dosing regimens 
will be as listed above  (see Figure  5).  
For Part C only: Patients located in a country where dupi[INVESTIGATOR_24888] ≥12 years old will be provided treatment with 
study drug until they are both (1) at least 12 years of age and (2) weigh at least [ADDRESS_24071] an end of treatment visit at the next scheduled study visit upon meeting both 
criteria, followed by [CONTACT_24961] -up visit after 12 weeks.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 63 
 CONFIDENTIAL  Figure  3: Part A Weight -Tiered Dosing Reg imens of Study Drug  
 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 64 
 CONFIDENTIAL  Figure  4: Part B Weight -Tiered Dosing Regimens of Study Drug  
 
 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 65 
 CONFIDENTIAL  Figure  5: Part C (OLE) Weight -Tiered Dosing Regimens of Study Drug  
 
8.2. Background Treatme nts 
Patients who undergo a trial of PPI [INVESTIGATOR_24889] A have the choice either to remain on the PPI [INVESTIGATOR_24890] A and B or stop the PPI 
[INVESTIGATOR_24891]; they then must remain off of PPI s during Parts A and B. Patients may 
adjust their PPI [INVESTIGATOR_24892] C.  Refer to the study binder for specific PPI [INVESTIGATOR_24893].  
8.3. Rescue Treatments and Procedures  
If medically necessary (eg, for treatment of intolerable EoE symptoms), re scue medications 
(systemic and/or  swallowed topi[INVESTIGATOR_11930]) or emergency esophageal dilation are allowed 
for study patients. For Parts A and B, an endoscopy with biopsy will be performed prior to the 
initiation of rescue therapy. Patients who unde rgo an endoscopy with biopsy due to the initiation 
of rescue therapy during Parts A or B will not undergo the subsequent scheduled endoscopy/biopsy 
at week 16 and/or week 52, respectively. Patients who receive rescue treatment during the double -
blind perio d of the study will not be eligible for the extended active treatment period unless an 
endoscopy with biopsy is performed prior to the initiation of rescue treatment.  For Part C (OLE), 
rescue treatment is also allowed. If rescue therapy is initiated durin g Part C (OLE), an 
endoscopy/biopsy before initiating rescue treatment is at discretion of the investigator discretion; 
future endoscopi[INVESTIGATOR_014]/biopsies ( week 100 and week 160) would still be required.   If the endoscopy 
with biopsies cannot occur due to COVID -19 restrictions, rescue treatment should be initiated 
without delay and these patients will be eligible to participate in Part C.  
 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 66 
 CONFIDENTIAL  Patients receiving rescue therapy may continue to receive study drug. They will remain blinded 
and will be asked to return to the clinic for all remaining study visits for the double -blind treatment 
period and the follow -up period, and participate in all a ssessments for these visits according to the 
Schedule of Events specified in Table  1, Table  2, Table  3, and Table  4 except for 
endoscopy/biopsy, as noted above. For the purpose of efficacy analyses for Part A, patients who 
receive rescue treatment during the study will be considered treatment failures.  
8.4. Dose Modification and Study Treatment Discontinuation Rules  
8.4.1.  Dose Modification  
Dose Modification, beyond what is specified by [CONTACT_25001] (see below), is not allowed.  
Since dose is weight -tiered, weight at baseline will be used to determine dose for the 16 -week 
double -blinded treatment period, weight at visit 8 (week 16) will be used to determine dose for 
start of the 36 -week exte nded active treatment period and weight at Visit 17 / week 52 (or start of 
open -label period) will be used to determine the dose for the open -label extension period. All 
patients (Part C) will receive higher exposure dupi[INVESTIGATOR_24894]  17 
(week  52, end of extended active treatment period) or start of open -label period (for re -entry 
patients). Dose adjustments (based on increased weight) will be made during Part C at specified 
in-clinic visits as indicated in Table  4.  
8.4.2.  Study Drug Discontinuation  
Patients who permanently discontinue from study drug should be encouraged to remain in the 
study. Those who agree and do not withdraw from the study  will be asked to return to the clinic 
for all remaining study visits per the visit schedule.  
Patients who permanently discontinue from study drug and who opt to withdraw from the study 
will be asked to complete study assessments, per Section  9.1.2  . 
[IP_ADDRESS].  Reasons for Permanent Discontinuation of Study Drug  
Study drug dosing will be permanently stopped in the event of:  
• Evidence of pregna ncy 
• Serious or severe allergic reactions considered related to study drug  
• Specific types of liver dysfunction [eg, Hy’s law is met (Malmberg, 2009 )] 
• Patient or legal parent/legal guardian withdraws ass ent or consent  
• Anaphylactic reaction or other severe systemic reaction deemed related to study drug  
• Diagnosis of a malignancy during study  
• Any infection that is opportunistic, such as TB and other infections whose nature or 
course may suggest an immunoco mpromised status  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 67 
 CONFIDENTIAL  • Severe laboratory abnormalities:  
o Neutrophil count ≤0.5 × 103/µL 
o Platelet count ≤50 × 103/µL 
o ALT and/or AST values >3 × ULN with total bilirubin >2 × ULN, excluding 
confirmed Gilbert’s Syndrome  
o Confirmed AST and/or ALT >5 × ULN (for more than 2 weeks)  
[IP_ADDRESS].  Reasons for Temporary Discontinuation of Study Drug  
Study drug dosing will be temporarily discontinued in the event of:  
• An infection that requires parenteral treatment with antibiotic, antifungal, antiviral, 
antiparasitic, or antiprotozoal agents, or requires oral treatment with such agents for 
longer than 2 weeks  
• Other intercurrent illnesses that may or may not require treatment with some prohibited 
medications (eg, systemic immunosuppressive/immunomodulating drugs) or major 
surgery, which could, in the opi[INVESTIGATOR_871], present an unreasonable risk 
to the patient as a result of his/her continued participation in the study and receiving 
study drug  
A decision to temporarily discontinue study drug and/or to reinstitute study treatme nt should be 
discussed with the medical monitor. The investigator may suspend study treatment at any time, 
even without consultation with the medical monitor if the urgency of the situation requires 
immediate action and if this is determined to be in the p atient’s best interest. However, the medical 
monitor should be contact[CONTACT_25002]. 
Resumption of study treatment after temporary discontinuation requires consultation and 
agreement between the investigat or and the medical monitor.  
After the condition leading to temporary discontinuation of study drug resolves, study drug dosing 
may resume. A decision to temporarily discontinue study drug and/or resume study drug dosing 
should be discussed with the Regener on Pharmaceuticals, Inc. medical monitor.  
If a patient requires a prohibited medication at any time during the study, the principal investigator 
[INVESTIGATOR_24895] (except for illness requiring prompt treatment). 
Based on the disc ussions, study drug may be continued or temporarily or permanently 
discontinued.  
8.5. Management of Acute Reactions  
8.5.1.  Acute Injection Reactions  
[IP_ADDRESS].  Systemic Injection Reactions  
Emergency equipment and medication for the treatment of systemic reactions must be avail able 
for immediate use. All injection reactions must be reported as AEs (as defined in Section  10.2.1 ) 
and graded using the grading scales as instruc ted in Section  10.2.4 . 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 68 
 CONFIDENTIAL  Acute systemic reactions following  injection of study drug (SC) should be treated using clinical 
judgment to determine the app ropriate response according to typi[INVESTIGATOR_24896].  
[IP_ADDRESS].  Local Injection Site Reactions  
Local injection site reactions must be reported as AEs and graded according to Section  10.2.4 . 
8.6. Method of Treatment Assignment  
In Part A, approximately 90 patients will be randomized in a 1:1:1 ratio to receive higher or lower 
exposure dose arms of dupi[INVESTIGATOR_12458]  (dose regimen according to the weight tier described in 
Section  8.1) or placebo according to a central randomization scheme provided by [CONTACT_25003]/IWRS 
to the designated study pharmacist (or qualified designe e). Randomization will be stratified 
according to weight at baseline (≥5 kg to <15 kg, ≥15 kg to <30 kg, or ≥30 kg to <60 kg).  
8.7. Blinding  
Study patients, the principal investigators, and study site personnel will remain blinded to all 
randomization assignme nts. For Parts A and B, study drug administration at the study sites will be 
performed only by [CONTACT_25004]/procedures. 
During the conduct of Parts A and B, the blinded Regeneron medical/study director, s tudy monitor, 
and any other Regeneron and contract research organization (CRO) personnel who are in regular 
contact [CONTACT_25005].  
If the primary analysis is performed on Part A data (see S ection  6.2), Part A will be unblinded for 
selected sponsor study personnel while Part B is ongoing. The team performing the primary 
analysis will be se parate from the ongoing study team. No study personnel involved in the day -to-
day conduct of the study will have access to any unblinded data before the database is locked for 
Part B of this study.  All participants will receive open -label dupi[INVESTIGATOR_24887] C.  
Blinded study drug kits coded with a medication numbering system will be used for the double -
blind (Part A) and extended active (Part B) treatment periods. In order to maintain the blind (until 
the database is locked for Part B), lists linking the se codes with product lot numbers will not be 
accessible to individuals involved in study conduct. Part C study drug will be labeled with 
dupi[INVESTIGATOR_12458].  
During the double -blind (Part A) and extended active (Part B) treatment periods, anti -drug 
antibody, drug c oncentration results, any post -treatment tissue eosinophil counts and histologic 
results, and biomarker results (eotaxin -3 and total IgE) will not be communicated to the sites, and 
the sponsor’s blinded study team will not have access to results associated  with patient 
identification until after the database is locked for the respective study part.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 69 
 CONFIDENTIAL  8.8. Emergency Unblinding (Applies to Part A and Part B only)  
Unblinding of treatment assignment for a patient may be necessary due to a medical emergency or 
any othe r significant medical event (eg,  pregnancy) and when a treatment decision is contingent 
on knowing the patient’s treatment assignment. Study drug will be discontinued for patients whose 
treatment has been unblinded (Section  8.4.2 ): 
• If unblinding is required:  
− Only the investigator will make the decision to unblind the treatment assignment.  
− Only the affected patients will be unblinded.  
− The designated stu dy pharmacist(s)/designee at the study site will provide the 
treatment assignment to the investigator. If there is no study pharmacist, the 
investigator for the site will unblind the patient. Unblinding is performed using the 
IVRS/IWRS which will notify Re generon.  
− The investigator will notify Regeneron and/or designee as soon as possible after 
unblinding the patient.  
Treatment assignment is not to be provided to site personnel, other than the unblinded  study 
pharmacist (when applicable), at any time during the conduct of the study, except in the case of a 
true emergency and when a treatment decision is contingent on knowing the patient’s treatment 
assignment. In the event that there is no study pharmaci st, the individual at the site fulfilling that 
role will be the only unblinded member of the site personnel.  
8.9. Treatment Logistics and Accountability  
8.9.1.  Packaging, Labeling, and Storage  
A medication numbering system will be used to label blinded investigational  study drug. Lists 
linking medication numbers with product lot numbers will be maintained by [CONTACT_25006] (or 
companies) responsible for study drug packaging. In order to maintain the blind, these lists will 
not be accessible to individuals involved in study  conduct. Part C study drug will be labeled with 
dupi[INVESTIGATOR_12458].  
Study drug will be stored at the site at a temperature of 2ºC to 8ºC; storage instructions will be 
provided in the pharmacy manual.  
8.9.2.  Supply and Disposition of Treatments  
Study drug will be shipped at a temperature of 2ºC to 8ºC to the investigator or designee at regular 
intervals or as needed during the study. At specified time points during the study (eg, interim site 
monitoring visits), at the site close -out visit, and following drug reconciliatio n and documentation 
by [CONTACT_25007], all opened and unopened study drug will be destroyed on site after sponsor 
approval or returned to the sponsor or designee .  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24072] be able to account for all opened and unopened study drug. These records 
should contain the dates, quantity, and study medication  
• dispensed to each patient  
• returned from each patient (if applicable), and  
• disposed of at the site or returned to th e sponsor or designee.  
All accountability records must be made available for inspection by [CONTACT_25008]; photocopi[INVESTIGATOR_24897].  
8.9.4.  Treatment Compliance  
All drug compliance re cords must be kept current and made available for inspection by [CONTACT_25009].  
8.10. Concomitant Medications and Procedures  
Any treatment administered from the time of informed consent/assent  to final study visit will be 
recorded. Any treatment administered from the time of first dose of study drug  to the final study 
visit will be considered concomitant treatment. This includes medications that were started before 
the study and are ongoing during the study.  
8.10.1.  Prohibited Medications an d Procedures  
Treatment with the following concomitant medications is prohibited through week 52 and may 
result in temporary or permanent discontinuation of study drug (see Section  8.4.2 ). While the 
investigator may suspend study treatment at any time, any change to study drug administration 
should be discussed with the medical monitor.  
• Swallowed topi[INVESTIGATOR_11930] (may be used as rescue treatment  for EoE) (Parts A 
and B only)  
• Systemic corticosteroids (may be used as rescue treatment for EoE) (Parts A and B 
only)  
− NOTE: One -time use of a corticosteroid as a part of the anesthetic preparation 
used during each endoscopy procedure is also allowed.  
• Systemic immunosuppressive/immunomodulating drugs (including, but not limited 
to, mepolizumab, omalizumab, cyclosporine, mycophenolate -mofetil, azathioprine, 
methotrexate, IFN -γ, or other immunomodulatory biologics)  
• Treatment with an investigational drug ( other than dupi[INVESTIGATOR_12458])  
• For Parts A and B: Initiation, discontinuation, or change in dosage regimen after 
baseline of the following medications (stable doses of these medications are allowed):  
− Proton pump inhibitors  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 71 
 CONFIDENTIAL  − Systemic leukotriene inhibitors  
• For Parts A and B: Initiation, discontinuation, or change in dosage regimen of nasal 
and/or inhaled corticosteroids within 8 weeks prior to visit 2, visit 8, or visit 17 
endoscopi[INVESTIGATOR_24898]  
• Initiation of SCIT, or change in dose for those patients on a stable d ose of SCIT, 
within 1  year prior to screening (For Parts A and B only)  
• SLIT, OIT, or EPIT (For Parts A and B only)  
 
• Treatment with a live (attenuated) vaccine, eg:  
− Chickenpox (varicella)  
− FluMist -influenza  
− Intranasal influenza  
− Measles (rubeola)  
− Measles -mum ps-rubella combination  
− Measles -mumps -rubella -varicella combination  
− Mumps  
− Oral polio (Sabin)   
− Oral typhoid  
− Rubella  
− Smallpox (vaccinia)  
− Yellow fever  
− Bacille Calmette -Guerin  
− Rotavirus  
− Varicella zoster (shingles)  
The following concomitant procedures are prohib ited during study treatment (for Parts A and B):  
• Major elective surgical procedures  
• Esophageal dilation (may be used as rescue procedure)  
• Initiation or change of food -elimination diet regimen  
8.10.2.  Permitted Medications and Procedures  
Other than the prohibited medications listed in Section  8.10.[ADDRESS_24073] the medical monitor.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
Regeneron Pharmaceuticals, Inc.  Page 72 
CONFIDENTIAL  8.10.3.  Restricted Medications and Procedures during the Follow -Up Period  
Patients may receive the prohibited medications/procedures listed in Section  8.10.1  as needed 
during the follow -up period, with the exception of live (attenuated) vaccine, which should not be 
used within [ADDRESS_24074] dose of study drug. Investigators are advised to  prescribe 
prohibited medications/procedures judiciously, only when they are absolutely required for the 
appropriate management of study patients.  
8.11. Poststudy Treatments and Procedures  
No poststudy treatments are required or planned.  
9. STUDY SCHEDULE OF EV ENTS AND PROCEDURES
9.1. Schedule of Events  
Study assessments and procedures are presented by [CONTACT_25010]  1. 
In light of the public health  emergency related to COVID -19, the continuity of clinical study 
conduct and oversight may require implementation of temporary or alternative mechanisms. 
Examples of such mechanisms may include, but are not limited to, any of the following:   phone 
contact,  virtual visits, telemedicine visits, online meetings, non -invasive remote monitoring 
devices, use of local clinic or laboratory locations, and home visits by [CONTACT_25011]. Additionally, 
no waivers to deviate from protocol enrollment criteria due to COVID -[ADDRESS_24075] only for the duration of the 
public health emergency.  
VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 73 
 CONFIDENTIAL  Table  1: Schedule of Events - Screening and Double -Blind Treatment Period  
 Screening Period  Part A:  16 -Week Double -Blind Treatment Period  
Study Procedure  Screening1, 3 
V1 Screening2 
V2 Baseline  
V3 V4 V5 V6 V7 DB EOT4 
V8 
Week (W)     W2 W4 W8 W12  W16  
Day (D)  D-85 to D -1 D1 D15 D29 D57 D85 D113  
Visit Window (Days [d])     ±7 d ±3 d ±3 d ±3 d +7 d  
Screening/Baseline:  
Inclusion/Exclusion  X  X      
Informed Consent/Assent  X        
Informed consent/assent for optional genomic sub -study  X        
Informed consent/assent for optional future biomedical 
research sub -study  X        
Med History/Demographics  X        
Age in months  X X X X X X X X 
Randomization    X      
Treatment:  
Training for SC Injection5   X X     
Administer Study Drug6   X X X X X  
Con Medications/Procedures  X X X X X X X X 
Efficacy:  
Weight, Height (or length for patients <2 years of age)  X  X X X X X X 
Pediatric EoE Sign/Symptom Questionnaire:7  
Patient version (PESQ -P) 
Caregiver version (PESQ -C)  
(Daily Diary)  
Pediatric EoE Impact Scale:7  
Patient version (PEIS -P) 
Caregiver version (PEIS -C)  
 X     X 
Global Impression of Change:8  
Patient version (GIC -P) 
Caregiver version (GIC -C) 
Clinician version (GIC -Clin)   
     X X 
Global Impression of Severity:8 
Patient version (GIS -P) 
Caregiver version (GIS -C) 
Clinician version (GIS -Clin)   
 X    X X 
Pediatric Eosinophilic Esophagitis Symptom Score: 15 
Caregiver version (PEESSv2.0)    X     X 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 74 
 CONFIDENTIAL   Screening Period  Part A:  16 -Week Double -Blind Treatment Period  
Study Procedure  Screening1, 3 
V1 Screening2 
V2 Baseline  
V3 V4 V5 V6 V7 DB EOT4 
V8 
Week (W)     W2 W4 W8 W12  W16  
Day (D)  D-85 to D -1 D1 D15 D29 D57 D85 D113  
Visit Window (Days [d])     ±7 d ±3 d ±3 d ±3 d +7 d  
Endoscopy with Biopsies and EoE -EREFS2, 9  X2a      X2,2b 
Exit Interview 16        X 
Safety10: 
Vital Signs11 X  X11 X11 X X X X 
Physical Examination  X  X     X 
Adverse Events  X X X X X X X X 
Laboratory Testing10, 12: 
Hematology  X  X  X   X 
Chemistry  X  X  X   X 
Pregnancy test (WOCBP)13 Serum   Urine  Urine  Urine  Urine  Urine  Urine  
Urinalysis14 X        
PK and ADA Samples10: 
Functional dupi[INVESTIGATOR_24899]    X  X   X 
Anti-dupi[INVESTIGATOR_24900]    X     X 
Biomarkers and Genomics:          
Serum Total IgE    X  X    
Eotaxin -3   X  X   X 
Optional pharmacogenetics DNA samples (cheek swab)    X      
ADA = anti -drug antibody; EoE -EREFS = Eosinophilic Esophagitis -Endoscopic Reference Score; EOS = end of study; EOT = end of treatment; PRO = patient -
reported outcome; ET = early termination; PEESS = Pediatric Eosinophilic Esophagitis Symptom Score ; PESQ -P = Pediatric EoE Sign/Symptom Questionnaire 
(patient version); PESQ -C = Pediatric EoE Sign/Symptom Questionnaire (caregiver version); PEIS -P = Pediatric EoE Impact Scale (patient version); PEIS -C = 
Pediatric EoE Impact Scale (caregiver version);  GIC -P = Gl obal Impression of Change (patient version); GIC -C = Global Impression of Change (caregiver 
version); GIC -Clin = Global Impression of Change (clinician version); GIS -P = Global Impression of Severity (patient version); GIS -C = Global Impression of 
Severity  (caregiver version); GIS -Clin = Global Impression of Severity (clinician version)   
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
Regeneron Pharmaceuticals, Inc.  Page 75 
CONFIDENTIAL  Table  2: Schedule of Events - Extended Active Treatment Period and Re -Entry Visit  
Part B:  36 -Week Extended Active Treatment Period  Re-Entry Visit (for patients who 
re-enter the study for Part C)13 
Study Procedure  V81 V9 V10 V11 V12 V13 V14 V15 V16 V1712 
Week (W)  W16  W20  W24  W28  W32  W36  W40  W44  W48  W52  
Day (D)  D113  D141  D169  D197  D225  D253  D281  D309  D337  D365  
Visit Window (Days 
[d]) +7 d ±7 d ±7 d ±7 d ±7 d ±7 d ±7 d ±7 d ±7 d +7 d
Screening for Part 
B/C:  
Inclusion/Exclusion  X X 
Informed Consent  X 
Medical History  X 
Treatment:  
Administer Study 
Drug4a, 4b X X X X X X X X X X 
Con Meds/Procedures  X X X X X X X X X X 
Efficacy:  
Age in months  X X X X X X X X X X 
Weight, Height (or 
length for patients 
<2 years of age)2 X4b X X X X4b X X X X X 
Pediatric EoE 
Sign/Symptom 
Questionnaire:5 
Patient version 
(PESQ -P) 
Caregiver version 
(PESQ -C) (Daily Diary)  
Pediatric EoE Impact 
Scale:5  
Patient version 
(PEIS -P) 
Caregiver version 
(PEIS -C) X X X 
VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 76 
 CONFIDENTIAL   Part B:  36 -Week Extended Active Treatment Period  Re-Entry Visit (for patients who 
re-enter the study for Part C)13 
Study Procedure  V81 V9 V10 V11 V12 V13 V14 V15 V16 V1712  
Week (W)  W16  W20  W24  W28  W32  W36  W40  W44  W48  W52   
Day (D)  D113  D141  D169  D197  D225  D253  D281  D309  D337  D365   
Visit Window (Days 
[d]) +7 d  ±7 d ±7 d ±7 d ±7 d ±7 d ±7 d ±7 d ±7 d +7 d   
Global Impression of 
Change:6 
Patient version 
(GIC -P) 
Caregiver version 
(GIC -C) 
Clinician version 
(GIC -Clin)  X    X     X  
Global Impression of 
Severity:6 
Patient version (GIS -
P) 
Caregiver version 
(GIS -C) 
Clinician version 
(GIS -Clin)  X    X     X  
Pediatric Eosinophilic 
Esophagitis Symptom 
Score:11 
Caregiver version 
(PEESSv2.0)  X           
Endoscopy with 
Biopsies and EoE-
EREFS7,7a X7,7a         X7,7a  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
Regeneron Pharmaceuticals, Inc.  Page 77 
CONFIDENTIAL  Part B:  36 -Week Extended Active Treatment Period  Re-Entry Visit (for patients who 
re-enter the study for Part C)13 
Study Procedure  V81 V9 V10 V11 V12 V13 V14 V15 V16 V1712 
Week (W)  W16  W20  W24  W28  W32  W36  W40  W44  W48  W52  
Day (D)  D113  D141  D169  D197  D225  D253  D281  D309  D337  D365  
Visit Window (Days 
[d]) +7 d ±7 d ±7 d ±7 d ±7 d ±7 d ±7 d ±7 d ±7 d +7 d
Safety:  
Vital Signs2,3,[ADDRESS_24076] 
(WOCBP)2,9 urine  urine  urine  urine  urine  urine  urine  urine  urine  urine  urine  
Urinalysis2,10 X X X 
PK and ADA 
Samples:  
Functional dupi[INVESTIGATOR_24901]2 X X X 
Anti-dupi[INVESTIGATOR_24902]2 X X X 
Biomarkers:  
Serum total IgE2 X X 
Eotaxin -32X X 
ADA = anti -drug antibody; EoE -EREFS = Eosinophilic Esophagitis -Endoscopic Reference Score; EOS = end of study; EOT = end of treatment; PEESS = 
Pediatric Eosinophilic Esophagitis Symptom Score;  PRO = patient -reported outcome; PESQ -P = Pediatric EoE Sign/Symptom Questionnaire (patient version); 
PESQ -C = Pediatric EoE Sign/Symptom Questionnaire (caregiver version); PEIS -P = Pediatric EoE Impact Scale (patient version); PEIS -C = Pediatric EoE 
Impact Scale  (caregiver version); GIC -P = Global Impression of Change (patient version); GIC -C = Global Impression of Change (caregiver version); GIC -Clin 
= Global Impression of Change (clinician version); GIS -P = Global Impression of Severity (patient version); GIS -C = Global Impression of Severity (caregiver 
version); GIS -Clin = Global Impression of Severity (clinician version)   
VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
Regeneron Pharmaceuticals, Inc.  Page 78 
CONFIDENTIAL  Table  3: Schedule of Events - Early Termination Visits and Unscheduled Visits  
Study Procedure  ET1
(Befo re Part C)  ET1
(During Follow -up) ET1
(During Part 
C) Unscheduled Visit 
(before Rescue 
Treatment)  Unscheduled Visit  
(For Other Reasons)  
Treatment:  
Con Meds/Procedures  X X X X X 
Efficacy:  
Age in months  X X X X X 
Weight, Height ( or length for  
patients <2  years of age ) X X X X 
Pediatric EoE Sign/Symptom 
Questionnaire:2 
Patient version (PESQ -P)  
Caregiver version (PESQ -C) (Daily Diary)  X X 
Pediatric EoE Impact Scale:2 
Patient version (PEIS -P) 
Caregiver version (PEIS -C) X X X X 
Global Impression of 
Change:3 
Patient version (GIC -P) 
Caregiver version (GIC -C) 
Clinician version (GIC -
Clin)  X X X 
Global Impression of 
Severity:3
Patient version (GIS -P) 
Caregiver version (GIS -C) 
Clinician version (GIS -Clin)  X X X X 
Pediatric Eosinophilic 
Esophagitis Symptom Score:6
Caregiver version 
(PEESSv2.0)  X X X 
Endoscopy with Biopsies with 
EoE-EREFS4 X4, 4a X4, 4a X4b 
Safety:  
Vital Signs  X X X X 
Physical Examination  X X X 
Adverse Events  X X X X X 
VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
Regeneron Pharmaceuticals, Inc.  Page 79 
CONFIDENTIAL  Study Procedure  ET1
(Befo re Part C)  ET1
(During Follow -up) ET1
(During Part 
C) Unscheduled Visit 
(before Rescue 
Treatment)  Unscheduled Visit  
(For Other Reasons)  
Laboratory Testing:  
Hematology  X X X 
Chemistry  X X X 
Pregnancy test (WOCBP)  urine  urine  urine  
Urinalysis5 X X X 
PK and ADA Samples:  
Functional dupi[INVESTIGATOR_24903]  X X X 
Anti-dupi[INVESTIGATOR_24904]  X X 
Biomarkers:  
Serum total IgE  X 
Eotaxin -3 X 
ADA = anti -drug antibody; EoE -EREFS = Eosinophilic Esophagitis -Endoscopic Reference Score; EOS = end of study; EOT = end of treatment; PEESS = 
Pediatric Eosinophilic Esophagitis Symptom Score; PRO = patient reported outcome; PESQ -P = Pediatric EoE Sign/Symptom Questionnaire (patient version); 
PESQ -C = Pediatric EoE Sign/Symptom Questionnaire (caregiver version); PEIS -P = Pediatric EoE Impact Scale (patient version); PEIS -C = Pediatric EoE 
Impact Scale (caregiver version);  GIC -P = Glob al Impression of Change (patient version); GIC -C = Global Impression of Change (caregiver version); GIC -Clin 
= Global Impression of Change (clinician version); GIS -P = Global Impression of Severity (patient version); GIS -C = Global Impression of Severity ( caregiver 
version); GIS -Clin = Global Impression of Severity (clinician version); WOCBP = Women of childbearing potential  
VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 80 
 CONFIDENTIAL  Table  4: Schedule of Events Open -Label Extension Part C (OLE) and EOS Schedule of Events  
Open -Label Extension Period  12-Week 
Follow -
Up 
Study 
Procedure  V 
171,7 PV 
1911 PV 
2011 V 
21 PV 
2211 V 
23 PV 
2411 V 
25 PV 
2611 V 
27 PV 
2811 V 
29 PV 
3011 V 
31 PV 
3211  
V 
33 PV 
3411 V 
35 PV 
3611 EOT  
V37 EOS13 
V38 
Week (W)  W 
[ADDRESS_24077] 
Visit     
+12 Wk  
Day (D)  D 
[ADDRESS_24078] 
Dose 
+84D  
Visit Window 
(Days [d])  ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d +7d 
Inclusion/ 
Exclusion  X                     
Treatment:   
Administer 
study drug 
 
                      
Study drug 
dispensation  
for  
 
Study drug 
dispensation  
for  
Study drug 
accountability  X   X  X  X  X  X  X  X  X  X  
Concomitant 
medications/ 
procedures  X X X X X X X X X X X X X X X X X X X X X 
 
 
Efficacy:  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
Regeneron Pharmaceuticals, Inc.  Page 81 
CONFIDENTIAL  Open -Label Extension Period  12-Week
Follow -
Up 
Study 
Procedure  V 
171,7 PV 
1911 PV 
2011 V 
21 PV 
2211 V 
23 PV 
2411 V 
25 PV 
2611 V 
27 PV 
2811 V 
29 PV 
3011 V 
31 PV 
3211 V 
33 PV 
3411 V 
35 PV 
3611 EOT  
V37 EOS13 
V38 
Week (W)  W 
[ADDRESS_24079] 
Visit 
+12 Wk
Day (D)  D 
[ADDRESS_24080] 
Dose 
+84D
Visit Window 
(Days [d])  ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d +7d
Age in 
Months  X9 X X X X X X X X X X X X X X X X X X X X 
Weight, 
Height (or 
length for 
patients <2 
years of 
age)14 X9 X X X X X X X X X X 
EoE-
EREFS10X X 
Endoscopy 
with biopsiesX X
Pediatric 
Eosinophilic 
Esophagitis 
Symptom 
Score:
Caregiver 
version 
(PEESSv2.0)[ADDRESS_24081] 
Scale:3 X9 X X X X 
VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 82 
 CONFIDENTIAL  Open -Label Extension Period  12-Week 
Follow -
Up 
Study 
Procedure  V 
171,7 PV 
1911 PV 
2011 V 
21 PV 
2211 V 
23 PV 
2411 V 
25 PV 
2611 V 
27 PV 
2811 V 
29 PV 
3011 V 
31 PV 
3211  
V 
33 PV 
3411 V 
35 PV 
3611 EOT  
V37 EOS13 
V38 
Week (W)  W 
[ADDRESS_24082] 
Visit     
+12 Wk  
Day (D)  D 
[ADDRESS_24083] 
Dose 
+84D  
Visit Window 
(Days [d])  ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d +7d 
Patient 
version 
(PEIS -P) 
Caregiver 
version 
(PEIS -C) 
Global 
Impression of 
Severity:4 
Patient 
version 
(GIS -P) 
Caregiver 
version 
(GIS -C) 
Clinician 
version (GIS -
Clin)  X9     X    X      X    X  
Safety:  
Vital signs X   X  X  X  X  X  X  X  X  X X 
Physical 
examination           X          X X 
Adverse 
events  X X X X X X X X X X X X X X X X X X X X X 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 83 
 CONFIDENTIAL  Open -Label Extension Period  12-Week 
Follow -
Up 
Study 
Procedure  V 
171,7 PV 
1911 PV 
2011 V 
21 PV 
2211 V 
23 PV 
2411 V 
25 PV 
2611 V 
27 PV 
2811 V 
29 PV 
3011 V 
31 PV 
3211  
V 
33 PV 
3411 V 
35 PV 
3611 EOT  
V37 EOS13 
V38 
Week (W)  W 
[ADDRESS_24084] 
Visit     
+12 Wk  
Day (D)  D 
[ADDRESS_24085] 
Dose 
+84D  
Visit Window 
(Days [d])  ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d ±7d +7d 
Laboratory Testing  
Hematology, 
Chemistry           X          X X 
Pregnancy 
test5 Urine  Urine Urine  Urine  Urine  Urine  Urine  Urine  Urine  Urine  Urine  Urine  Urine  Urine  Urine  Urine  Urine  Urine  Urine  Urine  Urine  
Urinalysis6          X          X X 
PK and ADA Samples:   
PK Sample12          X          X X 
Anti-
dupi[INVESTIGATOR_24905]           X          X  
Biomarkers:  
Collection of 
plasma and 
serum sample 
for 
exploratory 
research  X9         X          X X 
ADA = anti -drug antibody; EoE -EREFS = Eosinophilic Esophagitis -Endoscopic Reference Score; EOS = end of study; EOT = end of treatment; PEESS = 
Pediatric Eosinophilic Esophagitis Symptom Score; PRO = patient -reported outcome; PEIS -P = Pediatric EoE Impact Scale (patient version); PEIS -C = Pedia tric 
EoE Impact Scale (caregiver version); GIS -P = Global Impression of Severity (patient version); GIS -C = Global Impression of Severity (caregiver version); GIS -
Clin = Global Impression of Severity (clinician version); PV = Phone Visit; V = Clinic Visit  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 84 
 CONFIDENTIAL  9.1.1.  Footnotes for the Schedule of Events Tables  
[IP_ADDRESS].  Footnotes for Table 1  
1. For patients without a satisfactory prior endoscopy/biopsy (eg,  histological criteria were 
not met, or the biopsy was not performed while patient was on at least 8 weeks of PPI 
[CONTACT_3148]), the screening period will be extended for up to 12 weeks (day -85) to allow for 
at least 8 weeks of PPI [INVESTIGATOR_24906]/biopsies. For all other 
patients, the screening period will be shorter, with sufficient time to allow screening 
assessments and laboratory test results to be available prior to the baseline 
endoscopy/biopsies.  
2. The endoscopy/imaging for EoE -EREFS/biopsy procedures should be performed after all 
other efficacy and safety assessments.  
2a. The baseline esophageal endoscopy with biopsies and the stomach and/or 
duodenum endoscopi[INVESTIGATOR_24907] 1. For patients without a satisfactory prior historical 
endoscopy/biopsy, the baseline endoscopy/biopsies must be performed after at least 
8 weeks of PPI. Patients may be randomized as soon as their endoscopy/biopsy results 
are confirmed, and all other eligibility criteria are met.  
2b. For patients who receive rescue treatment during the double -blind treatment period, 
the endoscopy/EoE -EREFS/bio psy procedures will be performed prior to the initiation 
of rescue treatment. Patients undergoing endoscopy/biopsy prior to rescue will not 
undergo the subsequent scheduled endoscopy/biopsy at week 16 and/or week  52. 
3. Patients may be re -screened if they fai l the screening evaluation, unless the reason for 
screen failure is related to histologic or clinical disease severity inclusion criteria. The 
baseline endoscopy with biopsy and EoE -EREFS scoring will not be repeated for re -
screened patients. These results  will continue to be valid baseline data. Re -screening must 
occur within 6 months of the screen failure.  
4. Assessments indicated for this week 16 (end of treatment) visit should be performed for all 
patients. For patients who will enter extended treatment, t here are additional events listed 
for the week 16 visit in  Table  2. 
5. Patients and/or caregivers will be trained on administration of study drug.  
6. On schedu led in -clinic study visit days, study drug will be administered in the clinic (by 
[CONTACT_102], site staff, or caregiver) after all assessments are completed. Study drug 
administered at the study sites by [CONTACT_25012]/procedures. Study drug will be 
provided/dispensed for those doses scheduled to be administered at home before the next 
in-clinic visit. Study drug administration that occurs in clinic should occur per the S chedule 
of Events in Tables 1 and 2. Parents (or caregivers) will return the study kit box (for 
prefilled syringes) at each subsequent in -clinic visit. Parents (or caregivers) who prefer to 
have the clinic staff administer study drug may choose to have inj ections administered in 
the clinic.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 85 
 CONFIDENTIAL  7. The PESQ -P will be completed daily by [CONTACT_1962] >8 to <12 years of age (determined at the 
time of screening visit 1) just before going to bed for the night. The PESQ -C will be 
completed daily by [CONTACT_25013] >1 to <12 years of age (determined at the time of 
screening visit 1) after the patients go to bed for the night. The PESQ -P and PESQ -C will 
be completed via an electronic diary (diary) and site personnel should conduct regular 
checks of patient and caregiver diary compliance. The PEIS -P and PEIS -C will be 
completed during site visits as indicated in the Schedule of Events table by [CONTACT_25014], respectively.  
8. The GIS -P, GIS -C, GIS -Clin and the GIC -P, GIC -C, and GIC -Clin will be completed by 
[CONTACT_25015] ( >8 to <12 years of age determined at the time of screening 
visit 1), caregivers (of patients >1 to <12 years of age determined at the time of screening 
visit 1) , and study investigator/clinician, respectively.  
9. EoE-EREFS imaging  will be analyzed and scored by a central reading center. Minor 
esophageal features will be assessed by [CONTACT_093].  
10. Assessments will be performed and blood samples will be collected before the 
administration of study drug. In the event of suspected S AEs, such as anaphylaxis or 
hypersensitivity, functional dupi[INVESTIGATOR_24908] -dupi[INVESTIGATOR_24909].  
11. Patients will be closely monitored at the study site at visits 3 and 4 for a minimum of 
30 minutes after the administration of study drug. In addition to the predose assessments, 
AEs and vital signs (body temperature, blood pressure, respi[INVESTIGATOR_697], and heart rate) will 
be assessed at 30 minutes (±10 minutes) post -dose. Vital signs should be taken predose a t 
all other indicated visits.  
12. Tuberculosis testing will be performed on a country -by-country basis according to local 
guidelines if required by [CONTACT_25016].  
13. A negative result must be obtained prior to the randomization visit for all femal es post -
menarche. In case of a positive urine test, the study treatment will be withheld and a serum 
pregnancy test to confirm the pregnancy should be performed as soon as possible. A 
confirmed pregnancy will lead to study drug discontinuation in all cases . 
14. Urinalysis is only required for patients aged ≥6 years.  
15. The Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) version 2.0 will be 
completed by [CONTACT_25013] >1 to <12 years of age (determined at the time of 
screening visit 1).  
16. Exit interv iews will be conducted by a trained interviewer by [CONTACT_16470] 14 days of 
completing week 16/visit 8.  These interviews will be completed with caregivers.  Patients 
aged ≥8 to <12 years old (determined at the time of screening visit 1)  may also join a  
portion of the exit interview.   
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 86 
 CONFIDENTIAL  [IP_ADDRESS].  Footnotes for Table 2  
1. This visit is the same as the week 16 visit for the double -blind study portion ( Table  1), and 
all other assessments indicated for week 16 ( Table  1) should be performed. Endoscopy 
with biopsies at visit 8/week [ADDRESS_24086] be completed prior to adminis tration of study drug 
for Part B Extended Active Treatment.  
2. Study assessments will be performed, and blood samples will be collected prior to 
administration of study drug. In the event of suspected SAEs, such as anaphylaxis or 
hypersensitivity, functional dupi[INVESTIGATOR_24908] -dupi[INVESTIGATOR_24909] . 
3. In addition to predose assessments, AEs and vital signs (body temperature, blood pressure, 
respi[INVESTIGATOR_697], and heart rate) will be assessed at 30 minutes (±10 m inutes) post -dose.  
4. 4a. Study drug administration will continue through week 50.  
4b. Weight assessed at visit 8 / week 16 and visit 12 / week 32 will be used to determine 
weight -tiered dose for the 36 -week extended active treatment period. If weight has 
increased  at visit 12 such that the patient meets a larger weight tier, weight -tiered dosing 
will be re -assigned according to the patient’s weight at this visit. If weight is the same or 
decreased at visit 12, then weight -tiered dosing will remain as origina lly assigned at visit 
8 / week 16. The patient will remain within the original exposure dosing assignment (higher 
exposure group or lower exposure group). On scheduled in -clinic study visit days, study 
drug will be administered in the clinic (by [CONTACT_11581] t, site staff, or caregiver). Study drug 
administered at the study sites by [CONTACT_25017]/procedures. Study drug will be provided for 
those scheduled doses to be admini stered at home before the next in -clinic visit. Parents 
(or caregivers) will return the study kit box (for prefilled syringes) at each subsequent in -
clinic visit. Study drug administration that occurs in clinic should occur per the Schedule 
of Events table . Parents (or caregivers) who prefer to have the clinic staff administer study 
drug may choose to have injections administered in the clinic.  
5. The PESQ -P will be completed daily by [CONTACT_1962] >8 to <12 years of age (determined at the 
time of screening visit 1) just before going to bed for the night. The PESQ -C will be 
completed daily by [CONTACT_25013] >1 to <12 years of age (determined at the time of 
screening visit 1) after the patients go to bed for the night. The PESQ -P and PESQ -C will 
be completed  via an electronic diary (diary) and site personnel should conduct regular 
checks of patient and caregiver diary compliance. The PEIS -P and PEIS -C will be 
completed during site visits as indicated in the Schedule of Events table by [CONTACT_25018], respectively.  
6. The GIS -P, GIS -C, GIS -Clin and the GIC -P, GIC -C, and GIC -Clin will be completed 
during site visits by [CONTACT_1962] ( >8 to <12 years of age determined at the time of screening 
visit 1) , caregivers (of patients >1 to <12 years of age determine d at the time of screening 
visit 1) , and study investigator/clinician, respectively.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 87 
 CONFIDENTIAL  7. Endoscopy/imaging for EoE -EREFS/biopsy procedures should be performed after all other 
efficacy and safety assessments. Minor esophageal features will be assessed by [CONTACT_1275].  
7a. For patients who receive rescue treatment, endoscopy/EoE -EREFS/biopsy procedures 
will be performed prior to initiation of rescue treatment. Patients undergoing 
endoscopy/biopsy prior to rescue will not undergo the scheduled endoscopy/biopsy  at 
weeks 16 and 52.  
8. In addition to the predose assessments, AEs and vital signs (body temperature, blood 
pressure, respi[INVESTIGATOR_697], and heart rate) will be assessed at 30 minutes (±10 minutes) post -
dose at visit 8.  
9. In case of a positive urine pregnancy t est, the study treatment will be withheld and a serum 
pregnancy test to confirm the pregnancy should be performed as soon as possible. A 
confirmed pregnancy will lead to study drug discontinuation in all cases.  
10. Urinalysis is only required for patients aged  ≥6 years.  
11. The Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) version 2.0 will be 
completed by [CONTACT_25013] >1 to <12 years of age (determined at the time of 
screening visit 1).  
12. Assessments indicated for this week 52 (end of extended ac tive treatment) visit should be 
performed for all patients. For patients who will enter the open -label extension period, 
there are additional events listed for the week [ADDRESS_24087] of procedures to be performed for Re -Entry patient s, please see Table  4. 
[IP_ADDRESS].  Footnotes for Table 3  
1. Patients who are withdrawn from study drug will be asked to complete the 12 -week follow -
up period and the end of study visit.  
2. The PESQ -P will be completed daily by [CONTACT_1962] >8 to <12 years of age (determined at the 
time of scr eening visit 1) just before going to bed for the night. The PESQ -C will be 
completed daily by [CONTACT_25013] >1 to <12 years of age (determined at the time of 
screening visit 1) after the patients go to bed for the night. The PESQ -P and PESQ -C will  
be completed via an electronic diary (diary) and site personnel should conduct regular 
checks of patient and caregiver diary compliance. The PEIS -P and PEIS -C will be 
completed during site visits as indicated in the Schedule of Events table by [CONTACT_102] s and 
caregivers, respectively.  
3. The GIS -P, GIS -C, GIS -Clin and the GIC -P, GIC -C, and GIC -Clin will be completed 
during site visits as indicated by [CONTACT_1962] ( >8 to <12 years of age determined at the time of 
screening visit 1) , caregivers (of patients >1 to <12 years of age determined at the time of 
screening visit 1) , and study investigator/clinician, respectively.  
4. EoE-EREFS imaging will be analyzed and scored by a central reading center. Minor 
esophageal features will be assessed by [CONTACT_093].  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 88 
 CONFIDENTIAL  4a. For patients who receive rescue treatment, endoscopy/imaging for EoE -EREFS/biopsy 
procedures will be performed prior to initiation of rescue treatment. Patients undergoing 
endoscopy/biopsy prior to rescue will not undergo the any future scheduled 
endoscopy/ biopsy (weeks 16, 52, 100 and/or 160).  
4b. Endoscopy/imaging for EoE -EREFS/biopsy will be performed only if the unscheduled 
visit is for the purpose of administering rescue therapy.  
5. Urinalysis is only required for patients aged ≥6 years  
6. The Pediatric Eosin ophilic Esophagitis Symptom Score (PEESS) version 2.0 will only be 
completed by [CONTACT_25013] >1 to <12 years of age (determined at the time of 
screening visit 1)  at an early termination and/or unscheduled visit before rescue visit(s).  
[IP_ADDRESS].  Footnotes for Table 4  
1. This visit is the same as the week 52 visit for the extended active treatment period for those 
patients entering Part C immediately after Part B ( Table  2) or during the Safety follow -up 
period, and all other assessments indicated for week 52 ( Table  2) should be performed prior 
to this portion o f the visit.  
2. Endoscopy with biopsies at visit 17/week [ADDRESS_24088] be completed prior to administration of 
study drug for Part C - Open -Label Extension Period. Study drug administration is based 
on weight -tier (Section  8.1 Investigational and Reference Treatments)  Weight must be 
collected at all in -clinic visits . Dose is assigned to match weight group for baseline for Part 
C (Week 52) and re -assigned afte r week 52 only if weight increases . 
3. The PEIS -P and PEIS -C will be completed during site visits as indicated in the Schedule 
of Events table by [CONTACT_25019], respectively.  
4. The GIS -P, GIS -C, and GIS-Clin will be completed by [CONTACT_25020] (>8 to 
<12 years of age determined at the time of screening visit 1), caregivers (of patients ≥1 to 
<12 years of age determined at the time of screening visit 1), and study 
investigator/clinician, respectively.  
5. All females post -menarche must have monthly pregnancy testing during Part C  (Table  4). 
In case of a positive urine test, the study treatment will be withheld and a serum pregnancy 
test to confirm the pregnancy should be performed as soon as possible. A confirmed 
pregnancy wil l lead to study drug discontinuation in all cases.  
6. Urinalysis is only required for patients aged ≥[ADDRESS_24089] completed their end of study visit (Visit 18 in previous protocol 
versions) prior to entering the open -label extension period must complete the procedures 
indicated for the Re -Entry Visit ( Table  2) and are eligible for re -entry to the study for the 
open -label extension period and safe ty follow -up periods only.  The Re -Entry Visit for 
eligible re -entry patients may be combined with the week 52 Visit procedures for Part C 
(Table  4). 
8. The Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) version 2.0 will be 
completed by [CONTACT_25013] ≥1 to <12 years of age (determined at the time of 
screening visit 1).  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24090] 
study drug shipped to them and admini stered at home by [CONTACT_25021]/or caregivers; 
however, patients and their parents/caregiver have the option to come to the clinic and have 
study drug administered by [CONTACT_25022]. Phone contacts at any 
time during Part C are encouraged to ensure compliance and safety of study drug dosing.  
12. Blood samples for dupi[INVESTIGATOR_24910]. The PK sample collected may be used for dupi[INVESTIGATOR_24911] o verall clinical presentation at that time. In the event of suspected 
SAEs, such as anaphylaxis or hypersensitivity, additional blood samples may be collected 
at or near the event for PK and ADA assessments.  
13. The End of Study (EOS) visit may occur twice for Re-Entry patients.  
14. Weight -based dosing should be adjusted based on the patient’s weight at specified in -clinic 
visits.  
9.1.2.  Early Termination Visit  
Patients who are withdrawn from the study will be asked to return to the clinic for an early 
termination visit c onsisting of the assessments described in  Table  3. 
9.1.3.  Unscheduled Visits  
All attempts should be made to keep patients on the study schedule. Unscheduled visi ts may be 
necessary to repeat testing following abnormal laboratory results, for follow -up of AEs, or for any 
other reason, as warranted.  
9.1.4.  Re-Entry Visit  
Patients who have completed their end of study visit prior to entering the open -label extension 
period are eligible for re -entry to the study for the open -label extension period. The following 
study procedures are required at a Re -Entry Visit:  
• Part C re -entry criteria  (Section [IP_ADDRESS] ) 
• Informed consent  
• Updates for all relevant medical history and prior and concomitant 
medications/procedures  
• Physical Examination  
• Age, weight, height (length for patients <2 years of age)  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 90 
 CONFIDENTIAL  9.2. Study Procedures  
9.2.1.  Procedures Performed Only at the Screening/Baseline Visit  
The following procedures will be performed for the sole purpose of determining study eligibility 
or characterizing the baseline population: demographics and medical history. Tuberculosis testing 
will be performed on a country -by-country basis according to local guidelines if required by 
[CONTACT_25016] .  
9.2.2.  Efficacy Procedures  
[IP_ADDRESS].  Patient -, Caregiver -, or Clinician -Reported Outcome Measures  
NOTE: The patient -, caregiver -, or clinician -reported outcome measures will be completed per 
appropriate age range (at screening visit 1) for the respective outcome measures specified in the 
subsections below. For outcome measures to be completed on visit days with assessments and 
study drug administration at the clinic, these outcom e measures should be completed prior to 
receiving study drug. Patients ≥8 to <[ADDRESS_24091] 8 out o f 14 days of eDiary for the PESQ -C should be completed prior to baseline / visit 3.  
[IP_ADDRESS].1.  Pediatric EoE Sign/Symptom Questionnaire (PESQ)  
The PESQ has a patient version (PESQ -P) and caregiver version (PESQ -C). 
• The PESQ -P is a patient -reported outcome measure int ended to be completed 
independently by [CONTACT_25023] >8 to <12 years of age. The PESQ -P will measure 
occurrence and severity of EoE symptoms and will be completed once daily via an 
electronic diary.  
 
 
 
 
• The PESQ -C is an observer -reported outcome measure intended to be completed 
independently by [CONTACT_25024]. The PESQ -C 
will measure occurrence of signs of EoE and will be com pleted once daily via an 
electronic diary.  
 
 
 
 
[IP_ADDRESS].2.  Pediatric EoE Impact Scale (PEIS)  
The Pediatric EoE Impact Scale (PEIS) has a patient version (PEIS -P) and a caregiver version 
(PEIS -C). The PEIS -P and PEIS -C will be completed per the Schedule of Events in Table  1, 
Table  2, Table  3, and Table  4. 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00

Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 91 
 CONFIDENTIAL  • The PEIS -P is a patient -reported outcome measure intended to be completed 
independently by [CONTACT_25025] >8 to <[ADDRESS_24092] of EoE on patients’ health -related during the past 1 week.  
• The PEIS -C is intended to be completed independently by [CONTACT_25026] >1 to <[ADDRESS_24093] of the pediatric 
patient’s EoE on caregiver anxiety, social and professional activities, act ivities of 
daily living, and relationships during the past 1 week.  
[IP_ADDRESS].3.   Global Impression of Change (GIC)  
The GIC has a patient version (GIC -P), a caregiver version (GIC -C), and a clinician version ( GIC-
Clin). The GIC -P, GIC-C, and GIC -Clin will be completed per the Schedule of Events in Table  1, 
Table  2, and Table  3 . 
• The GIC -P is a single -item patient -reported outcome measure intended to be 
completed independently by [CONTACT_25025] >8 to <12 years of age. The GIC -
P will assess the patient’s impression about the overall change (improvement or 
worsening) in his/h er EoE condition since study treatment initiation.  
• The GIC -C is a single -item observer -reported outcome measure intended to be 
completed independently by [CONTACT_25027] >1 to <12 years of 
age. The GIC -C will assess the caregiver’s imp ression about the overall change 
(improvement or worsening) in the pediatric patient’s EoE condition since study 
treatment initiation.  
• The GIC -Clin is a single -item observer -reported outcome measure intended to be 
completed independently by [CONTACT_25028]-physician of all pediatric EoE patients 
in the study. The GIC -Clin will assess the study investigator’s/clinician’s impression 
about the overall change (improvement or worsening) in the pediatric patient’s EoE 
condition since study treatment initiation . 
[IP_ADDRESS].4.  Global Impression of Severity (GIS)  
The GIS has a patient version (GIS -P), a caregiver version (GIS -C), and a clinician version (GIS -
Clin). The GIS -P, GIS -C, and GIS -Clin w ill be completed per the Schedule of Events in Table  1, 
Table  2, Table  3, and  Table  4. 
• The GIS -P is a single -item patient -reported outcome measure intended to be 
completed independently by [CONTACT_25025] >8 to <12 years of age. The GIS -P 
will assess the patient’s impre ssion about the overall severity of his/her EoE condition 
during the past 1  week.  
• The GIS -C is a single -item observer -reported outcomes measure intended to be 
completed independently by [CONTACT_25027] >1 to <12 years of 
age. The GIS -C will assess the caregiver’s impression about the overall severity of 
the pediatric patient’s EoE condition during the past 1 week.  
• The GIS -Clin is a single -item observer -reported outcomes measure intended to be 
completed independently by [CONTACT_25029] r-physician of all pediatric EoE patients 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 92 
 CONFIDENTIAL  in the study. The GIS -Clin will assess the study investigator’s/clinician’s impression 
about the overall severity of the pediatric patient’s EoE condition during the past 1 
week.  
[IP_ADDRESS].5.  Pediatric Eosinophilic Esophagitis Symptom Score (PEESS)  
• The Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) version 2.0 - 
caregiver version is a caregiver reported outcomes measure which assesses the 
frequency and severity of EoE symptoms among pediatric patients (Franciosi, 2011 ). 
The PEESSv2.0 caregiver version consis ts of 20 items and has a one -month recall 
period. The total PEESSv2.0 score ranges from 0 to 100; higher scores indicate 
greater symptom burden of among pediatric EoE patients. This questionnaire will be 
collected on paper per the Schedule of Events ( Table  1, Table  2, Table  3 and 
Table  4). 
[IP_ADDRESS].6.  Exit Interview  
• Exit interviews will be conducted by a trained interviewer by [CONTACT_16470] 
14 days of completing week 16/visit 8.  These interviews will be completed with 
caregivers. Patients aged ≥8 to <12 years o ld (determined at the time of screening 
visit 1) may also join a portion of the exit interview.  This exit interview will support 
interpretation of clinically meaningful change in signs/symptoms during the study. 
Detailed instructions related to these inte rviews will be available at the clinical site. 
Patient caregiver contact [CONTACT_25030] a trained 
interviewer to schedule and complete the exit interview.  
[IP_ADDRESS].  Body Weight and Height  
Body weight in kg and height in cm (or lengt h for patients <2 years of age) will be measured at 
time points according to Table  1, Table  2, Table  3 and Table  4. Body mass index will be 
programmatically calculated based on the weight and height data . 
[IP_ADDRESS].  Endoscopy with EoE -EREFS, Biopsies, and Imaging  
Imaging for EoE -EREFS and biopsies will be assessed. Video is the preferred metho d of imaging, 
but photographs may be used in special circumstances (eg, technical difficulty). Training will be 
provided to study sites on performing these procedures and will be conducted prior to biopsies. 
All biopsies performed during this study will be  evaluated by a qualified central histology 
laboratory.   
The endoscopy/EoE -EREFS/ biopsy procedure will be performed per the Schedule of Events in 
Table  1, Table  2, Table  3 and Table  4.  
EoE-EREFS  
The EoE esophageal characteristics will be analyzed based on the EoE -EREFS, a validated scoring  
system for inflammatory and remodeling features of disease using both overall scores and scores 
for each individual characteristic (Hirano, 2013 ). Imaging should be collected for EoE -EREFS 
analysis and scoring by a centralized reading center.  Video is the preferred m ethod of imaging, but 
photographs may be used in special circumstances (eg, technical difficulty).  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 93 
 CONFIDENTIAL  The proximal and distal esophageal regions will be scored separately; the score for each region 
ranges from 0 to 9 and the overall score ranges from 0 to 18.  The major esophageal features 
include:   
• Edema (absent, present)  
• Rings (absent, mild, moderate, severe)  
• Exudates (absent, mild, severe)  
• Furrows (absent, mild, severe)  
• Stricture (absent, present)  
In addition to the major features above, data for the follow ing minor features will be assessed by 
[CONTACT_093]:  
• Crepe paper esophagus (mucosal fragility or laceration upon passage of diagnostic 
endoscope): absent, present  
• Narrow caliber esophagus (reduced luminal diameter of the majority of the tubular 
esophag us): absent, present  
• Stricture diameter  
Mucosal changes associated with gastroesophageal reflux disease will also be recorded using the 
Los Angeles classification system for erosions (No Erosions or Grade A, B, C, or D).  
Biopsies  
Biopsies will be obtained by [CONTACT_25031] (visit 2), week  16, week 52, 
week 100, and week 160 visits, and immediately prior to start of rescue medication or procedures 
(only applies to rescue medication/or procedures that occur before Week 52 visit) . The screening 
endoscopy should be performed at a time during the screening period that will allow results to be 
available prior to day -[ADDRESS_24094] 9  mucosal pi[INVESTIGATOR_24912] 3  esophageal regions:  3  proximal, 3  mid, and 3  distal. 
Two samples from each region will be used for histology (needed for study inclusion criteria, as 
well as endpoint assessment) and the others for RNA  extraction. To participate in the study, 
patients must have a peak intraepi[INVESTIGATOR_24759] ≥15 eos/hpf (400×) in at least 2 of the 3 
esophageal regions sampled. Residual biopsy samples processed for histopathological analyses 
may also be used for exploratory research; samples may be used for immunohis tochemical or 
RNAscope analyses (Section  9.2.7 ). 
In addition, biopsy specimens from the stomach and duodenum will be obtained at visit [ADDRESS_24095] stomach and/or duodenal abnormalities at baseline will have follow -up stomach 
and/or duodenal biopsies at week 16, week 52, week 100 and week 160.  
Biopsy samples for histopathological analyses will be sent to a central p athology laboratory for 
processing and analysis. If required by [CONTACT_25032], biopsy samples will be 
processed and analyzed by [CONTACT_12082], and the processed specimen will be sent to the 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 94 
 CONFIDENTIAL  central pathology laboratory for central rea ding. These samples will be assessed for peak 
eosinophil count per hpf, and EoE grade scores and stage scores will be assigned. Eosinophilic 
esophagitis grade and stage scores evaluate 8 features: eosinophil density, basal zone hyperplasia, 
eosinophil absc esses, eosinophil surface layering, dilated intercellular spaces, surface epi[INVESTIGATOR_24913], dyskeratotic epi[INVESTIGATOR_1663], and lamina propria fibrosis (absent/present).  
Assessment of lamina propria fibrosis may not be possible if the esophageal biops y specimens do 
not contain adequate amounts of subepi[INVESTIGATOR_24914], and then it will not be included in 
the overall EoE grade and stage scores. Severity (grade) and extent (stage) of abnormalities will 
be scored using a 4 -point scale (0 normal; 3 maximum change). The endoscopy with biopsies 
procedure will be performed the same way at all scheduled visits.  
Histology results will be interpreted by a pathologist at a central pathology reading center who will 
be blinded to the treatment assignment. Det ailed instructions for biopsy sample collection and 
handling will be provided in the study regulatory binders.  
Video and/or Photographs  
Video and/or photographs should be taken by [CONTACT_25033]. A copy o f these video and/or photographs will be requested from the study sites. 
Details for collecting and sending these video and/or photographs will be provided in the study 
regulatory binders. Video is the preferred method of imaging, but photographs may be us ed in 
special circumstances (eg, technical difficulty).  
9.2.3.  Safety Procedures  
[IP_ADDRESS].  Vital Signs  
Vital signs, including heart rate, blood pressure, respi[INVESTIGATOR_697], and body temperature will be 
collected predose and [ADDRESS_24096] 5  minutes.  
[IP_ADDRESS].  Physical Examination  
A thorough and complete physical examination will be performed at time points according to 
Table  1, Table  2, Table  3, and Table  4. Care should be taken to examine and assess any 
abnormalities that may be present, as indicated by [CONTACT_25034]’s medical history.  
[IP_ADDRESS].  Laboratory Testing  
Hematology, chemistry, urinalysis, and pregnancy testing samples will be analyzed by a central 
laboratory. Samples will be collected predose at time points listed in Table  1, Table  2, Table  3, 
Table  4. Detailed instructions for blood sample collection are in the laboratory manual  provided 
to study sites. Tests will include:  
Blood Chemistry  
Sodium  Creatinine   
Potassium  Blood urea nitrogen (BUN)   
Chloride  Aspartate aminotransferase (AST)   
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 95 
 CONFIDENTIAL  Carbon dioxide  Alanine aminotransferase (ALT)   
Calcium  Alkaline phosphatase   
Glucose  Lactate dehydrogenase (LDH)   
Albumin  Estimated glomerular filtration rate (eGFR)   
Total protein, serum  Total and indirect bilirubin   
Hematology  
Hemoglobin  Differential:  
Hematocrit   Neutrophils  
Red blood cells (RBCs)   Lymphocytes  
White blood cells (WBCs)   Monocytes  
Red cell indices   Basophils  
Platelet count   Eosinophils  
Urinalysis  
Microscopic analysis will only be done in the event of abnormal dipstick results.  
Color  Glucose  RBC  
Clarity  Blood  Hyaline and other casts  
pH Bilirubin  Bacteria  
Specific gravity  Leukocyte esterase  Epi[INVESTIGATOR_24915]  
• Pregnancy testing will be performed for all WOCBP. Serum or urine pregnancy testing 
will be performed at time points listed in Table  1, Table  2, and  Table  3, and Table  4. 
• Tuberculosis testing will be  performed on a country -by-country basis according to local 
guidelines if required by [CONTACT_25035].  
Abnormal Laboratory Values and Laboratory Adverse Events  
All laboratory values must be reviewed by [CONTACT_25036].  
Significantly abnormal test results that occur after start of treatment must be repeated to confirm 
the nature and degree of the abnormality. When necessary, appropriate ancillary investigations 
should be initiated. If the abnormality fails to r esolve or cannot be explained by [CONTACT_25037], the medical/study director must 
be consulted.  
The clinical significance of an abnormal test value, within the context of the disease under study , 
must be determined by [CONTACT_093].  
Criteria for reporting laboratory values as an AE are provided in Section  10.1.1 . 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 96 
 CONFIDENTIAL  9.2.4.  Drug Concentration and M easurements  
Samples for drug concentration measurement will be collected at visits listed in  Table  1, Table  2, 
and Table  3, and Table  4 . 
9.2.5.  Immunogenicity Measurements and Samples  
Samples for ADA and NAb assessment will be collected at time points listed in Table  1, Table  2, 
and Table  3, and Table  4. Samples positive in the ADA assay will be analyzed for the presence of 
neutralizing antibody in the NAb assay.  
9.2.6.   Pharmacodynamic and Exploratory Biomarker Procedures  
In this study, research a ssessments will be performed to explore EoE, how dupi[INVESTIGATOR_24916], type 2 inflammation, and predictors of dupi[INVESTIGATOR_24917]. Samples may also be used to evaluate markers related to toxicity, if needed.  
Samples for total IgE, serum, and eotaxin -3 (heparinized plasma) will be collected at time points 
according to  Table  1, Table  2, and  Table  3,. The biomarkers studied are relevant to the 
pathophysiology o f EoE, response to treatment (ie, assessment of type 2 inflammation), and 
dupi[INVESTIGATOR_24868], and will be assessed for predictive utility.  
Any residual samples left over from the main study may be used for exploratory research.  
[IP_ADDRESS].  Type 2 Inflammato ry and Disease -Related Biomarkers  
Eotaxin -3 and total IgE are measures of type 2 inflammation, and are known pharmacodynamic 
markers for dupi[INVESTIGATOR_24918], asthma, and nasal polyposis.  
[IP_ADDRESS].1.  Total IgE  
IL-4 and IL -13 regulate B cell class switching to IgE. Dupi[INVESTIGATOR_24919] 
(total and allergen -specific) in AD, asthma, and CRSwNP patients. Serum concentrations of total 
IgE will be measured at time points indicated in  Table  1, Table  2, and Table  3 . Modulation  of IgE 
is a pharmacodynamic measure. Data analysis will be described in the statistical analysis plan 
(SAP) and the results will be provided in the clinical study report (CSR).  
[IP_ADDRESS].2.  Eotaxin -3 
Eotaxin -3 (also know n as CCL26), an eosinophil chemokine, is up -regulated in esophageal mucosa 
of EoE patients relative to controls (Blanchard, 2006 ), and variants in the gene have been 
associated with disease risk. Eotaxin -3 mRNA expression in skin is down -regulated by [CONTACT_24983][INVESTIGATOR_24920] (Hamilton, 2014 ). Circulating concentrations have been shown to decrease in asthma and 
nasal polyposis patients treated with dupi[INVESTIGATOR_12458]. Eotaxin -3 will be measured in heparinized pla sma 
from samples collected at time points indicated in Table  1, Table  2, and Table  3. Modulation of 
eotaxin -3 is a pharmacodynamic measure. Data analysis will be  described in the  SAP and the 
results will be provided in the CSR.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 97 
 CONFIDENTIAL  [IP_ADDRESS].  EoE Diagnostic Panel and Type 2 Inflammation Transcriptomics  
The differential gene expression profiles of esophageal biopsies of EoE patients compared to 
healthy controls is the EoE diseas e transcriptome ( Sherrill, 2014 ). This disease gene expression 
signature [CONTACT_25081] a smaller gene set to be used as an EoE diagnostic panel (EDP) 
(Dellon, 2017 ). A gene signature [CONTACT_25082] 2 inflammation has been curated from the 
literature, pre -clinical experiments performed at Regeneron, and dupi[INVESTIGATOR_24921] a phase 2 study of EoE (Regeneron unpublished data). The gene lists 
comprising the EDP and type 2 transcriptomes can be found in the SAP. In a phase 2 study of EoE 
(R668 -EE-1324), dupi[INVESTIGATOR_24922], EDP and type 2 t ranscriptome 
signatures (Regeneron unpublished data).  
Normalized Enrichment Score (NES) reflects the degree to which the activity level of a set of 
transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts 
within a sample and is normalized by [CONTACT_25038] 
(Barbie,  2009 ) (Subramanian, 2005 ). NES scores will be calculated for each transcriptome 
signature [CONTACT_25083]  1, Table  2, Table  3 and Table  4 . 
9.2.7.  Biopsy Analyses  
Biopsy samples will be used for explorato ry research related to EoE, dupi[INVESTIGATOR_24923], and inflammation.  
Residual biopsy samples processed for histopathological analyses may also be used for exploratory 
research described above. Samples may be used for immunohistochemical or RNAscop e analyses.  
Biopsies processed for RNA extraction will be used for RNA expression profiling. RNA 
sequencing, qRT -PCR, and other methods may be used to evaluate expression profiles before and 
after treatment.  
9.2.8.   Future Biomedical Research (Optional)  
Patients/legal parents or legal guardians who agree for their child to participate in the future 
biomedical research sub -study will be required to assent/consent to this optional sub -study before 
samples are banked in long -term storage. The unused biomarke r samples for study -related 
research, as well as unused PK and ADA samples, will be stored for up to 15 years after the final 
date of the database lock. The unused samples may be utilized for future biomedical research that 
may or may not be d irectly related to the study, including being used as reference samples and 
assay development or validation. After 15 years, any residual samples will be destroyed. The 
results of these future biomedical research analyses will not be presented in the CSR.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 98 
 CONFIDENTIAL  [IP_ADDRESS].  Pharmacogenomic Analysis (Optional)  
Patients/legal parents or legal guardians who agree for their child to participate in the genomics 
sub-study will be required to assent/consent to this optional sub -study before collection of the 
samples. Cheek swab samp les for DNA extraction should be collected on day 1/baseline (predose), 
but can be collected at a later study visit. DNA samples will be collected for pharmacogenomics 
analyses to understand the genetic determinants of efficacy and safety associated with t he 
treatments in this study, and the molecular basis of EoE and related diseases. The samples will be 
single -coded as defined by [CONTACT_25039] (ICH) guideline E15. 
Samples will be stored for up to 15 years after the final date  of the database lock. If there are 
specific site or country requirements involving the pharmacogenomic analyses which the sponsor 
is unable to comply with, samples will not be collected at those sites.  
The purpose of the pharmacogenomic analyses is to ide ntify genomic associations with clinical or 
biomarker response to dupi[INVESTIGATOR_12458], other EoE clinical outcome measures, and possible AEs. In 
addition, associations between genomic variants and prognosis or progression of EoE, as well as 
related allergic/atopic d iseases, may also be studied. These data may be used or combined with 
data collected from other studies to identify and validate genomic markers related to the study 
drug, target pathway, or EoE and related diseases.  
Analyses may include sequence determina tion or single nucleotide polymorphism studies of 
candidate genes and surrounding genomic regions. Other methods, including whole -exome 
sequencing, whole -genome sequencing, and DNA copy number variation may also be performed. 
The list of methods may be exp anded to include novel methodology that may be developed during 
the course of this study or sample storage period. Results from the genomic analyses will not be 
reported in the CSR.  
Research findings from the optional genomic sub -study will not be disclos ed to the patient or 
principal investigator, even if they have implications for a patient’s health and management. 
Genetic results from this sub -study are for research purposes only and not for medical diagnosis 
or for reproductive decision -making  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24097] all clinical events occurring during the study data collection 
period, from the time of signing the informed consent form (ICF) to the e nd of study. Medical 
conditions that existed or were diagnosed prior to the signing of the ICF will be recorded as part 
of medical history. Abnormal laboratory values and vital signs observed at the time of informed 
consent should also be recorded as medic al history. Any subsequent worsening (ie, any clinically 
significant change in frequency and/or intensity) of a pre -existing condition that is temporally 
associated with the use of the study drug should also be recorded as an AE.  
At each visit, the invest igator will determine whether any AEs have occurred by [CONTACT_25040]. Adverse events may be directly observed, reported spontaneously by [CONTACT_25041]. Patients should be questioned in a general way,  without 
asking about the occurrence of any specific symptoms. The Investigator must assess all AEs to 
determine seriousness, severity, and causality, in accordance with the definitions in Section  10.2. 
The investigator’s assessment must be clearly documented in the site’s source documentation with 
the investigator’s signature. The investigator should follow up on SAEs (and AESIs) until they 
have resol ved or are considered clinically stable; AEs should be followed until they are resolved 
or last study visit, whichever comes first.  
Always report the diagnosis as the AE or SAE term. When a diagnosis is unavailable, report the 
primary sign or symptom as th e AE or SAE term with additional details included in the narrative 
until the diagnosis becomes available. If the signs and symptoms are distinct and do not suggest a 
common diagnosis, report them as individual entries of AE or SAE.  
Laboratory results, vit al signs, and other diagnostic result s or findings  should be appraised by [CONTACT_25042]. Isolated abnormal laboratory results, vital sign 
findings, or other diagnostic findings (ie, not part of a reported diagnos is) should be reported as 
AEs if they are symptomatic, lead to study drug discontinuation or  dose reduction,  require 
corrective treatment, or constitute an AE in the investigator ’s clinical judgment . 
For events that are serious due to hospi[INVESTIGATOR_059], the reason for hospi[INVESTIGATOR_24924] (diagnosis or symptom requiring hospi[INVESTIGATOR_059]). A procedure is not an AE or SAE, 
but the reason for the procedure may be an AE or SAE. Pre -planned (prior to signing the Informed 
Consent Form) procedu res, treatment s requiring hospi[INVESTIGATOR_5912] -existing conditions that do 
not worsen in severity, and admission for palliative or social care should not be reported as SAEs 
(see Section  10.2 for Definitions).  
For deaths, the underlying or immediate cause of death should always be reported as an SAE.  
Any SAE that may occur subsequent to the reporting period (end of the follow -up period) that the 
investigator assesses as related to study drug should also be reported.  
All AEs, SAEs , AESIs, and pregnancy reports are to be reported according to the procedures in 
Section  10.1.3.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 100 
 CONFIDENTIAL  10.1.2.  Reporting Procedure  
All events (serious and non -serious) must be reported with the investigator’s assessment of the 
event’s seriousness, severity, and causality to the (when applicable: blinded) study d rug. For SAEs 
and AESIs, a detailed narrative summarizing the course of the event, including its evaluation, 
treatment, and outcome should be provided on the AE CRF. Specific or estimated dates of event 
onset, treatment, and resolution should be included, when available. Medical history, concomitant 
medications, and laboratory data that are relevant to the event should also be summarized in the 
narrative. For fatal events, the narrative should state whether an autopsy was or will be performed, 
and include t he results if available. Information not available at the time of the initial report must 
be documented in a follow -up report. Source documents  (including hospi[INVESTIGATOR_24925], 
diagnostic reports, etc. ) will be summarized in the narrative on the AE CRF, and retained at the  
study center and available upon request.  
Urgent safety queries must be followed up and addressed promptly. Follow -up information and 
response to non -urgent safety queries should be combined for reporting to provide the most 
comple te data possible within each follow -up.  
10.1.3.  Events that Require Expedited Reporting to Sponsor  
The following events also require reporting to the sponsor (or designee) within 24 hours of learning 
of the event:  
• SAEs . 
• Adverse Events of Special Interest (AESI; s erious and nonserious) :  Adverse events 
of special interest for this study include the following:   
− Anaphylactic reactions  
− Systemic hypersensitivity reactions  
− Helminthic infections  
− Clinically symptomatic eosinophilia (or eosinophilia associated with clinical 
symptoms)  
− Any severe type of conjunctivitis or blepharitis  
− Keratitis  
− Severe injection site reactions  
− Herpes simplex infection  
− Arthralgia  
• Pregnancy:   Although pregnancy is not con sidered an AE, it is the responsibility of 
the investigator to report to the sponsor (or designee), within [ADDRESS_24098] udy drug. Any complication of pregnancy affecting a female study 
patient, and/or fetus and/or newborn that meets the SAE criteria must be reported as an 
SAE. Outcome for all pregnancies should be reported to the sponsor . 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24099] a causal relationship with the study drug. Therefore, an AE is any unfavorable and 
unintended sign (including abnormal laboratory finding), symptom, or disease  which is temporally 
associated with the use of a study drug, whether or not considered related to the study drug (ICH 
E2A Guideline. Clinical Safety Data Management: Definitions and Standards for Expedited 
Reporting, Oct 1994).  
10.2.2.  Serious Adverse Event  
An S AE is any untoward medical occurrence that at any dose:  
• Results in death  – includes all deaths, even those that appear to be completely unrelated 
to study drug (eg, a car accident in which a patient is a passenger).  
• Is life-threatening  – in the view of the  investigator, the patient is at immediate risk of 
death at the time of the event. This does not include an AE that had it occurred in a 
more severe form, might have caused death.  
• Requires in -patient hospi[INVESTIGATOR_24926]. In-
patient hospi[INVESTIGATOR_24927] a hospi[INVESTIGATOR_307] (any duration) or an 
emergency room visit for longer than 24 hours. Prolongation of existing hospi[INVESTIGATOR_24928] a hospi[INVESTIGATOR_24929], 
or is prolonged due to the development of a new AE as determined by [CONTACT_25043].  
• Results in persistent or significant disability/incapacity  (substantial disruption of 
one’s ability to conduct normal life functions).  
• Is a congenital anomaly/birth defect  
• Is an important medical event . Important medical events may not be immediately life -
threatening or result in death or hospi[INVESTIGATOR_059], but ma y jeopardize the patient or may 
require intervention to prevent one of the other serious outcomes listed above (eg, 
intensive treatment in an emergency room or at home for allergic bronchospasm; blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_1916]; or development of drug 
dependency or drug abuse).  
Criteria for reporting SAEs must be followed for these events.  
10.2.3.  Adverse Events of Special Interest  
An AESI, serious or non -serious, is one of scientific and medical interest specific to the sponsor’s 
product or program, for which ongoing monitoring and rapid communication by [CONTACT_25044]. Such an event might warrant further investigation in order to 
characterize and understand it.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 102 
 CONFIDENTIAL  10.2.4.  Severity  
The severity of  AEs will be graded according to the following scale:  
Mild:  Does not interfere in a significant manner with the patient’s normal functioning level. It 
may be an annoyance. Prescription drugs are not ordinarily needed for relief of symptoms, but may 
be giv en because of personality of the patient.  
Moderate:   Produces some impairment of functioning but is not hazardous to health. It is 
uncomfortable or an embarrassment. Treatment for symptoms may be needed.  
Severe:   Produces significant impairment of function ing or incapacitation and is a definite hazard 
to the patient’s health. Treatment for symptom may be given and/or patient hospi[INVESTIGATOR_057].  
If a laboratory value is considered an AE, its severity should be based on the degree of 
physiological impairment the va lue indicates.  
Injection Site Reactions  
The severity of injection site reactions will be graded according to the following scale (semi -colon 
indicates “or” within description of grade:  
Mild :  Pain that does not interfere with activity; mild discomfort to touch; <5 cm of erythema or 
induration that does not interfere with activity  
Moderate :  Pain that requires repeated use of non -narcotic pain reliever >24 hours or interferes 
with activity; discomfort with movement; 5.1 cm to 10 cm erythema or induration or  induration 
that interferes with activity  
Severe :  Pain that requires any use of narcotic pain reliever or that prevents daily activity; 
significant discomfort at rest; >10 cm erythema or induration; prevents daily activity; requires 
emergency room visit o r hospi[INVESTIGATOR_059]; necrosis or exfoliative dermatitis  
10.2.5.  Causality  
The investigator must provide causality assessment as to whether or not there is a reasonable 
possibility that the drug caused the AE, based on evidence or facts, his/her clinical judgment, an d 
the following definitions. The causality assessment must  be made based on the available 
information and can be updated as new information becomes available.  
For double -blinded studies using an active comparator, the investigator should consider all study  
drugs in determining event causality.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 103 
 CONFIDENTIAL  The following factors should be considered when assessing causality:  
• Temporal relationship: time to onset versus time drug was administered  
• Nature of the reactions: immediate versus long term  
• Clinical and pathologica l features of the events  
• Existing information about the drug and same class of drugs  
• Concomitant medications  
• Underlying and concurrent illnesses  
• Response to dechallenge (drug discontinuation) or dose reduction  
• Response to rechallenge (re -introduction of the drug) or dose increase, when applicable  
• Patient’s medical and social history  
Causality to the study drug (including study drug administration):  
• Related:  
− The AE follows a reasonable temporal sequence from st udy drug administration, 
and cannot be reasonably explained by [CONTACT_25045], patient’s clinical 
state (eg, disease under study, concurrent diseases, concomitant medications), or 
other external factors.  
or 
− The AE follows a reasonable temporal sequence from study drug administration, 
and is a known reaction to the drug under study or its class of drugs, or is predicted 
by [CONTACT_25046].  
• Not Related:  
− The AE does not follow a reasonable sequence from study drug administration, or 
can be reaso nably explained by [CONTACT_25045], patient’s clinical state 
(eg, disease under study, concurrent diseases, and concomitant medications) or 
other external factors.  
Causality to the study conduct (protocol -specified procedure):  
• Related:  
− The AE follows a reasonable temporal sequence from a protocol -specified 
procedure, and cannot be reasonably explained by [CONTACT_25045], 
patient’s clinical state (eg, disease under study, concurrent diseases, concomitant 
medications), or other externa l factors.  
• Not Related:  
− The AE does not follow a reasonable sequence from a protocol -specified procedure, 
or can be reasonably explained by [CONTACT_25045], patient’s clinical state 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 104 
 CONFIDENTIAL  (eg, disease under study, concurrent diseases, and concomitant medications) or 
other external factors.  
10.3. Safety Monitoring  
The investigator will monitor the safety of study patient at his/her site(s) as per the requirements 
of this protocol and consistent with current Good Clinical Practice (GCP). Any questions or 
conce rns should be discussed with the sponsor in a timely fashion. The sponsor will monitor the 
safety data from across all study sites. The medical/study director will have primary responsibility 
for the emerging safety profile of the compound, but will be sup ported by [CONTACT_25047] (eg, 
Pharmacovigilance; Risk Management; Biostatistics and Data Management). Safety monitoring 
will be performed on an ongoing basis (eg, individual review of SAEs) and on a periodic, 
cumulative aggregate basis.  
10.4. Notifying Health  Authorities, Institutional Review Board/Ethics 
Committee, and Investigators  
During the study, the sponsor and/or the CRO will inform health authorities, ECs/institutional 
review boards (IRBs), and the participating investigators of any S[LOCATION_003]Rs (suspected u nexpected 
serious adverse reactions) occurring in other study centers or other studies of the active study drug 
dupi[INVESTIGATOR_12458], as appropriate per local reporting requirements. In addition, the sponsor and/or CRO 
will comply with any additional local safety rep orting requirements. All notifications to 
investigators will contain only blinded information.  
Upon receipt of the sponsor’s notification of a S[LOCATION_003]R that occurred with the study drug, the 
investigator will inform the IRB/EC unless delegated to the sponsor . 
Event expectedness for study drug (dupi[INVESTIGATOR_12458]) is assessed against the Reference Safety 
Information section of the Investigator’s Brochure that is effective for expedited safety reporting.  
At the completion of the study, the sponsor will report all safety  observations made during the 
conduct of the trial in the CSR to health authorities and ECs/IRB as appropriate.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24100] of the COVID -19 
pandemic on patients will be summarized (eg, discontinuation due to COVID -19). Any additional 
analyses and methods required to investigate the impact of COVID -19 on the efficacy (eg, missing 
data due to COVID -19) and safety evaluation will be specified in the SAP.  
11.1. Statistical Hypothesis  
The following null hypothesis and alternative of the primary endpoint will be tested for the 
comparison of each dupi[INVESTIGATOR_24930] A: 
• Null hypothesis (H 0): The success rate (where success is achieving peak esophageal 
intraepi[INVESTIGATOR_24764] ≤6 eos/hpf at week 16) is equal between dupi[INVESTIGATOR_24931] (higher exposure group or lower exposure group) and placebo.  
• Alternative hypo thesis (H 1): The success rate differs at week 16 between dupi[INVESTIGATOR_24932].  
No formal hypothesis and adjustment for multiplicity will be undertaken for Parts B and C.  
11.2. Justification of Sample Size  
The planned sample size is a total of approximately 90 patients (1:1:1  ratio, 30 patients in the 
higher dupi[INVESTIGATOR_24933], 30 patients in the lower dupi[INVESTIGATOR_24933], and 30 
patients in the placebo group). See Section  3.2.2  for dose selection rationale.  
The assumptions used in sample size calculation were based on Part A of the R668 -EE-1774 study 
(a phase 3 study for adults and adolescents with EoE) and R668 -EE-1324 (a phase 2 study for 
adults with EoE). In Part A of the R668 -EE-1774, the proportions of patients achieving a peak 
esophageal intraepi[INVESTIGATOR_24764] ≤6 eos/hpf at week 24 were 59.5% and 5.1% for 
dupi[INVESTIGATOR_24765], respectively. In Part A of the R668 -EE-1774, the prop ortions of 
adolescent patients achieving peak esophageal intraepi[INVESTIGATOR_24764] ≤6 eos/hpf at 
week 24 were 36.4% and 0% for dupi[INVESTIGATOR_24765], respectively. The treatment group 
difference observed in adolescents was approximately 36.5%. In  the R668 -EE-1324 study, the 
proportions of patients achieving histologic response at week 12 were 65% and 0% for dupi[INVESTIGATOR_24932], respectively. The efficacy of dupi[INVESTIGATOR_24934] 12. Based 
upon the similarity of pathophysi ology and expected similarity of response between adults and 
pediatric patients, a similar proportion of responders at week [ADDRESS_24101] to 
the higher exposure dupi[INVESTIGATOR_24769]. The treatment group difference observed in the R668 -EE-
1774 Part A adolescents was assumed for the sample size calculation for this study in children 
aged ≥1 year to <12 years. It is estimated that with a total number of 90  patients (30  patients in the 
higher exposure dupi[INVESTIGATOR_24769], 30  patients in the lower exposure dupi[INVESTIGATOR_24769], and 
30 patients in the placebo group), at the 2 -sided 5% significance level using Fisher’s exact test, the 
study can provide 95% power to dete ct a treatment difference of 35.6% in the proportion of 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 106 
 CONFIDENTIAL  histologic responders (ie, patients achieving peak esophageal intraepi[INVESTIGATOR_24759] 
≤6 eos/hpf) at week 16 between placebo (5.1%) and each dupi[INVESTIGATOR_24771] (40.7%).  
Sample size ca lculations were made using nQuery Advisor 7.0.  
11.3. Analysis Sets  
11.3.1.  Efficacy Analysis Sets  for Part A  
For Part A, the full analysis set (FAS) includes all randomized patients in Part A; it is based on the 
treatment allocated (as randomized). Efficacy endpoints i n Part  A (double -blind treatment period) 
will be analyzed using the FAS.  
11.3.2.  Safety Analysis Set  for Part A  
For Part A, the  safety analysis set (SAF) includes all randomized patients who received any Part A 
study drug; it is based on the treatment received (as  treated). Treatment compliance/administration 
and all clinical safety variables will be analyzed using the SAF.  
11.3.3.  Analysis Set for Parts B and C  
For efficacy and safety analyses of Parts B and C, only a subset of SAF for Part A will be 
included, which is de fined as those  patients who received at leas t 1 dose of Part B or/and Part C 
study drug.  
11.3.4.  Pharmacokinetic Analysis Sets  for All Parts  
The PK analysis population includes all patients who received any study drug and who had at least 
[ADDRESS_24102] 1 non -missing result in the NAb assay (patients who are ADA -
negative are set to negative in the NAb analysis set).  
11.4. Statistical Methods  
For continuous variabl es, descriptive statistics will include the following information: the number 
of patients reflected in the calculation (n), mean, standard deviation, Q1, median, Q3, minimum, 
and maximum.  
For categorical or ordinal data, frequencies and percentages will b e displayed for each category.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 107 
 CONFIDENTIAL  11.4.1.  Patient Disposition  
The following will be provided:  
• The total number of screened patients who have signed the ICF  
• The total number of randomized patients:  received a randomization number  
• The total number of patients  who discontinued the study, and the reasons for 
discontinuation  
• The total number of patients who discontinued from study treatment, and the reasons 
for discontinuation  
11.4.2.  Demography and Baseline Characteristics  
Demographic and baseline characteristics will b e summarized descriptively by [CONTACT_1570], 
and by [CONTACT_25048].  
11.4.3.  Efficacy Analyses  
[IP_ADDRESS].  Primary Efficacy Analysis  
The primary  analysis of proportion of patients achieving a histologic response of peak esophageal 
intraepi[INVESTIGATOR_24759] ≤6 eos/hpf at week 16 will be analyzed using the Cochran -Mantel -
Haenszel (CMH) test to assess the difference in the proportion of responders in the FAS, adjusting 
for the randomization stratification factor (baseline weight group). The randomization 
stratific ation of baseline weight group may be pooled to ensure the sufficient sample size of each 
stratum.  
For the primary estimands of interest for the primary endpoint, the intercurrent events, strategies , 
and the corresponding missing data handling approaches a re provided as below:  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 108 
 CONFIDENTIAL  Endpoint 
Category  Estimands  
Endpoint(s)  Population  Intercurrent event(s) 
strategy and missing data 
handling  Population -level 
summary/Analysis   
Primary 
Endpoint  Proportion of 
patients achieving 
peak esophageal 
intraepi[INVESTIGATOR_24758] 
≤6 eos/hpf (400×) at 
week 16  FAS The intercurrent events will 
be handled as follows:  
• Treatment 
discontinuation: data 
collected after the 
patient discontinued 
treatment will be 
included in the analysis 
(Treatment policy 
strategy)  
• Initiat ion of treatment 
with systemic and/or 
swallowed topi[INVESTIGATOR_24935]: 
patients will be 
considered as non -
responders after such 
event (composite 
variable strategy)  
Note: the composite strategy 
will be considered if a 
patient receives rescue 
medication any time during 
the study.  
 
Missing data handling: 
patients with a missing value 
for the primary endpoint at 
week 16 due to study 
discontinuation or other 
reasons will be considered to 
be non -responders  Cochran -Mantel -Haenszel 
(CMH) test adjusti ng for 
the randomization 
stratification factor 
(baseline weight group) will 
be utilized.  
The estimated proportion of 
the treatment difference 
between dupi[INVESTIGATOR_24936], and its 2 -sided 
95% confidence intervals 
will be provided based on 
the CMH test. 
Sensitivity analyses will assess alternative methods to impute missing data. The sensitivity 
analyses will include tippi[INVESTIGATOR_24937] – 
multiple imputation (WOCF -MI) approach.  
Subgroup analyses (eg , by [CONTACT_8497]) may be performed. Details will be specified in the SAP.  
[IP_ADDRESS].  Secondary Efficacy Analysis  
Efficacy Endpoints at Week 16 (Part A)  
Secondary efficacy endpoints that measure binary responses (eg, peak esophageal intraepi[INVESTIGATOR_24938] <15 eos /hpf) will be analyzed in the same fashion as the primary endpoint.  
Continuous secondary efficacy endpoints will be analyzed using an analysis of covariance 
(ANCOVA) model for the FAS with treatment group, randomization stratification factor, and 
relevant baseline measurement as a covariate included in the model.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24103] -baseline up to 
week  16 (eg, change in the proportion of days with 1 or more EoE signs from baseline to week  16 
as measured by [CONTACT_24964] -C), missing data will be imputed by [CONTACT_24968] -mixture approach. 
Specifically, the WOCF -Multiple Imputation (WO CF-MI) approach, where the WOCF approach 
will be used for the missing data due to rescue treatment/AE/lack of efficacy and the MI approach 
will be used for the missing due to other reasons.  
For continuous efficacy data that are scheduled to be measured on ly once post -baseline up to 
week  16, missing values at week 16 will be imputed with patient’s baseline value or the available 
post-baseline value, whichever is worse, ie, a WOCF approach.   
The primary analysis of EoE -EREFS will be based on centralized rea dings.  
For transcriptome endpoints, the Wilcoxon rank -sum test will be used to test if the difference in 
median NES of the relative change from baseline to week 16 between the dupi[INVESTIGATOR_24939]. P -values will be rep orted.  
Efficacy Endpoints at Week 52 (Part B)  
Efficacy endpoints at week 52 (Part B) will be analyzed descriptively at given visits for treatment 
received in Part B as well as by [CONTACT_24969] A (double -blind treatment period). No 
missing values will be imputed. These descriptive analyses  may include statistical tests depending 
on the type of data in the same way as described above.  
Efficacy Endpoints (Part C)  
Efficacy data in Part C will be summarized with descriptive statistics for treatment received in 
Part C as well as by [CONTACT_24969] A (double -blind treatment period) and Part B 
(extended active treatment period). No missing values will be imputed.  
11.4.4.  Control of Multiplicity  
For multiplicity adjustment, a hierarchical procedure will be used to control the overall Type -[ADDRESS_24104] and then for the lower exposure 
dupi[INVESTIGATOR_24769]. The hierarchical order of the secondary endpoints will be specified in the SAP.  
As Part B and C data will be summarized using descriptive statistics, there is no multiplicity issue.  
11.4.5.  Safety Analysis  
Safety analysis will be based on the SAF in the respective study part. This includes reported 
TEAEs and other safety data (ie,  clinical laboratory evaluations and vita l signs). A descriptive 
summary of safety results will be presented for each study part by [CONTACT_25049]:  
• Part A: placebo, lower dupi[INVESTIGATOR_24933], higher dupi[INVESTIGATOR_24940] g roup    
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 110 
 CONFIDENTIAL  • Part B: lower dupi[INVESTIGATOR_24933], higher dupi[INVESTIGATOR_24941] A and Part B may be presented and details will be specified in SAP.  
• Part C: higher dupi[INVESTIGATOR_24933]  
[IP_ADDRESS].   Adverse Events  
Definitions  
For safety variabl es, 2 observation periods are defined:  
• The pretreatment period is defined as the time from signing the ICF to before the first 
dose of study drug.  
• The treatment -emergent period is defined as the day from first dose of study drug to 
end of study. The treatm ent-emergent period includes the double -blind treatment 
period, extended active treatment period, and open -label extension period (up to 160 
weeks in total) and the 12 -week follow -up period.  
− Treatment period: date of the first dose of study drug to week 16 0 visit date for 
those patients who completed the week 160 visit with available visit date; or date 
of the first dose of study drug to study day 1 121 (study day [ADDRESS_24105] dose 
date) or the date of patient last contact, whichever is earlier, for tho se patients who 
did not complete week 160 visit or had missing week 160 visit date  
− Follow -up period: date after the end of treatment period to end of study  
Treatment -emergent adverse events are defined as those that are not present at baseline or represent  
the exacerbation of a pre -existing condition during the treatment -emergent period.  
Analysis  
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA®). 
Summaries of all TEAEs by [CONTACT_12919]:  
• The number (n) and percentage (%) of patients with at least 1 TEAE by [CONTACT_3592]  
• TEAEs by [CONTACT_926] (according to the grading scale outlined in Section  10.2.4 ), 
presented by [CONTACT_3592]  
• Treatment -related TEAEs, presented by [CONTACT_25050], SOC and PT  
• TEAEs leading to permanent treatment discontinuation, presented by [CONTACT_3592]  
• Treatment -emergent AESIs (defined with a PT or a prespecified groupi[INVESTIGATOR_007])  
Serious adverse events leading to death and other SAEs will be summarized by [CONTACT_1570].  
[IP_ADDRESS].  Other Safety  
Vital Signs  
Vital signs (temperature, pulse, blood pressure, and respi[INVESTIGATOR_1487]) will be summarized by 
[CONTACT_25051] t time with descriptive statistics.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 111 
 CONFIDENTIAL  The number and percentage of patients with a treatment -emergent potentially clinically significant 
value (PCSV) will be summarized for each vital sign variable. The criteria for treatment -emergent 
PCSV will be defined in  the SAP.  
Laboratory Tests  
Laboratory test results will be summarized by [CONTACT_25052].  
Number and percentage of patients with a treatment -emergent PCSV will be summarized fo r each 
clinical laboratory test. The criteria for treatment -emergent PCSVs will be defined in the SAP.  
Shift tables based on baseline normal/abnormal and other tabular and graphical methods may be 
used to present the results for laboratory tests of intere st. 
[IP_ADDRESS].  Treatment Exposure  
The duration of exposure during part A, part B and part C of the study will be presented by 
[CONTACT_25053]:  
(Date of last study drug injection in the specific study part – date of first study drug injection in 
the specific study part) + 14 days  
Number (%) of patients exposed to study drug during each study part and cumulatively across 
study parts will be presen ted by [CONTACT_25054]. The time periods 
of interest will be specified in the SAP.  
In addition, duration of exposure during the study will be summarized for each treatment group 
using number of patients, means, standard devia tion, minimums, medians, and maximums.  
A summary of the number of doses by [CONTACT_25055].  
[IP_ADDRESS].  Treatment Compliance  
The compliance with study treatment will be calculated for each study part as follows:  
Treatment Compliance = (Number of stud y drug injections during exposure period)/(Number 
of planned study drug injections during exposure period) × 100%  
The treatment compliance will be presented by [CONTACT_25056]. The 
ranges of interest will be specified in the SAP.  
11.4.6.  Pharmacokinetics  
[IP_ADDRESS].  Analysis of Drug Concentration Data  
The concentrations of functional dupi[INVESTIGATOR_24942]. No formal statistical hypothesis testing will be performed .  
11.4.7.  Analysis of Immunogenicity  Data  
Immunogenicity will be characterized by [CONTACT_25057]:  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 112 
 CONFIDENTIAL  • Pre-existing immunoreactivity, defined as a positive ADA assay response at baseline, with 
all post -dose ADA results negative, or a positive assay response at baseline, with a ll post -
dose ADA assay responses less than 4 -fold over baseline titer levels  
• Treatment -emergent ADA response, defined as any post -dose positive ADA assay 
response when the baseline results are negative or missing  
• Treatment -boosted ADA response, defined as any post -dose positive ADA assay response 
that is 4 -fold over baseline titer levels when baseline is positive in the ADA assay  
• Maximum ADA titer values  
− Low (titer <1,000)  
− Moderate (1,000≤ titer ≤10,000)  
− High (titer >10,000)  
• NAb status for samples that ar e positive in the ADA assay  
Incidence of treatment -emergent ADA and NAb will be assessed as absolute occurrence (N) and 
percent of patients (%), grouped by [CONTACT_25058].  
Plots of drug concentrations will be examined and the influence of ADAs and NAbs on individual 
PK profiles evaluated. Assessment of impact of ADA and NAbs on safety and efficacy may be 
provided.  
11.4.8.  Analysis of Pharmacodynamic and Exploratory Biomarker Data  
Biomarker results will be summarized by [CONTACT_25059], measured values, ch ange from baseline, and 
percent change from baseline to each scheduled assessment time point with descriptive statistics. 
Exploratory analyses performed on biopsies will not be reported in the CSR. Other exploratory 
analyses may be performed but will not b e described in the SAP or CSR.  
11.4.9.   Timing of Statistical Analysis  
The primary analysis may be performed when the last patient completes [ADDRESS_24106] of the study will be made based on this primary 
analysi s. The assessment of primary and secondary endpoints specified in Section  4.1.1  and 
Section  4.1.2  will be analyzed descriptively in Part B as the final analysis. Part C will be described 
descriptively. Hence, there will be no need for alpha adjustment due to the primary analysis.  
In order to maintain study integrity (with respect to the extended active treatment and post -
treatment follow -up safety visits) in the event a decision is made to perform the primary analysis, 
a dissemination plan will be written. This plan will clearly identify th e team (including the 
statistician) that will perform the primary analysis and all related activities, restrict other clinical 
team members and other sponsor personnel from access to individual patient treatment allocation 
and site level analysis results, and ensure that the dedicated team will not participate in the data 
review or data decisions for the following extended active treatment safety analyses.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 113 
 CONFIDENTIAL  11.5. Statistical Considerations Surrounding the Premature Termination 
of a Study  
If the study is terminate d prematurely, only those parameters required for the development 
program and/or reporting to regulatory authorities will be summarized. Investigator and sponsor 
responsibilities surrounding the premature termination of a study are presented in Section  15.1. 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 114 
 CONFIDENTIAL  12. QUALITY CONTROL AND QUALITY ASSURANCE  
In accordance with ICH E6, the sponsor is responsible for quality assurance to ensure that the 
study is cond ucted and the data generated, recorded, and reported in compliance with the protocol, 
GCP, and any applicable regulatory requirement(s). The planned quality assurance and quality 
control procedures for the study are described in this section .  
12.1. Data Managem ent and Electronic Systems  
12.1.1.  Data Management  
A data management plan specifying all relevant aspects of data processing for the study (including 
data validation [quality -checking], cleaning, correcting, releasing) will be maintained and stored 
at Regeneron (sponsor).  
A medical coding plan will specify the processes and the dictionary used for coding. All data 
coding (eg, AEs, baseline findings, medication, medical history/surgical history) will be done 
using internationally recognized and accepted dictionari es. 
The CRF data for this study will be collected with an electronic data capture (EDC)/paper CRF.  
12.1.2.  Electronic Systems  
Electronic systems that may be used to process and/or collect data in this study will include the 
following:  
• IVRS/IWRS system – randomiza tion, study drug supply  
• EDC system – data capture  – Medidata Rave  
• Statistical Analysis System (SAS) – statistical review and analysis  
• Pharmacovigilance safety database  
• nQuery Advisor – sample size calculations  
• Digital archive system for endoscopic photographic and video images  
12.2. Study Monitoring  
12.2.1.  Monitoring of Study Sites  
The study monitor and/or designee (eg, CRO monitor) will visit each site prior to enrollment of 
the first patient, and periodically during the study. This study will use the principle s of risk -based 
monitoring (ICH). This means that the number of visits for any given site may vary based on site 
risk indicators. The investigator must allow study -related monitoring.  
The study monitors will perform ongoing source data review to verify tha t data recorded in the 
CRF by [CONTACT_1191], complete, and verifiable from source documents, 
that the safety and rights of patients are being protected, and that the study is being conducted in 
accordance with the current approved protocol version and any other study agreements, ICH GCP, 
and all applicable regulatory requirements.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 115 
 CONFIDENTIAL  12.2.2.  Source Document Requirements  
Investigators are required to prepare and maintain adequate and accurate patient records (source 
documents). The site is resp onsible to ensure quality within their records and systems and are 
accountable for ensuring that all source data and CRF data are timely, accurate, and complete.  
The investigator must keep all source documents on file with the CRF (throughout this protocol , 
CRF refers to either a paper CRF or an electronic CRF). Case report forms and source documents 
must be available at all times for inspection by [CONTACT_25060].  
12.2.3.  Case Report Form Requirements  
Study data  obtained in the course of the clinical study will be recorded on electronic case report 
forms (eCRFs) within the EDC system by [CONTACT_1146]. All required CRFs must be 
completed for each and every patient enrolled in the study. The investigator m ust ensure the 
accuracy, completeness, and timeliness of the data reported to the sponsor in the CRFs. After 
review of the clinical data for each patient, the investigator must provide an electronic signature. 
A copy of each patient CRF casebook is to be r etained by [CONTACT_25061].  
Corrections to the CRF will be entered in the CRF by [CONTACT_25062] a uthorized designee. 
All changes, including date and person performing corrections, will be available via the audit trail, 
which is part of the EDC system. F or corrections made via data queries, a reason for any alteration 
must be provided.  
12.3. Audits and Inspe ctions  
This study may be subject to a quality assurance audit or inspection by [CONTACT_25063]. Should this occur, the investigator is responsible for:  
• Informing the sponsor of a planned inspection by [CONTACT_25064], and authorizing the sponsor’s participation in the inspection  
• Providing access to all necessary facilities, study data, and documents for the inspection 
or audit  
• Communicating any information arising from inspection by [CONTACT_25065]  
• Taking all appropriate measures requested by [CONTACT_25066], CRFs, 
medical records, correspondence, ICFs, IRB/EC files, documentation of certification and quality 
control of supporting laboratories, and records relevant to the study maintained in any supporting 
pharmacy facilities. Conditions of study material storage are also subject to inspection. In addition, 
representatives of the sponsor may observe the conduct of any aspect of the clinical study or its 
supporting activities both within and outside of the investigator’s institution.  
In all instances, the confidentiality of the data must be respected.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 116 
 CONFIDENTIAL  12.4. Study Documentation  
12.4.1.  Certification of Accuracy of Data  
A declaration assuring the accuracy and content of the data recorded on the CRF/eCRF must be 
signed electronically by [CONTACT_093]. This signed declara tion accompanies each set of patient 
final CRF/eCRF that will be provided to the sponsor.  
12.4.2.  Retention of Records  
The investigator must retain all essential study documents, including ICFs, source documents, 
investigator copi[INVESTIGATOR_3110], and drug accountabilit y records for at least [ADDRESS_24107] be destroyed in a manner that ensures confidentiality.  
If the investigator’s personal situation is such that archiving can no longe r be ensured, the 
investigator must inform the sponsor (written notification) and the relevant records will be 
transferred to a mutually agreed -upon destination.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 117 
 CONFIDENTIAL  13. ETHICAL AND REGULATO RY CONSIDERATIONS  
13.1. Good Clinical Practice Statement  
It is the responsibili ty of both the sponsor and the investigator(s) to ensure that this clinical study 
will be conducted in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki, and that are consistent with the ICH guidelines for GCP and  applicable regulatory 
requirements.  
13.2. Informed Consent  
The principles of informed consent are described in ICH guidelines for GCP.  
The ICF used by [CONTACT_25067]/EC. A  copy of the IRB/EC -approved ICF and documentation 
of approval must be provided to the sponsor before study drug will be shipped to the study site.  
It is the responsibility of the investigator or designee (if acceptable by [CONTACT_427]) to obtain 
written informed consent from each patient and his/her parent(s) or legal guardian(s) prior to the 
patient’s participation in the study and after the aims, methods, objectives, and potential hazards 
of the study have been explained to the fullest possible exte nt in language that the patient and the 
parent(s) or legal guardian(s) can understand. The ICF should be signed and dated by [CONTACT_102]’s 
parent(s) or legal guardian(s) and the same investigator or designee who explained the ICF.  
Local law must be observe d in deciding whether 1 or both parents’/guardians’ consent is required. 
If only [ADDRESS_24108] document the reason the 
other parent or guardian did not sign. The patient may also be required to sign and date the ICF, 
as determined by [CONTACT_1201]/EC and in accordance with the local regulations and requirements.  
• Patients who can write but cannot read will have the assent form read to them before 
writing their name [CONTACT_25084].  
• Patients who can understand but wh o can neither write nor read will have the 
ICF/assent read to them in the presence of an impartial witness, who will sign and date 
the ICF to confirm that informed consent was given.  
The original ICF must be retained by [CONTACT_25068]’s study record, and a 
copy of the signed ICF must be given to the patient’s parent(s) or legal guardian(s).  
If new safety information results in significant changes in the risk/benefit assessment, or if there 
are significant changes to the study proced ures, the ICF must be reviewed and updated 
appropriately. All study patients and their parent(s) or legal guardian(s) must be informed of the 
new information and provide their written consent if they wish for the patient to continue in the 
study. The origi nal, signed revised ICF must be maintained in the patient’s study record and a copy 
must be given to the patient’s parent(s) or legal guardian(s).  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:[ADDRESS_24109] take all appropriate measures to ensure th at the anonymity of each study 
patient will be maintained. Patients should be identified by a patient identification number only, 
on CRFs or other documents submitted to the sponsor. Documents that will not be submitted to 
the sponsor (eg, signed ICF) must  be kept in strict confidence.  
The patient’s and investigator’s personal data, which may be included in the sponsor database, will 
be treated in compliance with all applicable laws and regulations. The sponsor shall take all 
appropriate measures to safegua rd and prevent access to this data by [CONTACT_13159].  
13.4. Institutional Review Board/Ethics Committee  
An appropriately constituted IRB/EC, as described in ICH guidelines for GCP, must review and 
approve:  
• The protocol, ICF, and any other materials  to be provided to the patients 
(eg, advertising) before any patient may be enrolled in the study  
• Any amendment or modification to the study protocol or ICF before implementation, 
unless the change is necessary to eliminate an immediate hazard to the patie nt, in which 
case the IRB/EC should be informed as soon as possible  
• Ongoing studies on an annual basis or at intervals appropriate to the degree of risk  
In addition, the IRB/EC should be informed of any event likely to affect the safety of patients  or 
the continued conduct of the clinical study.  
A copy of the IRB/EC approval letter with a current list of the IRB/EC members and their functions 
must be received by [CONTACT_25069]. The approval 
letter should include the study number and title, the documents reviewed, and the date of the 
review.  
Records of the IRB/EC review and approval of all study documents (including approval of ongoing 
studies) must be kept on file by [CONTACT_093].  
13.5. Clinical Study  Data Transparency  
Final study results will be published on a public clinical trial website according to applicable local 
guidelines and regulations. Treatment codes will be disseminated to each investigation site 
thereafter.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 119 
 CONFIDENTIAL  14. PROTOCOL AMENDMENTS  
The sponso r may not implement a change in the design of the protocol or ICF without an IRB/EC -
approved amendment. Where required per local legislation, regulatory authority approval will also 
be sought.  
15. PREMATURE TERMINATIO N OF THE STUDY OR CL OSE -
OUT OF A SITE  
15.1. Prem ature Termination of the Study  
The sponsor has the right to terminate the study prematurely. Reasons may include efficacy, safety, 
or futility, among others. Should the sponsor decide to terminate the study, the investigator(s) will 
be notified in writing.  
15.2. Close -out of a Site  
The sponsor and the investigator have the right to close -out a site prematurely.  
Investigator’s Decision  
The investigator must notify the sponsor of a desire to close -out a site in writing, providing at least 
30 days’ notice. The final  decision should be made through mutual agreement with the sponsor. 
Both parties will arrange the close -out procedures after review and consultation.  
Sponsor’s Decision  
The sponsor will notify the investigator(s) of a decision to close -out a study site in writing. Reasons 
may include the following, among others:  
• The investigator has received all items and information necessary to perform the study, 
but has not enrolled any patient within a reasonable period of time  
• The investigator has violated any fundame ntal obligation in the study agreement, 
including but not limited to breach of this protocol (and any applicable amendments), 
breach of the applicable laws and regulations, or breach of any applicable 
ICH guidelines  
• The total number of patients required f or the study are enrolled earlier than expected  
In all cases, the appropriate IRB/EC and health authorities must be informed according to 
applicable regulatory requirements, and adequate consideration must be given to the protection of 
the patients’ intere sts. 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 120 
 CONFIDENTIAL  16. CONFIDENTIALITY  
Confidentiality of information is provided as a separate agreement.  
17. FINANCING AND INSURA NCE  
Financing and insurance information is provided as a separate agreement.  
18. PUBLICATION POLICY  
Publication rights and procedures will be outlined in a separate clinical study agreement.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 121 
 CONFIDENTIAL  19. REFERENCES  
(CMS) TCfMMS. Proton Pump Inhibitors: Use In Pediatric Patients.  2013; U.S. Department of 
Health and Human Services Food and Drug Administration.  
 
Ally MR, Maydonovitch CL, Betteridge JD, Veerappan GR,Moawad FJ. Prevalence of 
eosinophilic esophagitis in a [LOCATION_002] military health -care population. Dis Esophagus 2015; 
28(6):505 -511. 
 
Arias A, Perez -Martinez I, Tenias JM,Lucendo AJ. Systematic review with meta -analysis: the 
incidence and prevalence of eosinophilic oesophagitis in children and adults in population -based 
studies. Aliment Pharmacol Ther 2016; 43(1):3 -15. 
 
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA 
interference reveals that oncogenic KR AS-driven cancers require TBK1. Nature 2009; 
462(7269):[ADDRESS_24110] C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, et al. IL -13 involvement in 
eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy 
Clin Immunol 2007; 120(6):[ADDRESS_24111] C, Stucke EM, Burwinkel K, Caldwell JM, Collins MH, Ahrens A, et al. Coordinate 
interaction between IL -13 and epi[INVESTIGATOR_24943]. 
J Immunol 2010; 184(7):[ADDRESS_24112] 2006; 
116(2):536 -547. 
 
CDC Growth Charts: [LOCATION_002].   2000; Centers f or Disease Control and Prevention (CDC).  
 
Chehade M, Jones SM, Pesek RD, Burks AW, Vickery BP, Wood RA, et al. Phenotypic 
Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the 
Consortium for Food Allergy Research. J Allergy Clin Immunol Pract 2018; 6(5):1534 -
1544.e1535.  
 
Collins MH, Martin LJ, Alexander ES, Boyd JT, Sheridan R, He H, et al. Newly developed and 
validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak 
eosinophi l count for disease diagnosis and monitoring. Dis Esophagus 2017; 30(3):1 -8. 
 
DeBrosse CW, Franciosi JP, King EC, Butz BK, Greenberg AB, Collins MH, et al. Long -term 
outcomes in pediatric -onset esophageal eosinophilia. J Allergy Clin Immunol 2011; 128(1):1 32-
138. 
 
Dellon ES. Epi[INVESTIGATOR_24944]. Gastroenterol Clin North Am 2014; 
43(2):201 -218. 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 122 
 CONFIDENTIAL   
Dellon ES, Aderoju A, Woosley JT, Sandler RS,Shaheen NJ. Variability in diagnostic criteria for 
eosinophilic esophagitis: a systematic review. Am J Gastroenterol 2007; 102(10):2300 -2313.  
 
Dellon ES,Hirano I. Epi[INVESTIGATOR_24945]. 
Gastroenterology 2018; 154(2):319 -332.e313.  
 
Dellon ES, Veerappan R, Selitsky SR, Parker JS, Higgins LL, Beitia R, et al. A Gene Expression 
Panel is Accurate for Diagnosis and Monitoring Treatment of Eosinophilic Esophagitis in Adults. 
Clin Transl Gastroenterol 2017; 8(2):e74.  
 
Falk GW. Clinical presentation of eosinophilic esophagitis in adults. Gastroenterol Clin North Am 
2014; 43 (2):231 -242. 
 
Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, et al. 
Development of a validated patient -reported symptom metric for pediatric eosinophilic 
esophagitis: qualitative methods. BMC Gastroenterol 2011; 11:126.  
 
Furuta  GT,Aceves SS. The National Biome Initiative: An allergy perspective. J Allergy Clin 
Immunol 2017; 139(4):[ADDRESS_24113], Mukkada VA, Khoury JC, Putnam PE,Backeljauw PF. Adrenal 
Insufficiency after Chronic Swallowed Glucocorticoid Thera py for Eosinophilic Esophagitis. J 
Pediatr 2016; 170:240 -245. 
 
Greuter T, Bussmann C, Safroneeva E, Schoepfer AM, Biedermann L, Vavricka SR, et al. Long -
Term Treatment of Eosinophilic Esophagitis With Swallowed Topi[INVESTIGATOR_24946]: 
Development and Eval uation of a Therapeutic Concept. Am J Gastroenterol 2017; 112(10):1527 -
1535.  
 
Hamilton JD, Suarez -Farinas M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupi[INVESTIGATOR_24947] -to-severe atopic dermat itis. J 
Allergy Clin Immunol 2014; 134(6):1293 -1300.  
 
Hirano D, Oka S, Tanaka S, Sumimoto K, Ninomiya Y, Tamaru Y, et al. Clinicopathologic and 
endoscopic features of early -stage colorectal serrated adenocarcinoma. BMC Gastroenterol 2017; 
17(1):158.  
 
Hiran o I,Aceves SS. Clinical implications and pathogenesis of esophageal remodeling in 
eosinophilic esophagitis. Gastroenterol Clin North Am 2014; 43(2):[ADDRESS_24114] IL13, Reduces Histologic and Endoscopic Activity in Patients With 
Eosinophilic Esophagitis. Gastroenterology 2019a; 156(3):592 -603.e510.  
 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 123 
 CONFIDENTIAL  Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, et al. Efficacy of 
Dupi[INVESTIGATOR_24948] a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. 
Gastroenterology 2019b.  
 
Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N,Achem SR. Endoscopic assessment of 
the oesophageal features of eosinophilic oesophagitis: validation  of a novel classification and 
grading system. Gut 2013; 62(4):489 -495. 
 
Hruz P, Straumann A, Bussmann C, Heer P, Simon HU, Zwahlen M, et al. Escalating incidence 
of eosinophilic esophagitis: a 20 -year prospective, population -based study in Olten County, 
Switzerland. J Allergy Clin Immunol 2011; 128(6):1349 -1350.e1345.  
 
Iuliano S, Minelli R, Vincenzi F, Gaiani F, Ruberto C, Leandro G, et al. Eosinophilic esophagitis 
in pediatric age, state of the art and review of the literature. Acta Biomed 2018; 89(8 -s):20-26. 
 
Kapel RC, Miller JK, Torres C, Aksoy S, Lash R,Katzka DA. Eosinophilic esophagitis: a prevalent 
disease in the [LOCATION_002] that affects all age groups. Gastroenterology 2008; 134(5):1316 -1321.  
 
Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic 
esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 
2011; 128(1):3 -20.e26; quiz [ADDRESS_24115] AJ, Bussmann C, et al. 
Guide lines on eosinophilic esophagitis: evidence -based statements and recommendations for 
diagnosis and management in children and adults. United European Gastroenterol J 2017; 
5(3):335 -358. 
 
 
Malmberg LP, Pelkonen AS, Mattila PS, Hammaren -Malmi S,Makela MJ. Ex haled nitric oxide 
and exercise -induced bronchoconstriction in young wheezy children - interactions with atopy. 
Pediatr Allergy Immunol 2009; 20(7):[ADDRESS_24116] labeling: report of the 
ISPOR PRO good research practices for the assessment of children and adolescents task force. 
Value Health 2013; 16(4):461 -479. 
 
Nhu QM,Moawad FJ. New Developments in the Diagnosis and Treatment of Eosinophilic 
Esophagitis. Curr Treat Options Gastroenterol 2019; 17(1):48 -62. 
 
O'Shea KM, Aceves SS, Dellon ES, Gupta SK, Spergel JM, Furuta GT, et al. Pathophysiology of 
Eosinophilic Esophagitis. Gastroenterology 2018; 154(2):33 3-345. 
 
Prasad GA, Alexander JA, Schleck CD, Zinsmeister AR, Smyrk TC, Elias RM, et al. 
Epi[INVESTIGATOR_24949], Minnesota. Clin 
Gastroenterol Hepatol 2009; 7(10):1055 -1061.  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 124 
 CONFIDENTIAL   
Schoepfer AM, Straumann A, Panczak R, Coslovsky M, Kuehni CE, Maurer E, et al. Development 
and validation of a symptom -based activity index for adults with eosinophilic esophagitis. 
Gastroenterology 2014; 147(6):[ADDRESS_24117] C, Stucke EM, Kemme KA, Collins MH, et al. Analysis and 
expansion of the eosinophilic esophagitis transcriptome by [CONTACT_25070]. Genes Immun 2014; 
15(6):361 -369. 
 
Singla MB,Moawad FJ. An Overview of the Diagnosis and Management of Eosinophilic 
Esophagitis. Clin Transl Gastr oenterol 2016; 7:e155.  
 
Spergel JM, Brown -Whitehorn TF, Beausoleil JL, Franciosi J, Shuker M, Verma R, et al. 14 years 
of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr 2009; 
48(1):[ADDRESS_24118], et al. 
Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double -blind, 
randomized, placebo -controlled trial. J Allergy Clin Immunol 2012; 129(2):[ADDRESS_24119] 
Endosc Clin N Am 2008; 18(1):99 -118; ix.  
 
Straumann A, Aceves SS, Blanchard C, Collins MH, Furuta GT, Hirano I, et al. Pediatric and adult 
eosinophilic esophagitis: similarities and differences. Allergy 2012; 67(4):477 -490. 
 
Straumann A, Spi[INVESTIGATOR_24950], Grize L, Bucher KA, Beglinger C,Simon HU. Natural history of 
primary eosinophilic esophagitis: a follow -up of 30 adult patients for up to 11.5 years. 
Gastroenterology 200 3; 125(6):1660 -1669.  
 
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set 
enrichment analysis: a knowledge -based approach for interpreting genome -wide expression 
profiles. Proc Natl Acad Sci U S A 2005; 102(43):[ZIP_CODE] -[ZIP_CODE]. 
 
Totri CR, Eichenfield LF, Logan K, Proudfoot L, Schmitt J, Lara -Corrales I, et al. Prescribing 
practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and 
Canada: The PeDRA TREAT survey. J Am Acad Dermatol 2017; 76(2):281 -285. 
 
Veerappan GR, Perry JL, Duncan TJ, Baker TP, Maydonovitch C, Lake JM, et al. Prevalence of 
eosinophilic esophagitis in an adult population undergoing upper endoscopy: a prospective study. 
Clin Gastroenterol Hepatol 2009; 7(4):[ADDRESS_24120] AJ, Verheij J, Lauwers GY, Walsh JC, et al. Reliability 
of histologic assessment in patients with eosinophilic oesophagitis. Aliment Pharmacol Ther 2018; 
47(7):940 -950. 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 125 
 CONFIDENTIAL   
Wechsler JB, Bolton SM, Amsden K, Wershil  BK, Hirano I,Kagalwalla AF. Eosinophilic 
Esophagitis Reference Score Accurately Identifies Disease Activity and Treatment Effects in 
Children. Clin Gastroenterol Hepatol 2018; 16(7):1056 -1063.  
 
Wen T, Stucke EM, Grotjan TM, Kemme KA, Abonia JP, Putnam PE,  et al. Molecular diagnosis 
of eosinophilic esophagitis by [CONTACT_25071]. Gastroenterology 2013; 145(6):1289 -
1299.  
 
 
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 126 
 CONFIDENTIAL  20. INVESTIGATOR’S AGREE MENT  
I have read the attached protocol: A Randomized, Double -Blind, Placebo -Controlled Study to 
Investigate the Efficacy and Safety of Dupi[INVESTIGATOR_24951].  
I agree to comply with the current International Council for Harmonisation Guideline for Goo d 
Clinical Practice and the laws, rules, regulations, and guidelines of the community, country, state, 
or locality relating to the conduct of the clinical study.  
I also agree that persons debarred from conducting or working on clinical studies by [CONTACT_25072] a partnership 
in which the sponsor is involved. I will immediately disclose it in writing to the sponsor if any 
person who is involved in the study is debarred, or i f any proceeding for debarment is pending, or, 
to the best of my knowledge, threatened.  
This document contains confidential information of the sponsor, which must not be disclosed to 
anyone other than the recipi[INVESTIGATOR_14251]/EC. I agree to ensure that this 
information will not be used for any purpose other than the evaluation or conduct of the clinical 
investigation without the prior written consent of the sponsor.  
 
 
 
   
(Signature [CONTACT_7919])   (Date)  
   
(Printed Name)    
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Clinical Study Protocol  R668 -EE-1877 Amendment 4  
 
Regeneron Pharmaceuticals, Inc.  Page 127 
 CONFIDENTIAL  SIGNATURE [CONTACT_11715] ’S RESPONSIBLE OFFIC ERS  
(Medical/Study Director, Regulatory Representative, Clinical Study Lead, and 
Biostatistician)  
To the best of my knowledge, this report accurately describes the planned conduct of the study.  
Study Title:  A Randomi zed, Double -Blind, Placebo -Controlled Study to Investigate the 
Efficacy and Safety of Dupi[INVESTIGATOR_24952]:  R668 -EE-1877  
Protocol Version:  R668 -EE-1877 Amendmen t 4 
 
See appended electronic signature [CONTACT_25085]’s Responsible Medical/Study Director  
 
 
See appended electronic signature [CONTACT_25085]’s Responsible Regulatory Liaison  
 
 
See appended electronic signature [CONTACT_25085]’s Responsible Clinical Study Lead  
 
 
See appended electronic signa ture page  
Sponsor’s Responsible Biostatistician  
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
Signature [CONTACT_11032]-RIM-00153963 v2.0
Signature [CONTACT_11032]-RIM-00153963 v2.0 ApprovedApproval/eSignature
02-Aug-2022 17:34:49 GMT[PHONE_006]
Approval/eSignature
02-Aug-2022 17:41:31 GMT[PHONE_006]
Approval/eSignature
02-Aug-2022 17:42:24 GMT[PHONE_006]
Approval/eSignature
02-Aug-2022 18:01:11 GMT[PHONE_006]
Approval/eSignature
02-Aug-2022 18:34:21 GMT[PHONE_006]
Approval/eSignature
03-Aug-2022 13:49:15 GMT[PHONE_006]
                                        VV-RIM-00153963-2.0 Approved - 03 Aug 2022 GMT-5:00
